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One need not be a rocket scientist to notice that increased food intake tends to be 
associated with obesity (Spiegelman, 1996); however, to understand the regulation 
of energy homeostasis in all its complexity will require boldly go where no 
molecular biologist has gone before. 
xlv 
ACKNOWLEDGEMENTS 
Many thanks to my supervisors Professor Sudhesh Kumar, Philip McTernan and 
Paul O'Hare for making this thesis possible and for their guidance on scientific 
matters. Thanks to Paul O'Hare specifically, with his creativity in obtaining 
funding for my research. This included exposure to the world of educationalists 
with an experience as GLF (group learning facilitator) at Warwick Medical 
School for me. 
Thanks to the anaesthetists and surgeons at Sollihull Hospital. Particular thanks 
go to all the patients who consented to donate samples for these studies and so 
made this research possible. Thanks to Sean James for his help with 
Immunohistochemistry and Anton Tonchev from Varna University, Bulgaria for 
sharing some of his hypothalamic human samples. Thanks to Adam Baker who 
helped with the microarray analysis and the jolly company of other PhD students 
in the lab. Thanks to all the secretaries and all helpers behind the scenes who 
helped me to keep high spirits and get going when the going got hard. 
Great thanks to my whole family, especially my husband Pierre (my star and star 
scientist) for his patience and for coping with separation for almost three years 
since the workplace of my thesis left us 70 miles apart. Thanks very much to my 
mother-in-law, Nicole Maxted, for the proofreading at short notice and her 
contribution of numerous commas. 
Finally, thanks to my cat (Posh) for calming my nerves. She suffered from being 
ignored and envied the laptop as the preferred thing on my lap instead of her. 
Doing what cats do, she bit the tail of the mouse off (the computer mouse) which 
resulted in prompt shortcut of the laptop systems but no change of her fortune. 
xv 
DECLARATION 
I declare that this thesis is a record of results obtained by me based on my own 
laboratory work, with the exception of the immunohistochemical analysis, where I 
received help by Sean James, and the microarray analysis by Adam Baker. This 
thesis was written by me and lead to publications as result of the work. The results 
of chapter 3 are about to be published in the Journal of Endocrinology and 
Metabolism. Co-authors aided in supervision, help with immunohistology and 
supply of human brain tissue. I have obtained the ethics for the attached paper of 
Kusminski et. al. (2007) and contributed with patient recruitment, dealt with the 
sampling, insulin and glucose analysis and contributed with intellectual input. 
None of the work has been previously submitted for a higher degree. 
All sources have been specifically acknowledged by means of reference. 
xv' 
SYNOPSIS 
There is a worldwide epidemic of obesity. Weight rise is a consequence of 
continuous positive energy balance which leads to accumulation of body fat. 
Recent insights into adipose tissue (AT) biology have led to the conclusion that 
the adipocyte is not just a storage depot for triglycerides but also an endocrine 
organ. AT secretes proteins, such as leptin, which control central appetite 
regulation in the human hypothalamus. In contrast, several other proteins and 
neurotransmitters regulate central energy balance, but can also influence AT 
metabolism to elicit feedback on fat accumulation. This suggests a close link 
between AT and the brain within an AT-to-brain crosstalk system including 
feedback circuits. This thesis examines firstly, the potential of crosstalk between 
AT and the brain by other adipokines and secondly, the brain-AT crosstalk by 
expression of neurotransmitters and their receptors in AT. The study establishes 
the presence of the adipokines adiponectin and resistin in human cerebrospinal 
fluid and immunohistochemistry showed adiponectin receptors in energy 
regulating nuclei of the hypothalamus. Furthermore, this thesis established that the 
orexigenic neurotransmitters NPY and ghrelin are secreted by human adipocytes, 
where they enhance lipid accumulation. Further, that NPY levels increase with 
obesity and its in vitro secretion is enhanced by insulin. This may play an 
important role in the pathogenesis of the metabolic syndrome and may induce an 
escape of the appetite behaviour towards positive energy balance. Finally, this 
thesis highlights the influence of a depot-specific innervation of AT on energy 
homeostasis by establishing presence of nicotinic receptors in human adipocytes, 
which may play a role in smoking induced changes in adipokine secretion and fat 
mass. 
In conclusion, this thesis suggests a tight interplay between AT and the brain and 
highlights its potential relevance in human pathophysiology. 
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Introduction 
1.1. Obesity 
Obesity is a condition in which excess fat has accumulated to such an extent that 
health is adversely affected (WHO, 1999) and is a consequence of continuous 
positive energy balance. This thesis explores the mechanisms of fat deposition 
and feedback mechanisms of energy homeostasis and in particular examines 
adipose tissue and its crosstalk with principle regulators of central energy 
balance. 
1.1.1. Obesity: The epidemic 
Worldwide, 300 million of the adult population are overweight or obese (WHO, 
2003). The number of obese and overweight people in the UK has tripled over 
the last two decades and more than 50% of British people have been categorised 
as obese (National Audit Office 2001). Based on observations taken over 10 
years, the Department of Health Annual Health Survey for England (2003) 
estimated a continuous average weight gain of about 0.35kg/year per adult 
person. Obesity has also begun to replace the more traditional causes of ill 
health like undernutrition and infectious diseases in third word countries (WHO, 
2003). These epidemic proportions of obesity are not restricted to adults and 
there is an even bigger concern in children (Chinn, 2001). With growing rates of 
childhood obesity, obesity related diseases and T2DM are increasingly seen at 
younger ages (Kaufman, 2002). Obesity is a chronic, progressive and relapsing 
disease and its management is a challenge (Kos, 2004). A closer understanding 
of human energy regulation gives hope to the development of much required 
effective treatments. 
2 
1.1.2 Definition of obesity and the metabolic syndrome 
The definition of obesity currently used by the WHO is based on the 
measurement of a person's body mass index (BMI). This is calculated by 
dividing the person's weight in kilograms by the square of their height in metres 
(kg/m2). A BMI of >30 kg/m2 is classified as obesity and the range between 25 
to 30 kg/m2 as overweight. 
WHO classification for Europids BMI 
Underweight <18.5 
Healthy/Lean 18.5-24.9 
Overweight 25-29.9 
Obese I 30-34.9 
Obese II 35-39.9 
Morbid Obesity >40 
Table 1.1.2: Obesity classification (Weisell, 2002). 
BMI is the most routinely used parameter to indirectly measure `fatness', due to 
its ease of determination and calculation. However, the risk of obesity related 
type 2 diabetes (T2DM) is better defined by a high waist-hip ratio (WHR) 
(Larsson, 1984) as the BMI index does not identify extremes of those with high 
fat or high muscle mass. Since abdominal fat as reflected by waist 
circumference is more harmful to health than other fat depots and correlates 
better with cardiovascular risk (Dobbelsteyn, 2001), the recent trend includes 
the combination of waist circumference as well as BMI in epidemiological 
studies. The use of CT scan, DEXA and MRI allows the measurement of depot 
specific distribution of adipose tissue, e. g. with cross sectional views of the 
abdomen. Other tools of body fat estimation are fat measurements with skin 
3 
callipers, the use of bioelectrical impedance (radio-frequency pulse), water 
immersion test and the less invasive air-displacement plethysmography (BOD 
POD) (Fields, 2002). While these methods are useful in research, they are not 
suitable, or their use justifiable, for routine clinical risk stratification. 
1.1.3 Obesity and adverse health 
Obesity has adverse health effects and leads to premature death (Calle, 1999). 
Death is caused indirectly and thus an exact calculation of obesity related 
mortality is difficult. However, there are estimates of a decrease of life 
expectancy by 3 to 14 years (Jebb, 2003). The mortality increases sharply with 
BMI above 30 kg/rn2 (Williamson, 1995; Allison, 1999) and is positively related 
to the duration of obesity. Obesity also increases the risk of certain cancers, e. g. 
endometrial, colon and postmenopausal breast cancer (Calle, 2003) and is 
positively correlated with the occurrence of sleep apnoea, joint disease and 
depression. Most importantly obesity is correlated with hypertension, 
dyslipidaemia and progressive increase of insulin resistance which can result in 
T2DM. The combination of these disease entities is also known as the metabolic 
syndrome, or `deadly quartet', and each individual component is associated with 
an increased incidence of cardiovascular disease and stroke. There is no 
unifying definition for the metabolic syndrome and no agreement by expert 
groups on the individual benchmarks of the clinical criteria for identification of 
this syndrome cluster (Alberti, 2005), which makes an estimate of its prevalence 
difficult. The role of the individual components in the pathogenesis of this 
syndrome is unclear and obesity and possibly insulin resistance are considered 
as their main drivers. The development of obesity related T2DM is a transient 
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process commencing with insulin resistance in which there is a compensatory 
increase in insulin production and pancreatic (3-cells secretion (DeFronzo, 1988; 
Raeven, 1989). This systemic hyperinsulinaemia is initially able to suppress 
hepatic insulin production and maintain normal glucose levels. With increased 
strain of the (3-cells the condition progresses to impaired glucose tolerance (IGT) 
and finally to overt T2DM which is defined by fasting hyperglycaemia 
(Bogardus, 1984; WHO, 1999). As the prevalence of obesity increases, the 
obesity epidemic is predicted to be followed by a diabetes epidemic (Mokdad, 
2003) and the term `diabesity' has been proposed with the increasing 
recognition of a connection between obesity and T2DM (Astrup, 2000). The 
association becomes apparent with the increased average BMI at diagnosis of 
T2DM, which is 28-29 kg/m2 (UKPDS Group, 1998). Data from the Nurses 
Health Study and Health Professionals Follow up Study (Chan, 1994; Colditz, 
1995) indicate that in subjects of a BMI of 35 kg/m2, the relative risk of 
developing T2DM increases by 40 fold in women and by 60 fold in men. A link 
between obesity and T2DM is also supported by the effect of weight loss, which 
can prevent and delay the onset of T2DM (Tuomilheto, 2001), alongside other 
metabolic complications of obesity. Weight loss of 10% of body weight not only 
reduces the blood pressure and cholesterol, but also reduces the risk of diabetes 
onset by 50% and decreases the HbA1C by 15% (Jung, 1997). The exact 
mechanism of obesity related T2DM is yet poorly understood and most likely 
multifactorial. 
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1.1.4. Obesity as dysregulation of energy homeostasis 
The two major contributing factors to the development of obesity are a change 
of eating habits leading to chronic nutrient excess with a combination of low 
exercise levels as a result of our sedentary lifestyle. Other contributing factors 
are behavioural, environmental and genetic variations, though single gene 
defects account for no more than 5% of morbid obesity (Yeo, 1998). With 
regards to polygenetic influences, evolution may have selected gene variants 
resulting in a genetic makeup that is designed to maximize survival in times of 
limited nutrient availability ('thrifty genotype hypothesis') (Neel, 1998). The 
price for these adaptive genes is continuous weight gain in an environment of 
excess energy-rich food and lack of exercise (Schwartz, 2004). The self reported 
calorific intake from 1980 to 2000 may have changed little (NICE, 2001), but 
today's diet is energy denser and unhealthy food is more readily available, 
especially in the form of a high fat diet. 
Obesity is associated with abnormal adipose tissue biology resulting in ectopic 
fat deposition and fat inflammation which are explained in detail in Section 
1.4.6.. The increase of fat mass also alters secretion of AT products like 
adipokines which are proteins predominantly produced in AT. Additionally, the 
brain coordinates energy status through input on short term energy availability 
and fuel stores from fat reserves. Central response can lead to a change in 
appetite or influence peripheral metabolism and efferent signals, via the 
brainstem, can regulate fat mass per se. A yet poorly understood area is the 
pathophysiology of central pathways of energy homeostasis, some of which may 
be responsible for the origin of common obesity and possibly T2DM. There are 
a few rare genetic central feeding disorders involving hypothalamic 
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popypeptides like proopiomelanocortin (POMC) deficiency (Krude, 1998) and 
central melanocortin receptor 4 (MC4R) deficiency (Yeo, 1998). Apart from 
which there is evidence of central resistance to satiety hormones like insulin and 
leptin (Schwartz, 2005), disturbed hypothalamic sensing of nutrients like 
glucose and fatty acids (Levin, 1999; Obici, 2002a; Lam, 2005) and other 
disturbances of the hypothalamic-pituitary-adrenal axis (Koshiyama, 2006). The 
exact mechanisms of central energy regulation are discussed in more detail in 
Section 1.3. With the communication between the two organs, the fat and the 
brain being essential for energy homeostasis and feedback, a disturbance of this 
crosstalk will ultimately lead to energy imbalance. A defect could involve 
various sites of the fat brain communication network and studies of the crosstalk 
may improve the understanding of the pathogenesis of obesity. 
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1.2. Principles of energy homeostasis 
Homeostatic processes seem to have evolved to maintain stable fuel stores in the 
form of adipose tissue in the face of continuing fluctuations in availability of 
food. A simple formula of energy input = energy output describes the principle 
of energy balance by which a stable body weight is maintained. Whereas energy 
input is derived purely from food, energy output is a sum of following 
components: basic metabolic rate (BMR), the thermogenic effect of food, and 
physical activity (Berne, 1998) (Figure 1.2. ). The BMR of an adult on an 
average day is 20-25kcal (84-105 kjoules)/kg of body weight (lkcal= 4184 
joules) and is dependent on gender, age, fat mass as well as fat-free mass. BMR 
can be measured by indirect calorimetry and the use of the respiratory quotient. 
In a positive energy balance, the energy or calorie intake is greater than the 
expenditure and the energy excess is stored as glycogen in the liver or 
triglycerides in fat. 
Carbohydrate 
Fat Energy = Energy 
Input output 
Protein 
Mechanical work 
> 20% of daily 
intake to support 
spontaneous 
activity 
Thermogenesis 
5-15% of daily 
intake 
Chemical 
reactions 
BMR=60-70 % 
of daily intake 
Fuel storage 
Figure 1.2.: Energy Flow in the human organism. (Modified from Berne, 1998) 
In the daily variation of food intake, which includes the overnight fast, there are 
two distinct phases: the anabolic phase after food intake and catabolic phase 
from 4 to 6 hours after food intake till the next. The aim of the catabolic 
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metabolism is to avoid hypoglycaemia with the insulin antagonist glucagon as 
its key player. The catabolic phase is characterised by mobilisation of fuel in 
form of substrate from liver, muscle and adipose tissue. This is in contrast to the 
anabolic phase whereby excess exogenous calories are stored as glycogen in 
liver or as triglycerides (TG) in adipose tissue. Excess accumulation of TG 
stores as fat lead to obesity. Whilst adaptive responses in feeding behaviour and 
other metabolic processes should allow stable body weight, the individual's set 
point of energy balance appears to be lost in obesity. The reasons for this 
malfunction are probably multifactorial and there is also the argument of 
favourable tendency towards energy preservation which challenges the 
hypothesis of energy homeostasis (Wilding, 1997). However, after a certain 
surplus of fat tissue has accumulated, the body responds with obesity derived 
complications and diseases in favour of the existence of a disturbance in energy 
balance. Identification of a simple defect in one of the energy regulation 
pathways could potentially lead to much sought after obesity drug development. 
1.2.1. Regulation of food intake 
Appetite is regulated centrally and modulated through various peripheral 
hormonal and neuronal signals, as well as nutrients like glucose and free fatty 
acids (FFA) themselves. The brain integrates visual, olfactory and gustatory 
sensory stimuli and input from regulators of award and cognitive brain functions 
with peripheral signals which converge on hypothalamic appetite regulating 
pathways. Figure 1.2.1. gives an overview of appetite control. Whilst short term 
signals determine the size of a meal and its frequency, the long term signals 
determine the fat storage (Griffin, 2000). Of great importance is also the 
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peripheral appetite regulation by the GI- tract, which includes the pancreas 
through insulin secretion and adipose tissue (AT) derived products like leptin. 
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Figure 1.2.1.: Simplified model of appetite control and its feedback 
mechanisms. 
Leptin and insulin share common pathways (Niswender, 2003) and are 
anorexigenic (appetite reducing), i. e., they are satiety signals. They may be 
considered as the first identified peripheral proteins which enable crosstalk with 
the brain. Leptin and insulin mediate their action through central hypothalamic 
pathways and compete with orexigenic (appetite or hunger stimulating) 
neuropeptides like ghrelin and neuropeptide Y (NPY) signalling. Their central 
pathways are dependent on phosphatidylinositol 3-kinase (PI3K), tyrosine 
phosphatase-1B (PTP-1B), suppressor of cytokine signaling-3 (SOCS-3), 
adenosine monophosphate (AMP) activated protein kinase (AMPK) and the 
Janus-family tyrosine kinase- (Jak-Stat) pathway in the periphery and the brain 
(Sahu, 2004; Schwartz, 2004; Fruhbeck, 2006). 
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1.2.2. Fuel utilisation and storage 
The metabolic pathways are too complex to review in detail, but in essence, 
complex polymers derived from macronutrients are broken down to monomers 
and used as energy and metabolic building blocks. These substrates are glucose, 
fatty acids, glycerol and amino acids. They are used for fuel and energy is 
produced in the mitochondria under aerobic conditions by the Citric acid cycle 
(Krebs cycle) in which AMP is converted to ATP under production of CO2 and 
water. Excess glucose and amino acids can be converted to glycerol and stored 
with excess FFA as TG by an increase of lipogenesis; excess glucose in the liver 
can also be stored as glycogen. Amino acids make up most of the body mass 
besides water and are building material of organs and musculature. Proteins are 
not stored to be available as energy source. As such their utilisation for fuel does 
not occur without loss of vital body mass and only occurs if no other source is 
available (Frayn, 2006). Fuel storage is enhanced by the anabolic hormone 
insulin, which inhibits catabolic pathways and is a switch from fat utilisation in 
the absence of insulin to carbohydrate utilisation in peripheral tissues. Both 
insulin and macronutrients regulate transcription factors and control gene 
expression of proteins involved in `switching' between fat and carbohydrate 
utilisation. One of such pathways in the liver is via a subfamily of forkhead 
transcription factors (FOXO), which turn off glycogenolyis and influence 
lipolysis (Imae, 2003). 
1.2.3. Carbohydrate metabolism 
Glucose is an obligatory fuel source of some organs; another important source 
are ketones which can be used as substrate by brain in prolonged starvation. In 
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normal individuals, fasting glucose levels are kept in a tight range through 
constant regulation of glucose absorption in the intestine, production by the liver 
and uptake by peripheral tissues such as muscle and adipose tissue (Saltiel, 
2001). Carbohydrates need to be converted to glycogen for storage in the liver 
and muscle, because of the high osmotic potency of glucose (Frayn, 2006). 
Depending on the type of tissue and the cellular status of the tissue, its fate 
within the metabolism varies. Glucose can potentially be oxidized completely to 
CO2 and H2O or incorporated into glycogen or TG for energy storage. Besides 
its potential use for de novo fatty acid synthesis, it can also be converted into 
non-essential amino acids or partially oxidized to lactate, which may return to 
the liver for gluconeogenesis, constituting the Cori-cycle (Herman, 2006). 
1.2.4. Insulin signalling 
Insulin is a key hormone of fuel metabolism, which includes glucose uptake to 
various cells, but also regulation of gluconeogenesis and glycogenolysis in the 
liver and down regulation of hepatic glucose output (Michael, 2000). As 
mentioned previously, insulin influences energy homeostasis in the brain as well 
as fat. It controls appetite in the arcuate nucleus (ARC) of the hypothalamus and 
influences adipogenesis as will be detailed in the related sections. Insulin 
secretion from the pancreatic ß-cell is not only stimulated in response to 
circulating glucose but also to several gut hormones like glucagon-like peptide-1 
(GLP-1). These gut hormones are also known as incretins (see below). 
Insulin as well as leptin use the IRS-PI3 kinase pathway for signalling not only 
in skeletal muscle, liver and adipocytes, but also by the hypothalamus in the 
regulation of central energy homeostasis (Niswender, 2003). Insulin binds to the 
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insulin receptor (IR) which is part of the tyrosine kinase receptor subfamily like 
IGF and insulin receptor-related receptor (IRR). IR is a cell-bound receptor with 
4 subunits consisting of two a and two ß chains. Phosphorylation of the IR 
through insulin binding allows subsequent interaction and phosphorylation of 
tyrosine residues on molecules of the insulin receptor substrate (IRS) family 
(Scsti, 2001), which provide docking sites for the Src homology 2 (SH2) domain 
of phosphatidylinositol 3-kinase (P13K). P13K converts the membrane lipid 
phosphatidylinositol (4,5) biphosphate (PIP2), to phosphatidylinositol (3,4,5) 
triphosphate (PIP3). This process activates 3' phosphoinositide kinase-1 (PDK- 
1), which in turn activates protein kinase B (PKB) otherwise known as Akt. 
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Figure 1.2.4.: Main insulin signalling pathways that regulate glucose 
metabolism in muscle cells and adipocytes as discussed in the text. Activation of 
phosphoinositide-3 kinase is a major pathway in the mediation of insulin 
stimulated glucose transport and metabolism. GLUT-4 is stored in intracellular 
vesicles. (Based on Cohen, 1999 and Frayn, 2006). 
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The kinases and enzymes involved in this cascade control a variety of cellular 
processes which also regulate the insulin mediated glucose transporter 4 
(GLUT4) translocation to the plasma membrane (Ono, 2001) and enable active 
glucose transport into the cells (Figure 1.2.4. ). GLUT4 is amongst others 
expressed in adipose tissue and responsible for insulin-stimulated glucose 
transport into these tissues (Shepherd, 1999). GLUT4 mediated glucose 
transport is the rate-controlling step in insulin-mediated glucose disposal which 
is diminished in insulin-resistant states (Saltiel, 2001) and, paradoxically, down 
regulated in obesity (Kahn, 1989; Herman, 2006) 
1.2.5 Lipid metabolism 
Lipids in form of TG are the main element of the surplus body fat defining 
obesity. As such, lipid metabolism has major implications for energy control and 
the pathogenesis of obesity. Lipids enter the body in form of chylomicrons 
formed after absorption and emulsification of dietary lipids which have been 
digested by the pancreatic lipases in the intestine. Chylomicrons deliver TG to 
peripheral tissues like muscle and adipose tissue where they are hydrolysed by 
lipoprotein lipase (LPL) to FFA and glycerol. In the liver, very low density 
lipoproteins (VLDL), low density lipoproteins (LDL) and high-density 
lipoproteins (HDL) are formed. Lipoproteins are transport molecules consisting 
of a hydrophobic core of TG and cholesterol esters surrounded by phospholipids 
and a family of proteins named apolipoproteins (Ganong, 1997). They can be 
distinguished by the density and indirectly, as lipid is less dense than protein, by 
their protein content with HDL containing more protein than lipid. Non- 
esterified fatty acids (NEFA) are the transport form of energy from storage 
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depots to utilisation sites. NEFA are FA bound to albumin and not esterified to 
glycerol or any other alcohol group. Its plasma concentrations are determined by 
the rate of AT lipolysis and cellular uptake. In order to produce energy, FFAs 
need to be activated in the cytoplasm by acyl-CoA synthetase and enter the 
mitochondria to be oxidised. The end product of each round of ß-oxidation is 
acetyl-CoA which enters the Citric-acid cycle, where it is further oxidized to 
CO2 to produce energy. The storage of TG in adipocytes will be discussed in the 
next chapter. Other lipids are phospholipids (constituents of cell membranes) 
and steroid compounds and are not used for fuel storage. The transport of FFA 
into cells is less clear than glucose, it is thought to enter partially through 
diffusion and mechanisms like Acetyl-coenzymeA (CoA) synthase, which 
esterifies FFA to CoA, enabling ATP dependent intracellular transport, or 
mediated by CD36 which is distributed in adipose tissue and skeletal muscle 
(Frayn, 2006). CD36 may be regulated by insulin and exercise and recruited 
from an intracellular pool similar to GLUT4 for glucose transport. 
1.2.6. Fuel sensing 
Glucose sensors enable cells to translate the changes in glucose flux and 
participate in systemic glucose homeostasis (Hermann, 2006). Glucose entering 
the cell changes gene transcription and modulates signal transduction networks 
through its metabolites and its sensors. For example, malonyl-CoA is a product 
of the enzyme acetyl-CoA carboxylase (ACC) and a metabolite implicated in 
glucose sensing in numerous tissues, including the pancreatic ß-cell and the 
hypothalamus where it can influence nutrient uptake (Obici, 2003; Hermann 
2006). Malonyl-CoA is an allosteric inhibitor of carnitine palmitoyltransferase 1 
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(CPT 1), which regulates the transport of long-chain fatty acyl-CoAs into the 
mitochondria (McGarry, 1983). In the presence of abundant glucose, malonyl- 
CoA accumulates and inhibits fatty acid oxidation. Another intracellular nutrient 
sensor is the enzyme AMPK which is activated through falling ATP levels 
(adenosine triphosphate) (Hardie, 2003). A decrease of the ATP/AMP ratio 
leads to AMPK activation and is a signal to switch from anabolic, energy 
consuming pathways to catabolic, energy producing pathways (Fruhbeck, 2006). 
The AMPK pathway is found in several tissues and influenced by the adipokines 
leptin and adiponectin (Havel, 2004). AMPK activation increases FA oxidation 
through indirect control of malonyl-CoA synthesis and possibly by its 
degradation, and inhibits TG synthesis (Ruderman, 2003). The activation of 
AMPK may protect from ectopic fat accumulation (Minokoshi, 2002; 
Yamauchi, 2002). Hypothalamic AMPK activation increases hyperphagia and 
induces weight gain (Minokoshi, 2004) which can be inhibited by leptin, insulin 
and high glucose levels (Fruhbeck, 2006). 
1.2.7. Energy homoeostasis and cytokine pathways 
Several cytokines and fat derived factors known as adipokines, such as leptin 
mediate their action through the Jak-Stat pathway (Figure 1.2.7.1), which is able 
to interact with insulin signalling via the IRS-P13K pathway and indirectly 
influence energy homeostasis. The enzyme tyrosine phosphatase-1B (PTP-1B), 
as well as suppressor of cytokine signaling-3 (SOCS3), can terminate signals by 
cleavage of phosphate from key tyrosine residues of both insulin and leptin 
(Schwartz, 2004, Fruhbeck, 2006) (Figure 1.2.7.2. ). 
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Figure 1.2.7.1.: Jak-Stat pathway. Leptin binding induces receptor dimerization, 
activating the associated Jaks (Janus-family tyrosine kinases), which 
phosphorylate the receptor leading to conformational change (A). This allows 
juxtaposition of Jaks, which enables tyrosine-phosphorylation of other Jaks (B). 
Jak activation allows association of Stats in the cytoplasmic region of the 
receptor. The receptor-bound Stats are phosphorylated by Jaks, dissociate from 
the receptor and form dimers (C). These active dimers translocate into the 
nucleus where they regulate gene expression (D) (Adapted from Fruhbeck, 
2006). 
Insulin 
receptor 
OB-RU f- 
PT'Y- IB 
P 
IRS 
. 3'lo. rOJ 
Figure 1.2.7.2.: Jak-Stat and IRS-PI3K interaction. Activation of the Jak-Stat 
pathway can also activate the IRS-PI3K pathway, presumably due to tyrosine 
phosphorylation of IRS proteins by Jak 2 (Modified from Fruhbeck, 2006). 
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The SOCS3 deficient phenotype is thus very similar to that induced by deletion 
of PTP-1B (Spanswick, 2000; Niswender, 2001) presenting with resistance to 
diet-induced obesity and increased sensitivity to both leptin and insulin. 
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1.3. Central regulation of energy homeostasis 
The concept of centrally derived human obesity has been first described in 1975, 
observed by the destruction of the ventromedial region of the hypothalamus 
(VMH) either by tumours, inflammation, congenital malformation or trauma 
(Bray, 1975). Similarly, lesions in the paraventricular nucleus of the 
hypothalamus (PVN) in rats were observed to cause obesity (Tokunaga, 1986) 
whilst ablation of the lateral hypothalamic area (LHA) was associated with an 
increased energy expenditure and reduced food intake (Teitelbaum, 1962). 
Imaging studies with functional MRI or PET have confirmed that taste, 
olfactory and visual signals as well as nutrients affect appetite and stimulate a 
diversity of brain centres including cortex, amygdale, area postrema, limbic 
system and hypothamalus (Tataranni, 2003) of which the hypothalamus, with its 
many nuclei, appears to have a switchboard function. Information on energy 
balance from the brain and peripheral organs is collected and further processed 
in the hypothalamus, which has connections to other higher centres and the 
periphery. 
1.3.1. Hypothalamic anatomy 
The brain obtains input on both energy stores and fuel status to control the 
maintenance of a stable body weight. It is able to respond to afferent signals of 
energy status by short term regulation, e. g. in mediating appetite changes, 
influencing endogenous glucose production and modulating energy expenditure 
through mobilisation of fat stores (Schwartz, 2005). This necessitates sensing 
and translation of peripheral input into anabolic and/or catabolic signals by 
neuronal circuits which mediate energy regulation. A pivotal role has been 
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identified for the ARC, which mediates its action through second order neurons 
to other energy regulating centres of the hypothalamus like the PVN, but also 
the brainstem via the nucleus tractus solitarius (NTS) which sends efferent vagal 
signals to the periphery to mediate peripheral energy metabolism. There are two 
primary populations of neurons in the ARC (Figure 1.3.1.1. ); a catabolic or food 
inhibiting circuit of neurones expressing proopriomelanocortin (POMC)- a 
melanocortin precursor peptide- and the cocaine-and amphetamine-regulated 
transcript (CART) (Schwartz, 1997; Morton 2004); and the orexigenic hormone 
NPY and agouti related protein pathway (AGRP) (Cone, 2001). Whilst the 
catabolic population is stimulated by leptin, the latter is inhibited; several other 
hormones and nutrients act through ARC neurons although they may also have 
direct effects on other brain centres (Schwartz, 2002). 
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Figure 1.3.1.1.: Hypothalamic appetite regulating neurons in the ARC. The 
anorexigenic POMC and orexigenic NPY/AGRP neurons are interconnected. 
Electrophysiological studies show that insulin, leptin, ghrelin, melanocortin and 
nutrients act on both sets of neurons (Adapted from Cone, 2001). 
The anatomical location of the ARC is at the base of the third ventricle above 
the median eminence, which is especially permeable for certain proteins like 
insulin and leptin as one of the circumventricular organs of the blood brain 
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barrier (BBB) (Johnson, 1993). The neuronal connections within the 
hypothalamus and its communication with other brain areas are complex and not 
yet fully understood. A simplified model of hypothalamic appetite regulating 
sites is shown with Figure 1.3.1.2.. 
NPY Y1, Y5, 
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Figure 1.3.1.2: Section through the middle hypothalamus. ARC arcuate 
nucleus, VMN ventromedial nucleus, LHA lateral hypothalamic nucleus, SN 
supraoptic nucleus, DMN dorsomedial nucleus, PVN paraventricular nucleus in 
dotted line situated in the anterior hypothalamus and therefore only shown in 
relation. 
NPY and other neurons from the ARC project with their axons to the PVN. The 
LHA was originally regarded as the `feeding' centre and holds numerous NPY 
neurons and receptors. It contains orexin and MCH expressing neurons and 
glucose sensitive neurons. It entertains close connections to other areas of the 
medial hypothalamus and the brainstem. This is thought to allow processing of 
visceral functions like taste, gastric distension and the sleep-wake cycle 
(Bernardis, 1996). The VMN is thought to be a key target for the appetite 
inhibiting hormone leptin (Satoh, 1997), receives input form the ARC and 
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projects to the NTS and other hypothalamic nuclei like the dorsomedial nucleus 
(DMN) (Stanley, 2005). The DMN is thought to have an integrative information 
processing role and collects input from various other nuclei through extensive 
neuronal connections (Elmquist, 1997). 
1.3.2. Central nutrient sensing 
The hypothalamus is directly sensitive to glucose and lipids (Levin, 1999; Lam, 
2005) and can also respond indirectly to circulating macronutrients by 
corresponding changes of insulin and leptin levels (Obici, 2003). Hypothalamic 
nutrient sensing is thought to be mediated through accumulation of malonyl- 
CoA (see Section 1.2.6. ) which in turn inhibits ß-oxidation and subsequently 
leads to decreased food intake and increased hepatic insulin sensitivity (Obici, 
2003). FFA can enter BBB bi-directionally and intracerebroventricular (icv) 
infusion of long chain FFA in rats reduces food intake and NPY gene expression 
and hepatic insulin sensitivity (Obici, 2002a). Hypothalamic lipid sensing is 
therefore believed to regulate hepatic glucose metabolism via activation of vagal 
fibres which supply the liver (Schwartz, 2005). Whilst AMPK activation in the 
ARC and PVN increases appetite (see above) reduction in AMPK expression 
reduces food intake and body weight, e. g. by leptin, MCR agonists, glucose and 
insulin whilst the orexigenic AGRP increases AMPK activity (Fruhbeck, 2006). 
1.3.3. Proteins with central action on energy balance 
A humoral signal that regulates central energy homeostasis should meet the 
following criteria: its serum levels should be linked with obesity; it should enter 
the BBB and possess central receptors located in areas of energy regulation 
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(McMinn, 2000). Two proteins fulfilling these criteria are the important 
peripheral regulators of carbohydrate and fat metabolism: insulin and leptin. 
They are key regulators of catabolic cerebral energy homeostasis and convey 
signals that reduce food intake and increase energy expenditure (Schwartz, 
2004). 
1.3.4. Central role of insulin 
Insulin was the first hormone shown to play a part in central appetite control. 
Long before the identification of insulin in 1923, Bernard (1854) induced 
diabetes by puncture of the fourth cerebral ventricle ("pigüre diabetique"). 
Studies documented that icv administration of insulin increased hepatic insulin 
sensitivity and glucose production whilst reducing food intake (Woods, 1979). 
This supported Bernard's assumption of a possible central origin of diabetes. 
Contrary to this and once the cerebral glucose uptake was shown to be 
independent of insulin (Seaquist, 2001), the brain was considered by most as 
generally insulin insensitive. However, the determination that insulin entered 
through the BBB, the presence of insulin receptors and their location in brain 
areas which control food intake and energy homeostasis outweighed other data 
(Schwartz 1992a; Baura, 1993). The insulin detected in the adult brain is 
primarily of pancreatic origin entering across the BBB. Insulin sensing and 
insulin receptors are located in the hypothalamus (Schwartz, 1992a). Central 
action of insulin is mediated through the IRS-P13 pathway, (Nilwender, 2003), 
which is the same signalling pathway, which is thought to be defective in the 
pathogenesis of peripheral insulin resistance (White, 2003); whilst blockade of 
the hypothalamic insulin receptor results in hepatic insulin resistance and 
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increased hepatic gluconeogenesis (Obici, 2002c). As such hypothalamic insulin 
resistance was proposed as a contributor to hyperglycaemia in T2DM (Obici, 
2002b), and further supported the central action of insulin. 
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1.4. Adipose tissue 
1.4.1. Adipose tissue morphology 
Fat can represent up to 30-40% of body mass. AT is composed of adipocytes 
and its precursors, a connective tissue matrix, nerve tissue, stromovascular cells 
and immune cells. Pre-adipocytes are precursors of adipocytes, which are 
undifferentiated cells and serve as a store for adipocyte recruitment when cell 
expansion is necessary. The different cell types function as an integrated unit. 
Endothelial cells form the vasculature; the predominant immune cell is the 
macrophage with some leukocytes, and usually constitutes 5 -10% of cells; this 
can increase to up to 40% of the cell population within an adipose tissue depot 
with diet induced weight gain (Weisberg, 2003). WAT is the main form of fat in 
the human adult. It serves as a store of substrate/energy but also as support 
tissue and heat regulator. Heat insulation per se is a more typical function of the 
brown fat in animals, which is richer in mitochondria and enables hibernation. 
In humans the brown fat which is the prevailing form of the foetus is gradually 
lost during childhood (Symonds, 2004). WAT is formed before birth but its 
expansion occurs rapidly after birth, with an increase in hypertrophic growth 
(cell size) and hyperplastic growth (Gregoire, 1998) (see below). WAT 
adipocytes are unilocular and have a diameter which ranges from 25-200 
microns. 
1.4.2. Adipose tissue distribution 
There are two general patterns of fat distribution: upper body and lower body 
obesity. The first type is associated with an increase of subcutaneous (Sc) 
abdominal and intra-abdominal omental fat and also called central obesity. It is 
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typical of the fat accumulation in men and thus also known as `android' or `male 
type obesity' (Abate, 1996). In contrast, the obesity pattern in women is 
typically described by fat accumulation in the gluteofemoral area and thighs and 
also called `gynoid type obesity' (Amer, 1998). After the menopause, however, 
when the site of oestrogen production changes from the ovary to the fat 
(Björntorp, 1995), women also tend to develop central obesity. This distribution 
of WAT is critical in relation to the manifestation of obesity related 
complications like cardiovascular disease and T2DM which is increased in 
central obesity (Vague, 1980, Clausen, 1996). Central adiposity is associated 
with an increase in visceral fat mass to which the increased health risk was 
traditionally attributed (Despres, 1995). However, an argument against its sole 
contribution in disease risk is its proportion to overall fat mass which can only 
account for 20% in an obese individual. The remaining 80% are composed of Sc 
fat and are likely to have a considerable impact on an obese individual's 
metabolic profile (Abate, 1996; Montague, 2000). However, the catecholamine 
responsiveness of abdominal cells is greater than in gluteo/femoral regions, 
which triggers lipolytic activity (see below) (Wahrenberg, 1989) and could 
explain the increased insulin resistance seen in central obesity (Stears, 2001). As 
such it is still unclear as to which abdominal fat depot is responsible for the 
enhanced disease risk (Fain, 2004). Besides the gender difference of fat 
distribution and the overall higher fat mass in women (Krothiewski, 1983), there 
are also ethnical diversities. For instance, age and BMI matched people of Asian 
origin have a much higher percentage of body fat than white Europeans 
(Deurenberg, 1998; He, 2001). This may contribute to the much higher 
cardiovascular mortality and risk of T2DM in the South Asian 
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population(Abate, 2001); a similar fat related cardiovascular risk was also 
reported in the Afro-Caribbean population (Bhopal, 2002). 
1.4.3. Adipose tissue expansion 
WAT is unique in its ability to increase rapidly in mass which naturally occurs 
after birth (Gregoire, 1998) or energy excess. The expansion of fat mass usually 
entails a combination of an increase of adipocyte cell number (hyperplastic 
growth) and cell differentiation of pre-adipocytes (collectively called 
adipogenesis) as well as an increase in cell size (hypertrophic growth). 
Preadipocytes are derived from pluripotent stem cells which can differentiate 
into mature adipocytes but also chondrocytes, osteoblasts or myocytes. Thus the 
process of adipocyte acquisition requires replication and clonal expansion of 
preadipocytes, which are located in the stromal-vascular fraction of adipose 
tissue to enable adipose tissue growth (Feve, 2005). The ability of adipocytes to 
proliferate gives no limits to the extent of adiposity and adipocyte 
hypercellularity is a classical sign of obesity (Faust, 1984). 
1.4.3.1. Adipogenesis 
The process of adipogenesis can be divided into the basic stages of growth 
arrest, cell expansion and cell differentiation. From in vitro models, it was 
derived that the initial stage of adipogenesis or preadipocyte differentiation 
requires re-entrance of growth arrested cells into the cell cycle, which is a cyclic 
process that controls mitosis in all eukaryotic systems. One cell cycle composes, 
the doubling of the genome during the S phase followed by the cellular division 
during mitosis (M phase). In between the M and S phase are the Gap 1 and 2 
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(G I and 2) phases which allow the cells to prepare for DNA synthesis or mitotic 
division. This is regulated by transcription factors like tumour suppressor 
retinoblastoma protein (Rb) and E2F, which initiate transcription of further 
proteins depending on their phosphorylation status (MacDougal, 1995). In 
addition, contact inhibition represses in vitro clonal expansion, arrests cell 
proliferation and commits the cell to differentiation. However, given the correct 
hormonal stimuli, contact inhibition is not required for in vitro differentiation 
(Gregoire, 1998). 
Adipocyte differentiation is coordinated by two main groups of transcription 
factors CCAAT/enhancer binding proteins (C/EBPs) and peroxisome 
proliferators- activated receptor-y (PPARy). C/EBPs are induced in the early 
stages of adipogenesis which initiate further transcription factors and eventually 
also induce PPARy, and are thus responsible for maintaining PPARy expression. 
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Figure 1.4.3.1.: Balance between pro- and anti-adipogenic environmental 
signals (Modified from Feve, 2005). 
PPARy belongs to a family of nuclear receptors that initiate the transcription of 
a multitude of genes and is predominantly expressed in adipocytes (Schwarz, 
1997). After their activation by hormonal and nutrient stimuli, both transcription 
factors, especially C/EBPa, control gene expression of AT specific proteins 
related to the metabolic actions of insulin such as resistin (Seo, 2003), leptin 
(Mason, 1998), and GLUT-4 (Gross, 2004) for which they are vital. 
Furthermore, FFA are endogenous ligands of peroxisome proliferators- activated 
receptors (PPARs) and regulate their gene expression which can control 
adipogenesis. 
The potential to undergo differentiation is also depot-specific and Sc pre- 
adipocytes differentiate more easily than visceral pre-adipocytes (Prins, 1997). 
Figure 1.4.3.1. displays some of many transcription factors, nutrients and 
hormones that influence adipogenesis. Factors promoting adipogenesis include 
insulin in part through activation of the insulin like growth factor-1 receptors 
(IGF-1R), a family of receptors which regulate insulin mediated growth. IGF- 
1Rs signal primarily through IRS with subsequent increase in activity of P13-K 
which is thought to be vital to adipocyte differentiation (Xia, 1999; Miki, 2001). 
Glucocorticoids can induce differentiation trough glucocorticoid receptors 
present in preadipocytes which stimulate expression of C/EBPS (Cao, 1991) and 
PPARy (Wu, 1996). In addition, 11 ß-hydrosteroid dehydrogenase 1 (11(3- 
HSD1), the enzyme responsible for conversion of inactive cortisone to active 
cortisol sensitises tissue to glucocorticoids and is significantly elevated during 
adipocyte differentiation with higher expression in visceral adipose tissue 
(Stears, 2001). Furthermore, there are inhibitors of adipogenesis which hinder 
the turnover of new adipocytes such as tumour necrosis factor alpha (TNFcL), 
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interleukin 6 (II. 6) (Knowler, 1981; O'Rahilly, 1997), and interferon gamma 
(IFNy). The mechanism may be indirect inhibition of C/EBPct and PPARy, e. g. 
by TNFa (Wu, 1999) or mediation through the activators of transcription 
(STAT), e. g. 1L6 (Stephens, 1999; Stewart 1999). As some of these cytokines 
are also secreted by the mature adipocyte (adipokines) their action may be part 
of an AT growth controlling feedback mechanism. 
1.4.3.2. Hypertrophic growth 
Fat cell size is primarily controlled by its needs as storage organ of TG and the 
availability of surplus calories leads to increase in cell size. The storage of post- 
prandial TG leads to an increase of adipocyte cell size and adipose tissue has an 
almost unlimited capacity of cellular expansion which leads to obesity 
(Fruhbeck, 2001). The most abundant molecules in AT are TG, which are 
broken down to NEFA and transported as a complex with albumin. Plasma 
NEFA concentrations are derived from AT lipolysis and dependent on the 
uptake from plasma for oxidation to carbon dioxide or for re-esterification to 
TG. 
1.4.4. Adipose tissue turnover 
The most obvious function of AT is the accumulation and storage of surplus 
substrate as lipids in the anabolic phase in form of FFA, glucose, which can be 
converted to glycerol for TG synthesis or to FA by de novo lipogenesis which is 
stimulated by insulin. FAs are esterified to form TG for deposit in the adipocyte 
lipid droplet (Figure 1.4.4.1. ). In contrast, the NEFA released from the adipocyte 
does not convert to carbohydrate, but can be utilised for ketogenesis in the liver. 
However, the glycerol released from TG breakdown can be substrate for 
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gluconeogenesis in the liver similar to alanine and lactate; this process is 
inhibited by insulin and stimulated by glucagon (Frayn, 2006). 
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Figure 1.4.4.1: Fatty acid and glucose metabolism in WAT. NE norepinephrine, 
AD adrenaline (Adapted from Frayn, 2006). 
The balance between the sequestering of TG and their eventual release is 
controlled by two principal processes of lipolysis and lipogenesis. Lipogenesis is 
defined as the uptake of FFA, mostly from dietary and hepatic sources from the 
circulation with the help of the enzyme lipoprotein lipase (LPL) to be esterified 
with glycerol-3-phosphate (derived from glucose by glycolysis) to form TGs. 
Lipolysis is the sequestering of TG and the release of FFA into the circulation 
through hydrolysation of triglycerides to glycerol and fatty acids mediated by 
hormone sensitive lipase (HSL) and relevant isoforms (Ramsay, 1996). LPL is 
situated within the luminal side of the capillary endothelium and activated by 
insulin, cortisol (Stears, 2001), oestrogens and its gene expression increased by 
PPARy (Frayn, 2006). The resulting fat storage in the underlying form of TG is 
further enhanced by simultaneous inhibition of HSL by insulin. The 
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ubiquitously expressed enzyme HSL is activated via phosphorylation by 
epinephrine, norepinephrine, glucagon, and testosterone. The differential action 
of sex steroids on adipose tissue turnover may be responsible for the difference 
in depot fat distribution between male and female subjects (Ramirez, 1997). 
Insulin inhibits HSL partially through decreases of cyclic adenosine 
monophosphate (cAMP) required for HSL activation (Onuma, 2002). Overall 
insulin is a potent promoter of adipose tissue storage (Figure 1.4.4.2). Increased 
glucose uptake after induction of GLUT4 allows improved G3P availability for 
fatty acid re-esterification. The pathways that mediate insulin's metabolic effects 
diverge downstream and show differential sensitivity to varying levels of insulin. 
The antilipolytic effect of insulin requires much lower insulin concentrations 
than stimulation of glucose transport. Hence, even in insulin-resistant states in 
which glucose transport is impaired, sensitivity to insulin's antilipolytic effect is 
relatively preserved, resulting in maintenance or expansion of adipose stores 
(Kahn, 2000). 
Other regulators of adipose tissue turnover are nutrients through independent 
pathways and gene regulation of carbohydrate responsive element binding 
protein (ChREBP) and sterol responsive element binding protein (SREBP) 
(Frayn, 2006). 
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Figure 1.4.4.2.: Insulin as promoter of adipose tissue storage. Many of insulin's 
metabolic pathways are regulated by P13K signalling. Insulin promotes 
adipocyte differentiation, lipogenesis by uptake of glucose and FFA and through 
induction of transcription factors like SREBP-1c. Insulin also inhibits lipolysis 
(Adapted from Kahn, 2000). 
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Figure 1.4.4.3.: Nutrients and hormones alter adipocyte gene expression with 
which they regulate adipose tissue mass (Based on Frayn, 2006). 
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1.4.5. White adipose tissue and its innervation 
Another key regulator of fat homeostasis, especially fat mobilization, is AT 
innervation. Sympathetic nervous system (SNS) denervation leads to weight 
gain through increase of WAT mass and hypercellularity suggesting a pivotal 
role of the SNS in the development of obesity (Bowers, 2004; Bartness, 2005). 
Evidence of SNS innervation of adipocytes other than through transmitter 
spillover from blood vessels was finally highlighted by Cinti (2001), who 
observed nerve fibres in close proximity to adipocytes. WAT has also sensory 
innervation with CGRP as one of its mediators, but parasympathetic nervous 
system innervation is controversial. The lack of immunoreactivity for the 
parasympathetic marker vesicular acetylcholine transporter (VAChT) in WAT 
argues against this claim (Bartness, 2005). However, studies which have used 
vagal denervation show changes of fat metabolism with increase of fat growth 
and induction of insulin resistance. This findings support parasympathetic 
control of fat and a possible role in the pathogenesis of T2DM (Kreier 2002; 
Fliers, 2003). 
Traditionally it was believed that adrenaline derived from the adrenal medulla 
(Hillarp, 1954) was the principal stimulant which activates membrane bound ß- 
adrenergic receptors of WAT to activate lipolysis. This was supported by the 
evidence of rigorous lipolytic activity induced by adrenaline when added to 
isolated adipocytes in vitro. Based on the observation that adrenal demedullation 
does not inhibit lipolysis and lipid mobilisation, it is now believed that the 
neurotransmitter noradrenaline (NA) acts as the principal initiator of lipolysis in 
WAT mediated through control of cerebral sympathetic innervation and its 
postganglionic release (Bartness, 2005). There are marked differences in adipose 
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tissue from humans and rodents, not only by the lack of BAT but also 
differences of receptor type and distribution in WAT. As such, the predominant 
catecholamine receptor in human adipose tissue is the ß-2 adrenoceptor as one 
of four G-protein-coupled adrenergic subtypes (a-adrenoceptor and ß-1,2,3 
adrenoceptor) (Amer, 1996; Sennitt, 1998; Rayner, 2001). 
The human WAT shows depot specific innervation (Dodt, 1999) with higher 
lipolytic activity in visceral fat (Hoffstedt, 1997). The fact that Sc adipocytes 
possess more cx2- and fewer ß-adrenoceptors than visceral fat cells explains in 
part the lower lipolytic capacity of Sc tissue (Mauriege, 1987). Also, there is a 
gender dimorphism in lipolytic activity and the typical male fat distribution is in 
part related to a greater a2-adrenergic activity and resistance to NA in the upper 
body combined with an overall reduced lipolytic activity (Lafontan, 2000; 
Ramis, 2006). 
The turnover of NA in WAT increases with cold exposure (Garofalo, 1996) and 
fasting (Migliorini, 1997), which in turn decreases the adipokine leptin; as such, 
this implies a tight connection of SNS and leptin regulation. SNS blockade, e. g. 
by use of a -methyl-p-tyrosine (a-MPT)- an inhibitor of a rate limiting step in 
catecholamine synthesis increases circulating leptin levels and leptin gene 
expression. Not surprisingly, the observed leptin increment in obesity is 
associated with reduced sympathetic innervation (Rayner, 2001). Conversely, as 
part of a feedback regulation, central leptin can stimulate sympathetic activity in 
WAT (Rayner, 2001) (Figure 1.4.5. ) 
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Figure 1.4.5.: Sympathetic regulation of WAT: NA stimulates ß-adrenoceptors, 
which leads to mobilisation of free fatty acids and inhibits the secretion of 
leptin. The adrenal medulla derived adrenalin stimulates ß-adrenoceptors in the 
liver which raises blood sugar, but may only have little influence on WAT other 
than at times of hypoglycaemia (Adapted from Rayner, 2001). 
1.4.6. The endocrine function of adipose tissue 
With the discovery of the first adipokines it became apparent that fat is able to 
exert endocrine effects and influence other systems. The pleiotropic functions of 
AT thus comprise autocrine (influence on same cell type), paracrine (local 
involvement of other cell types) and endocrine effects. Through their presence 
in circulation they can influence the regulation of glucose, blood pressure, 
regulate systemic inflammation and central appetite and mediate feedback on 
energy homeostasis. Figure 1.4.6. gives a simplified overview of the diverse 
systemic actions of adipokines. 
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Figure 1.4.6.: Pleiotropic effects of leptin, adiponectin and ASP (Adapted from 
Havel, 2004). 
The adipokines relevant to the topic and these studies are leptin, adiponectin, 
resistin which are discussed later in separate sections. Additionally, the 
inflammatory adipokines, e. g. interleukin-6 (IL-6) and tumour necrosis factor-a 
(TNF-ct), have been under much scrutiny and have been associated with the state 
of subclinical inflammation found in obesity (Pickup, 1997). Most of these 
inflammatory cytokines are not AT specific but are also produced by 
macrophages and only a third of circulating human IL-6 is thought to be derived 
from mature adipocytes within AT (Mohamed-Ali, 1997). TNF-a and IL-6 have 
been associated with cachexia, reduced fat storage and T2DM (Stears, 2001); 
they reduce LPL activity (Greenberg, 1992) and stimulate lipolysis (Nonogaki, 
1995; Botion, 1999). The increase of lipolytic activity can contribute to elevated 
systemic NEFA (Makino, 1998). 
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Adipokine Function Obesity 
Leptin Energy homeostasis by Increase (Considine, 1996) 
regulating energy intake 
and expenditure, satiety 
and appetite (Montague, 
1997) 
Adiponectin Energy homeostasis, Decrease (Hotta, 2001) 
enhances AMPK activity 
(Yamauchi, 2001; 2002) 
Resistin Insulin resistance Controversial (Tovar, 
(Steppan, 2001a) 2005) 
TNF-a Reduce LPL activity, Increase in AT in humans 
stimulate lipolysis (Botion, and rodents (Kern, 1995) 
1999), decrease insulin 
sensitivity, (Fruhbeck, 
2001) 
IL-6 Mediator of inflammation Increased plasma 
and host defence, concentration in humans 
influences insulin and rodents (Vozarova, 
sensitivity, reduces LPL 2001) 
and increases HDL activity 
(Fasshauer, 2003) 
ASP Increases TG synthesis Increased (Sniderman, 
(Cianflone, 2003) 2000) 
Angiotensinogen Regulator of blood Increased (Stears, 2001) 
pressure (Stears, 2001) 
PAI-1 Potent inhibitor of Increased in the metabolic 
fibrinolytic pathway syndrome and T2DM 
(Fruhbeck, 2001) (Juhan-Vague, 1997) 
Table 1.4.6.: Adipokines. Summary of relevant adipokines by review of 
literature as referenced. 
Other adipokines are the adipokine acylation stimulating protein (ASP) which is 
purely adipocyte derived (Sniderman, 2000) and plasminogen activator 
inhibitor-1 (PAI-1), which is also produced by other cells (Alessi, 1997). ASP 
increases the efficiency of adipocyte TG synthesis, inhibits HSL mediated 
lipolysis (Cianflone, 2003) and enhances the postprandial lipid clearance 
(Murray, 1999). Whilst ASP levels are higher in obese subjects (Sniderman, 
2000) the role of ASP in the pathogenesis of obesity is uncertain. PAI-1 is a key 
inhibitor of fibrinolysis and found in higher levels in cardiovascular disease 
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(Juhan-Vague, 1996). Angiotensinogen as well as angiotensin-converting 
enzyme (ACE) are also widely expressed in human AT, higher in visceral fat, 
increased in obesity and associated with obesity related hypertension (Stears, 
2001). Other AT derived proteins are retinoids (Tsutsumi, 1992), oestrogens and 
some more recently discovered adipokines visfatin, obestatin and nesfatin. The 
function of these adipokines are summarised in Table 1.4.6.. Adipokines can 
take part in central energy regulation, e. g. leptin, or influence insulin secretion 
and sensitivity (Pischon, 2004; Harris, 1998). As such a dysregulation of 
adipokine function could contribute to the development of obesity (Rajala, 
2003). 
1.4.7. Dysregulation of adipose tissue function 
There are at least two disease entities with common features attributable to a 
dysfunctional fat regulation. They are characterized by `too little and too much' 
fat mass. The abundance of AT is characterized by the obese phenotype and the 
opposite by the complete or partial loss of AT is found in lipodystrophy or 
lipoatrophy. Lipodystrophy usually result from rare genetic disorders with 
marked pheno- and genotypic heterogeneity, but can also be caused by immune 
disease or be drug-related, e. g. a consequence of retroviral therapy in patients 
with HIV infection. These patients suffer from metabolic complications similar 
to those found with obesity, such as insulin resistance/T2DM, hepatic steatosis, 
hypertriglyceridemia and leptin deficiency, whilst leptin therapy in these 
patients partially reverses the insulin resistance and hyperlipidaemia (Lee, 
2006). Similarly, mice with surgical removal of fat also develop insulin 
resistance (Weber, 2000). 
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Another feature of obesity is ectopic fat accumulation which is accumulation of 
excess TG in non-adipocytes. Non-AT is not adapted for TG storage which 
leads to steatosis, intramyocellular lipid accumulation and ß-cell lipotoxicity 
(Shimabukuro, 1998) and lipid induced cell death (lipoapoptosis). Failure to 
confine surplus NEFA to WAT and increased lipolysis can have the 
consequence of chronically high circulating NEFA levels and is thought to be 
diabetogenic (Unger, 2003; Makino, 1998). These are toxic to the pancreatic ß- 
cell (Mason, 1999) and impair insulin signalling in liver and muscle (Dresner, 
1999; McGarry, 2002). Whilst the causality of NEFA and insulin resistance is 
not without controversy and some studies claim the elevation of NEFA is rather 
a consequence of insulin resistance and a response to high sympathetic tone 
(Byrne, 1999). 
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1.5. Crosstalk of adipose tissue and the brain 
Adipokines are secreted into the systemic circulation and can mediate endocrine 
actions through widely expressed receptors. This enables them to communicate 
with various organs including the CNS (see above). The concept of a 
hypothalamic-adipocyte axis was described as early as 1991 by Roncari (1991). 
Most recent theories of the fat-brain axis assume that the same appetite 
regulating molecules and/or their receptors are expressed in both sites: the 
hypothalamus and the adipocyte and that they are able to modulate adipogenesis 
(Shimizu, 2005). 
1.5.1. The blood-brain barrier and blood-CSF barrier 
To enable a circulating protein to be a mediator of central action it needs to be 
able to cross the blood-brain or blood-cerebrospinal fluid (CSF) barrier. The 
tight junctions between the cerebral endothelial cells at the blood-brain interface 
(BBB) and between choroid plexus epithelial cells (blood-CSF barrier) regulate 
the entry of molecules (Saunders, 1999). CSF is produced by the choroid plexus, 
which is a highly vascularised paraventricular `cauliflower' like structure of 
convoluted pia mater. The adult human CSF volume is about 120 -150mL with a 
turnover of about 5 hours. It is produced with a rate of about 2lmIJhr and 
considered to be constant within a normal intraventricular pressure range 
(Katzmann, 1970). After circulating from ventricles to the spinal canal and over 
the cerebral hemispheres, it eventually drains into the venous blood absorbed by 
the arachnoid granulations of the superior sagittal sinus. Production and 
absorption through the choroid plexus are at a steady state and movement of 
molecules within the CSF enhanced by microvilli of the outer membrane of the 
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choroids by the epididymal cells. The epididymal cells have tight junctions and 
allow only selective entry into the CSF. A high gradient can therefore be 
maintained between the choroid plexus vessels and CSF, allowing only 
particular lipophilic molecules to enter (Saunders, 1999); with this it has a 
dynamic regulatory role of the BBB barrier in the entry of circulating proteins; 
the presence of a protein in the CSF therefore assumes a certain role and 
function. A steady state and equalisation of brain/plasma and CSF/plasma ratio 
is not achieved because of the `sink effect' of CSF entertained by its continuous 
turnover, which reduces the steady state concentration of molecules penetrating 
into CSF and brain with the effect being greater with slower penetrating 
molecules of larger radius and more lipid-insoluble molecules (Davson, 1969; 
Saunders, 1999). Proteins can enter the CSF from the blood or the brain. Brain 
derived proteins enter into the CSF primarily through the ventricular and 
cisternal space and their concentration between normal ventricular and lumbar 
spine is decreasing. This is in contrast to the blood derived proteins which are 
higher in the lumbar region (Reiber, 2001). The kinetics of the actual protein 
transport across the BBB are poorly understood. Entry is possible by simple 
diffusion, facilitated diffusion or by receptor mediated transcytosis (Saunders, 
1999) as proposed for the insulin blood brain transport by Baura (1996). Insulin 
transport has recently received much attention in the search of a vector to enable 
entry of drugs into the CSF (Boado, 2007). Tanycytes, which are bipolar cells 
bridging the cerebrospinal fluid (CSF) to the portal capillaries may link the CSF 
to neuroendocrine events (Peruzzo, 2000). 
The human ARC in the adult brain is separated from the peripheral circulation. It 
is in close communication with the median eminence, which is especially 
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permeable for some proteins and is one of the circumventricular organs which 
have permeable fenestrated capillaries (Johnson, 1993). 
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Figure 1.5.1.: The blood brain barrier (a) Cerebral endothelial cell, tight 
junction (arrow); (b) choroid plexus epithelial cell (Ep) tight junction; (c) 
arachnoid tight junction (adapted from Saunders, 1999) 
The appetite regulating proteins insulin and leptin enter the CSF through 
saturable transport (Baura, 1993), whilst NPY, polypeptide P (PYY) and GLP-1 
enter the BBB through non-saturable mechanisms similar to diffusion (Kastin, 
1999; Nonaka, 2003; Kastin, 2002). Experimental methods testing the entry of 
these proteins typically involve intravenous injection of the radioactive labeled 
protein in question, vascular depletion studies and estimation of the effect of 
additional unlabeled protein on the total radioactivity through uptake of the 
protein in the brain parenchyma (Nonaka, 2003). 
The BBB can be affected by several disorders which have been intensively 
studied in connection with penetration of pharmacological agents. Of particular 
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interest is the increased permeability of the BBB for insulin in experimentally 
induced diabetes (Banks, 1997), a possible disturbance of BBB with 
hypertension, cerebral ischemia and Alzheimers' disease (Banks, 1996). The 
changing albumin quotient in many neurological diseases however, is an 
indicator of changing CSF flow rate rather than morphological "leakage" of the 
BBB (Reiber, 2003). 
1.5.2. Transport from CSF to hypothamic sites of appetite regulation 
In understanding the mechanisms of transport from the CSF to the hypothalamus 
brain-perfusion studies in rodents have suggested a differential regulation of the 
CNS entry of proteins depending on the brain area in question (Zlokovic, 2000). 
For instance, despite extensive research of leptin transport to the ARC as site of 
its action, leptin entry is poorly understood. Many neurons of the hypothalamus 
nuclei are isolated from the BBB circulation yet express a high number of leptin 
receptors (Baskin, 1999). Hypothalamic neurons are extremely sensitive to 
binding of leptin, yet due to too low maximal binding capacity the exact binding 
constants are difficult to determine (Corp, 1998). Hypothalamic leptin uptake is 
up to 37 times faster than in other brain regions and appears to be mediated by 
high affinity transporters with KM of 0.2ng/mL (Zoklovic, 2000). Whilst leptin 
receptors are found at the BBB (Bjorbaek, 1997), there is no evidence that they 
are able to assist the transcytosis of this protein (Zlokovic, 2000). It is thus yet 
unclear whether leptin transport to its hypothalamic sites of action is CSF 
derived, blood derived (Banks, 1996) or through diffusion from the median 
eminence of the hypothalamus which lacks the BBB (Zlokovic, 1995; Zlokovic, 
2000). 
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1.5.3. Central action of adipokines: `The fat-brain axis' 
The adipokine leptin signals satiety through interaction with neurons in the ARC 
leading to reduced food intake. Its central action is well described and will be 
detailed in Section 1.6.2.. However, little is known about the potential central 
action of the adipokines adiponectin or resistin in humans and there is little 
evidence from rodent studies. Table 1.5.3. gives an overview of central effects 
of adipokines and proteins involved in the regulation of hypothalamic energy 
homeostasis. 
1.5.4. Neurotransmitters and fat metabolism: `The brain-fat axis' 
Whilst AT stores have to match the body's overall surplus or deficit of energy 
there must input about the body's energy status from one or more sources. 
Nerve fibres are located in close proximity of adipocytes (Cinti, 2001). It is well 
established that various neurotransmitters especially neurotransmitters of the 
sympathetic system can influence AT. These can be activated by stimulation of 
the autonomic nervous system via NTS and allow feedback on energy status to 
the AT as shown by the example of central acting leptin (see below). The 
neurotransmitter and gut hormone ghrelin which will also be further discussed in 
a separate section can also influence adipose tissue mass through central 
activation as shown by intracerebroventricular (icv) infusion (Theander-Carrillo, 
2006). Whilst it may appear surprising to find ghrelin as the orphan ligand of the 
growth hormone secretagogue receptor (GHSR) predominantly produced in the 
gastrointestinal tract and act as neurotransmitter in the brain (Kojima, 1999), it 
is reasonable to assume that neurotransmitters including ghrelin may also be 
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secreted by adipocytes. Some neurotransmitters have more recently been shown 
to be present in WAT at mRNA level (Yang, 2003). 
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1.6. Leptin 
1.6.1. Leptin in adipose tissue 
Leptin, or OB protein, is a 16kDA protein consisting of 167 amino acids. It was 
identified through cloning of the gene responsible for severe obesity of the 
ob/ob mouse (leptin deficient mouse) in 1994; it is released predominantly from 
adipocytes (Zhang, 1994). Increased deposition of TG in adipose tissue raises 
leptin secretion. Leptin shows depot specific expression which is 2.5 times 
higher in Sc abdominal versus omental fat (Montague, 1997). Its peripheral 
actions ranges from activation of the immune system, haematopoesis and 
angiogenesis; it is also a modulator of fertility and can act as growth factor in 
the brain (Rayner, 2001). Moreover, it is an important regulator of energy 
homeostasis especially through central regulation of satiety which will be 
discussed separately in Section 1.5., but also a regulator of peripheral 
metabolism. Circulating leptin levels show strong positive correlation with fat 
mass (Considine, 1996) that has led leptin to be regarded as `the lipostatic 
factor' (Havel, 2004). Complete leptin deficiency in rodents and humans as well 
as defects in the leptin receptor result in marked hyperphagia and severe obesity 
(Pelleymounter, 1995; Montague, 1997; Strobel, 1998), which is reversible with 
recombinant (rh) leptin treatment through reduction of hyperphagia and fat mass 
(Farooqi, 1999). These mutations are however rare and leptin plasma levels in 
ordinary human obesity are severely elevated (Considine, 1996), which is 
thought to be due to leptin resistance. Thus, not surprisingly, leptin treatment of 
obese patients without leptin deficiency does not result in effective weight 
reduction (Hukshorn, 2000). Leptin deficiency and gene mutations of leptin and 
its receptor carry the clinical phenotype of obesity. In leptin deficiency or 
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resistance excess TGs are stored in maladaptive non-adipose tissue highlighting 
the potential of leptin as protector from ectopic lipid storage. This protective 
effect is thought to be mediated through upregulation of AMPK (Minokoshi, 
2002; Unger, 2003). Leptin is antidiabetogenic: it lowers glucose and improves 
insulin signalling (Harris, 1998; Minokoshi, 2004), but leptin can also inhibit 
insulin gene expression through use of other receptor isoforms and inhibit 
insulin secretion in the pancreatic ß-cells (Ahren, 1999; Seufert, 1999; Kieffer, 
1997). Leptin is tightly regulated by SNS innervation of WAT (Rayner, 2001), 
which could be responsible for reduced leptin with fasting and cold exposure. 
Other important regulators of leptin in WAT are glucocorticoids (Halleux, 
1998), cytokines like TNF-a and insulin (Rayner, 2001; Cammisotto, 2005) 
(Figure. 1.6.1. ). There is also evidence that nutrients like glucose and lipids 
induce leptin mRNA expression (Wang, 1998). 
Leptin 
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TNF« 124.96 h) 
Figure 1.6.1: Regulators of leptin production in WAT. Factors which involve 
the SNS are shaded (Adapted from Rayner 2001). 
Leptin follows a circadian rhythm and rapid changes in ob-gene expression, e. g. 
with fasting are rapidly reversible and not associated with a change in body 
adiposity (Trayhurn 1995). Thus a short term leptin regulation needs to be 
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carefully distinguished from a long term regulation which can enable energy 
storage. 
The leptin receptor is a member of the cytokine receptor family. Alternative 
splicing of the gene product leads to different transcripts: the long, three short 
and the soluble forms of the leptin receptor (Chan, 2002). The soluble receptor 
is the major leptin binding protein and modulates leptin action by increasing its 
clearance and preventing binding to the ubiquitous membrane receptor 
(Lammert, 2001; Huang, 2001). The relationship of free and bound leptin levels 
is functionally important and altered with BMI and age (Magni, 2005). Leptin is 
able to interact with various signalling factors and establish cross-talk with 
different signal transduction systems, e. g. it can signal with the Jak-Stat and 
IRS-P13K pathways (Fruhbeck, 2006) as described above. 
1.6.2. Central action of leptin 
Leptin meets the criteria essential for central action and covers the prerequisites 
for a role in energy homeostasis: circulating leptin is positively correlated with 
obesity; it enters the CNS through the vascular blood-brain barrier in a saturable 
mechanism (Baura, 1996) and the blood-CSF barrier (Schwartz, 1996b) with 
help of the short forms of the leptin receptor (El-Hashimi, 2000). Choroid plexus 
binding sites for leptin have been confirmed by Malik (1996). Leptin inhibits 
NPY mRNA expression/ synthesis and NPY release in the ARC and the leptin 
receptor ob-R is co-expressed with NPY in the neurons of the ARC (Stephens, 
1995; Schwartz, 1996a). In rodent models of leptin deficiency (ob/ob mouse) 
NPY is over-expressed consistent with a negative feedback regulation (Wilding, 
1993). Simultaneously to NPY inhibition leptin elicits opposite activity on the 
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anorexigenic POMC neurons which contains ob-R and increases its expression 
in the ARC (Thornton, 1997). aMSH (melanin stimulating hormone) derived 
from the precursor POMC is also anorexigenic and acts through the melanin 
concentrating hormone receptor MC4-R in the LHA, which is another 
downstream regulator of leptin. aMSH can also be found in the general 
circulation and inhibits leptin expression in the adipocyte through MCIR and 
MC5R (Shimizu, 2005), which may be part of a feedback mechanism. CSF 
leptin levels are higher in the obese than in lean subjects and decrease after 
weight loss (Nam, 2001); and serum leptin levels have a similar association with 
BMI. The fact that leptin signalling at the hypothalamus inhibits food intake but 
the plasma and CSF levels are elevated in obesity led to the theory of leptin 
resistance in obesity. Interruption of hypothalamic pathways, e. g. through 
microinjection of colchicine inhibit the effect of leptin which implies the 
importance of intact central pathways and also suggests the possibility of central 
leptin resistance in obesity (Kalra, 1998). Additionally, BBB studies propose 
that a considerable part of the leptin resistance is due to a defect in the transport 
system which may be further enhanced by obesity related hypertriglyceridaemia 
(Caro, 1996; Banks, 2003). This disruption could potentially be bypassed by 
intranasal leptin administration (Kastin, 2006). Another proposed mechanism of 
leptin resistance is disturbed leptin signalling at the level of the hypothalamus 
(Fei, 1997). Neuronal activation of the leptin receptor involves the Jak-Stat 
pathway (Cowley, 2001) and SOCS-3 expression (see also Section 1.2.7. ) and 
its disturbance may lead to resistance (Gao, 2004). A reduction of the 
intrahypothalamic leptin signals leads not only to increased hunger, but also to 
suppression of plasma thyroid hormone levels (Spiegelman, 2001) which are 
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otherwise increased by leptin (Ahima, 1996). Taken together, the precise 
mechanisms underlying leptin resistance have not yet been securely established, 
but emphasise the central role of the adipokine leptin in appetite control. 
1.6.3. The feedback cycle of leptin 
Leptin exhibits feedback via sympathetic neurons to WAT. Evidence of 
sympathetic connection between appetite regulating centres and AT was gained 
through studies using retrograde tracers and injection of pseudorabies virus 
(PRV) into fat pads, in hamsters. These showed that PRV could be traced back 
to the NST of the brainstem (Mercer, 1998) and the PVN (Bartness, 1998). 
Stimulation of the PVN, which amongst other regions of the hypothalamus 
contains leptin receptors, induces sympathetically mediated lipolysis (Bartness, 
1998) which in theory should lead to fat shrinkage in return. 
Food intake 
{-ve) Leptin (+ve) 
Hypothalamus 
OB-Rb receptors 
Glucose (+ve) 
(+ve) Other utilisation 
(+ve) it peripheral -s UCP1 in BAT (+ve) 
Sympathetic / 
nervous (+ve) 
system 
tissues 1º UCP2 and UCP3? 
WAT 
Leptin (-ve) o/ 
Other secretions (variable) 
Fatty acids (+ve) 
UCP2 (+ve) 
Figure 1.6.3.: Feedback loop between fat and brain via SNS. Hypothalamic 
leptin signalling not only inhibits food intake but also stimulates sympathetic 
activity through NA release. Sympathetic stimulation increases glucose 
utilisation, and possibly also heat production through uncoupling proteins in fat 
and muscle and provides negative feedback to adipocytes to limit further leptin 
production (Adapted from Rayner, 2001). 
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Further peripheral studies have identified a short feedback loop in the adipocyte 
itself, by which leptin's paracrine function is inhibited by leptin itself via post 
receptor blockade by SOCS-3 (Wang, 2005). This enables fat storage when AT- 
derived leptin levels are rising, e. g. with increasing fat mass and would 
otherwise not succeed in obesity and enhance ectopic fat accumulation. 
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1.7. Adiponectin 
1.7.1. Adiponectin in adipose tissue and circulation 
Adiponectin also known as ACRP30 (30kDa protein), AdipoQ and GBP28, was 
discovered in 1993 and is thought to be one of the most abundant adipocyte- 
specific gene products (Trujillo, 2005; Kadowaki, 2005). 
Cl 1 28 31 112 245 
NH 000H 
Signal Collagen-like domain Globular domain 
peptide Cys'55 
Adiponectin 241 
NHz COOH 
i 
processing 
gAdiponectin 
r 
Figure 1.7.1.1.: Structure and domains of adiponectin. Adiponectin is composed 
of an N-terminal collagen-like sequence and a C-terminal globular region. Clq 
is shown in comparison. gAdiponectin is the truncated form of adiponectin 
(Adapted from Kadowaki, 2005). 
Adiponectin belongs structurally to the collagen complement Clq family and is 
composed of a distinct globular head domain and collagen-like tail (Figure 
1.7.1.1. ). The adipocyte produced hormone adiponectin is abundant in serum 
and circulates in multimers held together with disulfide bonds, which range 
from trimers to high molecular weight forms (HMW) of 12-18 subunits 
(Pajvani, 2003) (Figure 1.7.1.2. ). The cysteine residue at position 155 is critical 
to HMW formation and integrity of its structure (Waki, 2003). Another 
circulating form of adiponectin is the truncated form of a globular domain only 
(Kadowaki, 2005). However, the full length forms are the main forms in human 
plasma with metabolic activities different from the truncated form (Spranger, 
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2006). The C-terminal domain of the trimeric forms of adiponectin activate 
AMPK and lead to increased fatty acid oxidation and reduction of serum 
glucose (Yamauchi, 2002; Berg, 2001). The hexameric, medium molecular 
weight (MMW) forms and HMW multimers of adiponectin, however, activate 
NF-KB pathways and inhibit cell apoptosis (Tsao, 2003; Hug 2004). 
HMW 
MMW 
S-S 
LMW 
LMW 
Figure 1.7.1.2.: Multimer formation of adiponectin. SDS PAGE gel on left 
depicting three different isoforms. MMW, Medium molecular weight; LMW, 
low molecular weight; S-S, disulfide bridge (Kadowaki, 2005). 
Adiponectin inhibits adipocyte differentiation (Yokota, 2002) and is a key 
regulator of insulin sensitivity and tissue inflammation and has anti- 
arteriosclerotic effect. Circulating adiponectin levels are reduced in T2DM, 
obesity (Hotta, 2001; Arita, 1999) and obesity related hypertension (Ohashi, 
2006) as well as cardiovascular disease (Arita, 1999; Okamoto, 2000). 
Adiponectin serum levels are in fact predictive of T2DM (Lindsay, 2002) and 
cardiovascular disease (Pischon, 2004) and high levels are associated with 
smaller MI risk in men, respectively. But, adiponectin levels are not predictive 
of future BMI (Yamamoto, 2004). The adipocyte secretion rate of adiponectin in 
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obesity declines by about 30% per weight unit (Hoffstedt, 2004), which is able 
to override the increased adiponectin production resulting from an increase in 
adipocytes/ fat mass with a net result of decreased circulating adiponectin levels 
in obesity. The human adiponectin gene at genomic locus 3q27 is thought to be 
linked with susceptibility to T2DM and the metabolic syndrome (Kissebah, 
2000). HMW isoforms are at least partially responsible for some of 
adiponectin's beneficial effects with a decline of HMW structures in subjects 
with T2DM (Pajvani, 2004). Studies examining the isoforms have shown that 
administration of either glucose or insulin to mice results in a severe reduction 
of circulating HMW adiponectin (Pajvani, 2003). As such, hyperinsulinaemia 
may induce reduction of not only adiponectin expression but HMW formation 
which has been further affirmed by in vitro insulin treatments of adipocyte cell 
lines (Fasshauer, 2004). Additionally, impairment of adiponectin in the ability to 
form multimeric units has been postulated to occur in T2DM patients (Waki, 
2003). 
The globular head domain appears to enhance AMPK activity in myocytes, for 
which it has high affinity, and reduces muscle triglyceride and NEFA content 
through an increase of ß-oxidation (Yamauchi, 2002). The full length 
adiponectin enhances AMPK in the liver, where it inhibits the expression of 
hepatic gluconeogenesis and the rate of endogenous glucose production in mice 
(Combs; 2001) which ultimately reduces hepatic glucose output (Berg, 2001; 
Yamauchi, 2002). The expression of adiponectin is not only reduced by insulin, 
but also IL-6 and TNF-ct (Kappes; 2000) and increased by PPAR-y agonists in 
form of pharmacologically available insulin sensitising drugs known as 
thiazolidinediones (TZDs), e. g. Rosiglitazone (RSG) (Combs, 2002). 
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In search of receptors mediating the antidiabetic action of adiponectin, two 
adiponectin receptors were cloned distinct from G-protein coupled receptors 
termed adiponectin receptor 1 (AdipoRl) and 2 (AdipoR2) which share 66% 
sequence homology (Kadowaki, 2006). They were shown to mediate many of 
the metabolic effects of the globular and full-length protein, e. g. increased 
AMPK, PPR-a activities, glucose uptake and fatty-acid oxidation (Yamauchi, 
2003; Kadowaki, 2005). Both receptors are expressed in adipocytes whilst 
AdipoRl is predominantly expressed in the skeletal muscle and AdipoR2 is 
abundant in the liver. These receptors appear downregulated in obesity 
(Kadowaki, 2005) and are negatively regulated by insulin (Tsuchida, 2005). A 
novel extracellular receptor, T-cadherin, which is expressed in endothelium and 
smooth muscle, has been observed to bind the more abundant larger multimeric 
forms of adiponectin (Hug, 2004) and its function needs yet to be further 
clarified. 
1.7.2. Adiponectin in the brain 
More recent studies suggest central action of adiponectin in rodents and a role in 
thermoregulation. Rodent studies examining adiponectin's effect by use of icv 
injection of adiponectin observed weight loss and increased cellular Fos nuclear 
protooncogene (c-Fos) activity (immediate early gene and a marker of early 
neuronal stimulation (Hughes, 1995) in the PVN of wildtype mice (Qi, 2004). 
However, a more recent study in humans failed to show presence of adiponectin 
in CSF (Spranger, 2006) and it remains unclear whether adiponectin has a 
central role in humans. 
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1.8. Resistin 
1.8.1. Resistin in adipose tissue 
Resistin or FIZZ3 is a l4kDa polypeptide; it belongs to a family of cysteine- 
rich-C-terminal proteins, known as resistin like molecules (RELM, 
RELMalpha/FIZZI and RELMbeta/FIZZ2) of FIZZ (found in the inflammatory 
zone) involved in inflammatory processes (Holcomb, 2000; Steppan, 2001b). 
Resistin was thought to be secreted and circulate as dimer (Banerjee, 2001), but 
more recent evidence shows that it circulates as a multimer of a dimeric form 
dependent upon a single intermolecular disulfide bond (Graveleau, 2005). The 
complex structure of resistin is shown in Figure 1.8.1.; it comprises a carboxy- 
terminal disulfide-rich beta-sandwich "head" domain and an amino-terminal 
alpha-helical tail segment. The disulfide bridges enable formation of a hexamer 
and trimer which may dictate the bioactivity of this molecule (Patel, 2004). 
A B 
Resistin 
C 
C6 
18 
112 
, 
16 
Figure 1.8.1.: X-ray crystallography of resistin molecule. A: Resistin monomer. 
B: Resistin hexamer. C: Orientation of disulphide bridges binding n-terminal 
regions (Adapted from Patel, 2004). 
The resistin gene was discovered in the search of genes which are 
downregulated by PPAR-y agonists (Steppan, 2001 a). Injection of recombinant 
58 
resistin in mice has shown to induce insulin resistance. This effect was 
neutralized by antibodies to resistin leading to normalization of glucose 
homeostasis. In addition, resistin also inhibits adipogenesis in murine 3T3-L1 
cells (Steppan, 2001 a). Taken together, these studies support a role of resistin in 
the pathogenesis of diabetes and obesity (Steppan 2001b, Kim 2001). The 
mechanism of resistin action is thought to be an increase of hepatic glucose 
production and glucose uptake and impairment of insulin signalling through 
mechanisms which remain to be identified. Resistin's effect on insulin 
metabolism in humans is more controversial and some studies have failed to 
show a correlation with insulin sensitivity (Savage, 2001) with conflicting 
results of resistin expression following TZD treatment (Way, 2001; Patel, 2003) 
and the regulation of resistin by insulin, e. g. on cultured human adipocytes 
(Way, 2001; Rajala 2002). Our group has shown that serum resistin is increased 
by approximately 20% in T2DM compared with non-diabetic subjects and that 
RSG blocks the insulin-mediated release of resistin secretion in vitro 
(McTernan, 2003). A more recent study by Graveleau (2005) showed that 
human resistin caused a reduction in insulin-stimulated glucose uptake in 
cardiomyocytes which implies a role of resistin in insulin resistance also in 
human subjects. 
Also controversial is the role of resistin in the pathogenesis of obesity with 
contradicting associations with body mass (Tovar, 2005), which may in part be 
explained by the counter-regulation of protein and its mRNA expression (Rajala, 
2004). The net effect of increased adipocyte number in obesity on resulting 
serum resistin levels may be overshadowed by resistin's depot specific 
distribution which is best observed in central obesity. Whilst there is some data 
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showing resistin mRNA levels are highest in human and rodent visceral fat 
(Atzmon, 2002), data from our study group suggests that there is no significant 
difference amongst abdominal Sc and omental depot protein expression of 
resistin (McTernan, 2002) and showed that the expression is about 4-fold higher 
in abdominal AT versus thigh AT (McTernan, 2002). The source of resistin in 
human visceral fat is not solely the adipocyte, but a mixture of cells from 
preadipocyte, epithelial cell, and macrophage, which may increasingly infiltrate 
adipose tissue in obesity and may explain the association with insulin resistance 
(Fain, 2004). Furthermore, resistin is an inflammatory marker and serum resistin 
levels are associated with high serum CRP (Al-Daghri, 2005). In agreement with 
this, our group showed that resistin influences proinflammatory cytokine levels 
in isolated Sc adipocytes as well as pathways of the innate immunsystem 
(Kusminski, 2007). 
1.8.2. Resistin and central action 
Resistin mRNA expression and immunoreactivity has been noted in the ARC 
and other areas of the mouse hypothalamus (Morash, 2002; Wilkinson 2005). 
Evidence from neurophysiological studies shows that resistin inhibits the 
stimulated release of dopamine and noradrenaline from hypothalamic neuronal 
endings similar to leptin (Brunnetti 2004) and central administration of resistin 
was shown to promote short term satiety in rats (Tovar, 2005). However, resistin 
was not found in rodent CSF and there is no current evidence of its ability to 
cross the BBB (Caja, 2005a). Also, to date, there have been no reports which 
examined the central role of resistin in humans. 
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1.9. The pancreatic polypeptide family and DPP-IV 
1.9.1. Neuropeptide Y and the brain 
NPY is a member of the pancreatic polypeptide (PP) hormone family and is 
related to the pancreatic polypeptide Y (PPY) and PYY. NPY is one of the most 
ample neurotransmitters in the brain and is one of the most potent orexigenic 
hormones. It was first isolated in 1982 (Tatemoto, 1982) and is derived from 
splicing of the precursors prepro-neuropeptide Y in form of a 36 amino acid 
peptide (Figure 1.9.1.1. ). 
29 64 - 67 1 
Y YC SR 
Figure 1.9.1.1.: Structure of human prepro-neuropeptide Y. The protein NPY is 
shown in grey (Minth, 1984). 
NPY binds to transmembrane-domain G-protein coupled receptors, NPY YI- 
Y6 (Larhammar, 1996), of which Y3 has not been cloned yet (Zukowska, 2003) 
and Y6 is not functional in species other than the mouse (Herzog, 1992); as such 
there are 4 human recognised receptors: Yi, Y29 Y4 and Y5. This receptor family 
lacks sequence identity, particularly between Y1, Y., and Y5 receptors, which are 
only 30% identical (Brain, 2006). The activation of these receptors modifies the 
action of adenyl cylclase and leads to changes of intracellular calcium (Toth, 
1993) 
NPY is a neurotransmitter abundant in the brain, peripheral sympathetic nerves 
and adrenal medulla, where it is colocalized with catecholamines but is also 
found in most other tissues (Everitt, 1984). In the CNS, NPY is an inhibitory 
neurotransmitter and exhibits anxiolytic, anti-stress, anti-depressant, anti- 
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convulsant and anti-nociceptive actions in addition to its hypertensive, potent 
appetite-stimulating effects and has potential to shift circadian rhythms. NPY is 
also involved in the regulation of angiogenesis, vasoconstriction, mood 
regulation and fertility (Chronwall, 2004). Microinjection of NPY into the 
paraventricular nucleus of the hypothalamus (PVN) stimulates feeding (Stanley, 
1986) and chronic icv infusion causes obesity (Clark, 1984). ARC NPY 
secretion and expression are negatively regulated by leptin and insulin 
(Stephens, 1995; Schwartz, 1996b; Sahu, 1995) and positively by ghrelin 
(Nakazato, 2001). Hypothalamic expression of NPY is enhanced in leptin 
deficient ob/ob mice (Wilding, 1993) and additional NPY knockout in 
combination to leptin knockout decreases obesity (Erickson, 1996). NPY 
circulates in serum and CSF. Whilst a clear association with serum levels and 
BMI could not be established (Baranowska, 2000), it appears that CSF NPY 
levels do not correlate with BMI, but decrease after weight loss (Nam, 2001). 
The effect of NPY on energy balance is mediated by a combination of receptors 
and Y1, Y2, Y4 and Y5 have been postulated to be responsible for the appetite 
regulation of NPY (Wynne, 2005). Whilst knockout mice lacking NPY from 
central and enteric neurones are normal weight with normal response to 
starvation (Erickson, 1996), Y1 knockout mice show transiently reduced daily 
food intake and higher leptin levels (Pedrazzini, 1998) and Y2 hypothalamus 
specific knockout mice show reduced body weight and increased expression of 
hypothalamic NPY (Sainsbury, 2002). This observations led to the study of 
NPY receptor agonists and antagonist in the hope to reveal potential new anti- 
obesity agents. This has proven difficult because the multiple effects mediated 
by these receptors besides weight regulation, e. g. Y4 receptor knockout mice 
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show overtly aggressive behaviour. Whilst Y5 antagonists failed to prove an 
antiobesity effect in clinical trials (Block, 2002), studies are currently evaluating 
the prospects for Y2 agonists. Y2 receptors have a predominantly presynaptic 
location where they act to inhibit NPY release. Y2 also mediates anticonvulsant 
actions and antinociceptive effects of NPY in the hippocampus making Y2 a 
potential anticonvulsant therapeutic (E1-Bahh, 2005) and analgesic, e. g. for the 
treatment of neuropathic pain (Moran, 2004). 
1.9.2. NPY and the adipocyte 
NPY is coreleased with noradrenaline, it favours energy storage by central 
action on appetite but central administration also increases LPL activity in WAT 
suggesting a peripheral role of NPY in lipogenesis (Billington, 1991; Zarjevski, 
1993, Karvonen, 1998). NPY mediates an antilipolytic effect in human adipose 
tissue (Valet, 1990; Castan, 1994; Labelle, 1997) which is thought to be 
mediated by receptor Y1 in humans (Bradley, 2005), the same receptor may also 
stimulate leptin secretion in adipocytes (Serradeil-La Gal, 2000) whilst the role 
of Y5, which also shows gene expression in adipose tissue, is not clear. 
Experiments with in vitro co-culture of rat sympathetic neurons with the 3T3-L1 
cell line of adipocytes (Turtzo, 2001) show inhibition of ß-adrenergic lipolysis. 
This inhibition was suggested to be the effect of NPY induction via the 
sympathetic system (Bartness, 2005). Cell treatment with NPY in co-culture was 
also shown to inhibit leptin secretion (Bartness, 2005) where as iv injection of 
NPY increased leptin mRNA and Yl mRNA expression in sheep adipocytes 
(Dyer, 1997). 
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1.9.3. PYY 
The gut hormone PYY belongs to the same family as NPY with which it shares 
70% of sequence homology. PYY is released postprandially in two forms: 
PYYI. 36 and PYY3.36 and its levels are proportional to meal size (Adrian, 1985). 
Like NPY, PYY is also converted by DPP-IV (Eberlein, 1989). PYY signals 
through NPY receptors. PYY1.36 is an agonist at the Yl/Y2 receptors and 
promotes feeding, whereas PYY3.36 is an antagonist at the Y2 receptor and 
inhibits feeding (Grandt, 1994), an effect which is absent in Y2 knockout mice 
(Batterham, 2002). PYY3_36 can cross the BBB via diffusion (Nonaka, 2003) and 
inhibits ARC NPY neurons and reduces hypothalamic NPY mRNA expression 
(Batterham, 2002). Intravenous administration of PYY3-36 reduces hunger and 
measured food intake by 30% in humans and its effect lasting up to 12 hours 
(Batterham, 2002), whilst icv administration of PYY1.36 and PYY3_36 increase 
food intake in rodents probably because of a bypass of ARC Y2 receptors and 
action through Y1 and Y5 (Stanley, 2005). Furthermore, a recent report has 
noted that the attenuated response of PYY in obese subjects is associated with 
reduced satiety (le Roux, 2006) and PYY3.36 could thus offer potentially 
effective antiobesity therapy. 
1.9.4. DPP-IV 
The presence of dipeptidyl peptidase-IV (DPP-IV), a highly specific protease 
also known as CD26 in the immune system, influences amongst other proteins 
the affinity of NPY to its receptors by acting as a converting enzyme. DPP-IV 
cleaves off proline in the penultimate position of many peptides like NPY, PYY 
and GLP-1, but NPYI_36 is one of its best substrates (Mentlein, 1999). DPP-IV is 
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found in the endothelium and epithelial cells, serum and activated immune cells 
(Mentlein, 1999). It shifts NPY activities from Y1 towards receptor Y2 and Y5 
pathways with generation of NPY3_36 from NPY1_36, and can therefore also be 
seen as endogenous YI receptor antagonist (Zukowska-Grojec, 1997a) in a 
similar way it modulates the action of PYY. 
Figure 1.9.4.: Crystallographic structure of DPP-IV which consists of two 
subunits. The full-length DPP-IV is a type II transmembrane protein (Adapted 
from Rasmussen, 2003). 
DPP-IV inhibitors have recently become available as anti-diabetic 
pharmacological agents to sustain a prolonged incretin effect (Ahren, 2004). The 
so called incretin effect has been revealed by the finding that after oral intake of 
glucose plasma insulin levels are greater than those observed when glucose is 
given intravenously (McIntyre, 1965) and is entertained by insulin release 
through secretion of gut hormones like glucagon like peptide -1 (GLP-1) 
through contact with food. GLP-1 is a 30 amino acid protein derived from the 
cleavage of the proglucagon molecule derived primarily from the gut 
(enteroendocrine L-cells from the terminal ileum). Whilst DPP-IV truncates the 
65 
Cell membrane 
N-terminus of the active metabolite by cleavage of 2 amino acids and is 
responsible for the short half-life of GLP-1 (7-36) of 1-3 minutes (Hui, 2005), 
the levels of immunoreactive GLP-1 have been shown to increase up to five fold 
by DPP-IV inhibition (Ahren, 2004). GLP-1 has also shown to have anorexic 
properties (Donahey, 1998; Alvarez, 2005). Its central action is primarily 
mediated through CRH neurons in the PVN (Larsen, 1997) and appears to 
activate the brainstem by increased c-Fos immunoreactivity (Yamamoto, 2003). 
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1.10. Ghrelin 
1.10.1. Ghrelin and the brain 
The neurotransmitter ghrelin, a 28 amino acid peptide is a product of splicing of 
its precursor prepro-ghrelin an 117aa peptide of 13.3kDa (Kojima, 1999). 
Propro-Ghrelin (Human) 
Propro- 1 23 24 51 52 117 
Signal 
Sequence 
Pro- -23 -1 1 28 29 94 
Ghrolin (Human) 
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Figure 1.10.1.: Structure of Ghrelin. The molecular weight of preproghrelin is 
13.3kDa and 3kDa of the mature ghrelin (Adapted from Kojima, 1999). 
Ghrelin is the orphan ligand of the growth hormone secretagogue receptor type 
la (GHS-R 1 a), which was originally identified in the hypothalamus, but the 
primary production sites of this peptide are the stomach and colon (Kojima, 
1999), which makes ghrelin a mediator of the gut-brain axis. Ghrelin mRNA is 
expressed in almost all tissues including endocrine tissues like pituitary, adrenal 
gland, thyroid, ovary, testis and the fat (Gnanapavan, 2002). 
Ghrelin exists in two different isoforms. Des-octanoyl ghrelin does not activate 
GHS-Rla, which is dependent on the octanoyl modification of the third serine 
residue of ghrelin (Hosoda, 2000). The acetylation of ghrelin is achieved by a 
unique post-translational acylation with octanoic acid. The natural ghrelin acyl- 
modifying enzyme is not yet known. Further it is currently unclear whether des- 
acylated ghrelin is a precursor of acetylated ghrelin or a product of the 
deacylation (Kojima, 2005) and which receptor is used by des-acetylated 
ghrelin. The gut hormones PP and oxyntomodulin (OXM) have been shown to 
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suppress ghrelin hormone secretion or expression which in part explains their 
anorexigenic activity (Stanley, 2005). 
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Figure 1.10.2.: Structure of human octanylated ghrelin (C8: 0). Human Ghrelin 
is a 28-amino acid peptide in which Ser 3 is modified by a fatty acid in this case 
n-octanoic acid (Adapted from Kojima, 2005). 
There is a strong association of ghrelin with obesity and the fasting total ghrelin 
plasma levels are reduced in human obesity (Tschop, 2001) and its nocturnal 
raise is blunted in obese subjects (Yildiz, 2004). The levels rise again after 
weight loss and gastric surgery (Vendrell, 2004). Ghrelin serum levels are also 
reduced in insulin resistance and diabetes (Poykko, 2003; Katsuki, 2004) and 
show an inverse relationship with circulating plasma insulin levels (Holdstock, 
2003). As serum ghrelin reaches peak plasma levels just before meals and 
stimulated by sympathetic activation (Mundinger, 2006) after which they 
rapidly fall, it is thought that the role of ghrelin is to be that of a meal initiator 
(Cummings, 2001). Peripheral and icv administration of ghrelin leads to 
increased food intake and eventually to obesity in rodents (Tschop, 2000; Chen 
2004) and also stimulates food intake in humans (Wren, 2001). The anabolic 
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effect is mainly mediated by GHS-Rla, through octanylated ghrelin (Kojima, 
1999). Targets of the anabolic action of ghrelin are AGRP and NPY neurons 
located at the ARC (Tschop, 2002) via activation of GHS-R (Nakazato, 2001) 
which leads to an increase of NPY and inhibition of POMC and aMSH 
production. The participation of ghrelin induced GH activation through GHS-R1 
in food intake is unclear (Stanley, 2005). A recent study by Toshinai (2006) in 
rats shows that des-acetylated ghrelin activates central orexin neurons and also 
mediates an orexigenic effect, though different to acetylated ghrelin. Whilst 
acetylated ghrelin stimulates prolactin, ACTH and cortisol secretion in humans 
(Arvat, 2001) des-acetylated ghrelin does not (Broglio, 2004). A small 
proportion of ghrelin is also produced centrally and ghrelin neurons are found in 
the hypothalamus projecting to ARC and LHA where they potentially 
communicated with NPY neurons and orexin neurons (Stanley, 2005). However, 
it is probably mainly peripheral ghrelin which mediates central effects and 
ghrelin has been shown to cross the BBB (Banks, 2002) with species-specific 
differences in transport of octanylated and des-acetylated ghrelin, e. g. contrary 
to mouse ghrelin both forms of human ghrelin can pass the mouse BBB bi- 
directionally (Banks, 2002). The observed differences amongst species warrant 
further study of ghrelin isoforms in human physiology. 
1.10.2. Ghrelin and the adipocyte 
Rodent studies suggest that ghrelin is antilipolytic (Morimoto, 1998). As such 
studies examining icv ghrelin have shown that it can modulate adipocyte 
metabolism by mRNA induction of AT regulating enzymes like LPL, which 
may be similar to leptin's peripheral feedback, through influence on the 
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sympathetic innervation of AT (Theander-Carrillo, 2002). Also, there is the 
possibility that ghrelin is also expressed in AT itself. Ghrelin mRNA expression 
was found in human AT by Gnanapavan (2002) and both ghrelin and GHR-la 
have been shown to be expressed in rodent adipocytes (Zhang W, 2004) where 
ghrelin also induces adipocyte differentiation (Choi, 2003; Thompson, 2004). 
Whilst the effects of ghrelin on WAT have mainly been studied in rodents little 
is known on the effect of ghrelin isoforms in humans. 
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1.11. Aims 
The adipokine leptin and its importance in central energy regulation as one of 
the principal regulators of cerebral catabolic action on long term energy balance 
not only demonstrates that `fat communicates with the brain', but also highlights 
the possibility of other adipokines and hormones participating in a feedback 
cycle of brain-adipose tissue energy homeostasis. In addition, obesity induced 
leptin resistance is an example of uncertain pathophysiology. Its regulation is 
dependent on two important regulator of energy homeostasis - the fat and the 
brain - which are potential dysfunctional organs in the pathogenesis of obesity 
and insulin resistance. As such, the core theme of this thesis is to explore the 
interaction of adipose tissue and the brain to search for additional feedback 
circuits of energy homeostasis. The first part of the thesis will discuss the 
crosstalk between fat and the brain and focus on the adipokines adiponectin and 
resistin to determine whether these adipokines are present in CSF and whether 
they could have a role in human energy homeostasis. A further aim is to 
examine the presence of adiponectin receptors in the nuclei of the human 
hypothalamus, which are known to participate in energy regulation. The thesis 
continues with the study of the role and the presence of the neurotransmitters 
and the appetite regulators NPY and ghrelin in human adipose tissue. These 
studies will examine their impact on adipose tissue metabolism and its 
modulation by obesity and in vitro insulin treatment, which could give further 
insight into the pathophysiology of the metabolic syndrome. This includes 
exploring the interaction of these neurotransmitters with other regulators of 
energy homeostasis like leptin and their influence on other adipokines. Since 
adipose tissue innervation enables crosstalk from the brain to adipose tissue 
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through efferent brain stem signals as cumulative response to hypothalamic 
energy regulatory impulses, this thesis scrutinizes the expression of previously 
unidentified receptors regulating neurotransmitter release in human adipose 
tissue. It investigates for presence of nicotinic receptors (CHRNA) in WAT 
which modulate neurotransmitter release, e. g. NPY, and which are affected by 
smoking. 
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Chapter 2 
General materials and methods 
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2.0. General materials and methods. 
The following section contains a description of general materials and methods 
that were most regularly used throughout the thesis. Further information on 
methods specific to certain work is outlined within the appropriate chapter 
whilst specific reagents are documented in Appendix I and II. 
2.1. Adipose tissue collection and processing 
2.1.1. General 
Subcutaneous abdominal, thigh and omental adipose tissue was collected from 
consenting subjects undergoing elective surgery, e. g. gastric bypass or hip 
surgery, also liposuction material was collected from cosmetic surgery with 
approval by the local ethics committee. Patients with history of malignancy, 
steroid treatment, endocrine therapy or acute inflammatory problems were 
excluded. 
Adipose tissue (AT) was used fresh without use of preservatives e. g. formalin. It 
was chopped finely with scissors, transferred into a 50mL centrifuge tube and 
immediately placed in liquid nitrogen for rapid freezing. Frozen samples were 
transferred straight from liquid nitrogen into a -80°C freezer for storage until 
future use. These samples where further used for extraction of protein or RNA 
as is detailed in the following sections. Processing of AT continued for isolation 
of adipocytes and pre-adipocytes (see below). 
2.1.2. Isolation of subcutaneous and omental adipocytes 
Adipose tissue was finely minced with surgical scissors and removal of obvious 
vessels and connective tissue as much as possible and mixed with a ratio of 2: 1 
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of collagenase (Worthington Biochemical Corporation, Lakewood, New Jersey, 
USA) in sterile 50mL centrifuge tubes alternatively with liposuction material: 
25-30mL of liposuction material was poured into each centrifuge tubes and 
10mL of collagenase added. Collagenase was prepared at a concentration of 
lmg/mL reconstituted in lx Hanks balanced salt solution (HBSS, GibcoBRL, Life 
Technologies, Paisley, UK). The mixtures were shaken and immersed into a 
shaking warm water bath (37°C, 100cycles/min) for approximately 30 minutes 
(min), with additional hand shaking at 10 min intervals. When the mixture was 
very smooth and homogenous, it was filtered through sterile cotton mesh 
(Medistore, UK) into falcons and then centrifuged at 360 xg (g-force= 1.12 x 
10-5 tip Radius in cm x rpm2; rpm= revolutions per minute) for 5 min. This 
separates adipocytes from pre-adipocytes. The oily supernatant was discarded. 
The adipocyte layer (after oil layer) was poured into falcons and washed with 10 
-15mL of warm (water bath) DMEM/F-12 phenol red free medium (15% foetal 
calf serum (FCS) and Dulbecco's minimal essential medium, both from 
GibcoBR', (Life TechnologiesTM, Paisley, UK) containing 1% transferrin (Sigma, 
Dorset, UK), penicillin (100units/mL) and streptomycin (100 tg/mL) (Sigma, 
Dorset, UK) and dispersed with gentle rocking. The remaining layer of 
previously centrifuged material contained a preadipocyte pellet and was treated 
separately (see below). The adipocyte Phenol red mixture was centrifuged at 
190 xg for 30 seconds (s) and the wash repeated till the liquid below the 
densely packed layer was clear. This liquid was then removed with a 2mL 
pipette. The remaining dense layer of adipocytes was used for tissue culture at 
amounts of lmL of adipocytes which were added to falcons with 5mL of cell 
culture medium to be incubated for 48 hours (hr) with the treatment of choice. 
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Some of the adipocytes (200 µL) were treated with 500mL of RIPA buffer for 
protein extraction (see below) or treated with RNALaterTM (Ambion, AMS 
Biotech, UK) and then frozen at -80°C. 
2.1.3. Preadipocyte separation 
After the adipocyte layer was poured off, the remaining supernatant was 
carefully removed to leave a preadipocyte pellet. This pellet was resuspended in 
lysis buffer (see Appendix I) and left at room temperature for 15-20 min and 
then centrifuged at 360 xg for 5 min. If the supernatant was very bloody, the 
lysis buffer wash was repeated. Otherwise the supernatant was taken off and the 
preadipocyte pellet resuspended in 2mL 10% Dimethyl sulphoxide (DSMO) in a 
15% foetal calf serum mix containing penicillin (100units/mL) and streptomycin 
(100µg/mL) and aliquoted into cryogenic vials. Samples were stored at -80°C 
overnight and then removed into liquid nitrogen. 
2.2. Adipocyte cells culturing methods 
After the final centrifugation, step aliquots of 1 mL of adipocyte were 
resuspended into warm 25cm3 flasks each containing 5m1 DMEM/F-12 
(containing 15% foetal calf serum (FCS) and Dulbecco's minimal essential 
medium, both from GibcoBR' (Life TechnologiesTM, Paisley, UK) containing 1% 
transferrin, penicillin (100units/mL) and streptomycin (100µg/mL) (Sigma, 
Dorset, UK). The final cell concentration is estimated approx 500,000cell/mL as 
determined by haemocytometer analysis. At this stage, various treatments were 
added (see individual chapters) and at least two flasks were left untreated as to 
act as controls to be compared with treated cells. 
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2.3. Sample preparation for Western blot analysis 
2.3.1. Protein Extraction Method (RIPA) 
This method was used to extract protein from whole AT or cells for use in 
Western Blot analysis. For deep frozen adipose tissue or adipocytes, frozen 
fragments were broken or cut off with a scalpel from the remainder sample 
under sterile conditions, diluted in 600µL of RIPA buffer (Appendix I) and 
sequestered. After transfer into eppendorfs and flash freezing in liquid nitrogen, 
thawed samples were centrifuged at 25,000 g for 20 min at 4°C. Subsequently, 
the liquid below a fat layer was transferred to clean labelled eppendorfs by using 
a fine bore needle and syringe. Samples were stored at -80°C till further use. 
Their concentration was estimated with spectrometry. 
Treated adipocytes and preadipocytes were treated in a similar manner. The 
medium and liquid mix were transferred into 15mL tubes and centrifuged at 140 
xg for 30 s. The infranatant (medium) was removed and 500µL of the 
remainder sample containing adipocytes transferred into eppendorfs with 200µL 
of RIPA (containing ALLN) (100µL of RIPA for preadipocytes). The samples 
were flash frozen, thawed, centrifuged at 25,000 xg for 30 min at 4°C and the 
infranatant transferred to eppendorfs as described above. 
2.3.2 Quantification of protein content 
The BioRad method is a cuvette reaction using a BioRad DC (detergent 
compatible) kit containing reagents S (alkaline copper tartrate), A (surfactant 
solution) and solution B (dilute folin reagent) (BioRad, Hercules, California, 
USA) (Peterson 1979) (Appendix I). It was used for determination of protein 
content of extracted samples derived from various adipose tissue depots 
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(subcutaneous thigh and abdomen and omental fat), treated and un-treated 
adipocytes and preadipocytes. To ensure a homogenous specimen, all samples 
were thoroughly thawed and vortexed and 3µL pipetted into a polypropylene 
cuvette (Starstedt, Germany) and 125µL of a pre-made mixture of 20µL reagent 
S and 980µL reagent added. Finally, lmL of solution B was added to each 
cuvette and the mixture incubated for 15 min at room temperature (RT). At the 
same time, a standard curve of optical density to protein concentration was 
constructed using known dilutions of bovine serum albumin (BSA, First Link 
LTD, UK) (2µg/mL) in the range 0-100µg/mL. Protein concentrations were 
calculated (tg/3pL). The optical density of protein samples were then analysed 
on a 6505 UV/VIS spectrophotometer (Jenway, UK) at a wavelength of 65OnM. 
2.4. Western blot analysis 
The general principle of a Western blot is to identify a specific protein of a 
certain size with the help of electrophoresis, after which the protein is blotted 
into a PVDFTM membrane. In a second stage, an antibody against the protein of 
interest was added and the antigen/antibody complex visualised by a 
chemiluminescent assay with the use of a secondary antibody, as described in 
full detail below. 
2.4.1. Preparation of protein samples for electrophoresis 
After protein quantification the samples were thawed and aliquoted into 
eppendorfs and their volume calculated depending on amount required for 
loading (e. g. 10 -60µg of protein). Loading buffer was added at a minimum ratio 
of 1: 2 of sample versus loading buffer (Table 2.4.1. ) and mQH2O added to 
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standardise volumes. After vortex and quick spin the centrifuged samples were 
heated to 95°C for 5 min before loading into electrophoresis gel. Prepared was 
also a marker (Amersham, UK), which was diluted 1: 5 with the same loading 
buffer. 
Reducing loading buffer for Western analysis: 
REAGENT FINAL CONCENTRATION QUANTITY 
Tris HC1(pH6.8) 
(Biorad, Hercules, USA) 125mM 625µL 
SDS (10%) (Sigma, UK) 4% 1000µL 
Glycerol (Sigma, UK) 20%(w/v) 500µL 
DTT (Sigma, UK) 6.5 x 10"3%M (w/v) 200µL 
Bromophenol Blue 2.5x 10-3%M (w/v) 125µL 
mQH2O 100% 250µL 
Table 2.4.1.: Contents of reducing loading buffer. Strong reducing loading 
buffer: contains additional ß-Mercapthoethanol 6µL per sample. Non-reducing 
loading buffer: without addition of DTT. 
2.4.2. Electrophoretic protein separation 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to separate proteins. In order to optimise for individual proteins and 
depending on its size, various gel concentrations were used alongside 4.5% 
stacking gel, pH 6.8, e. g., 8%-15% of resolving gel, pH 8.8. The recipes for each 
gel are listed in Table 2.4.2. The gel casting unit was assembled according to the 
manufacturers' instructions and water tightness tested after the glass plates were 
slotted in. The resolving gel was prepared as outlined above and poured to 2/3 of 
the total height of the plates. To enhance polymerisation and reduce meniscus 
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formation about 3mm of milliQ treated water (mQH2O) was layered over the gel 
with help of a syringe. 
RESOLVING GEL: 
REAGENT CONCENTRATION QUANTITY QUANTITY QUANTITY 
FOR 10% FORM FOR15% 
1OX10cm GEL 10X10cm 1OX10cm 
GEL GEL 
1.5M Tris-HC1, 10% (w/v) 5.2mL 5mL 5mL 
0.4% SDS (pH 
8.8) 
mQH2O 50 % 7.8mL 6.78mL 4.8mL 
Ammonium 3.3 x 10-2% (w/v) 100µL 10OµL 100µL 
Persul hate 
TEMED 3.3 x 10-4% (v/v) 10µL 10µL 10µ. L 
STACKING GEL: 
REAGENT CONCENTRATION QUANTITY FOR 
I OX 10cm GEL 
30% Acrylamide, 0.8%Bis- 
Acrylamide (37.5: 1) 
4% (w/v) 1.3mL 
0.5M Tris-HCI, 0.4% SDS 
(pH 6.8) 
0.125M 2.5mL 
mQH2O 60% 6. lmL 
Ammonium Persulphate 0.1%(w/v) 50µL 
TEMED 5x 10-4% (v/v) 10µL 
Table 2.4.2.: Quantities of reagents that are contained in resolving gel and 
stacking gel. 
The stacking gel was prepared according above recipe and poured over the 
resolving gel once set. Combs were inserted to created wells (7mm thickness, 
15 teeth of lcm wide each or 10 teeth of 15cm each). Air bubbles were 
minimized by introducing the comb at an angle and any loss of gel was 
immediately replaced. On setting, the comb was removed and wells were 
vigorously flushed with water in a syringe. 
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Gels encased within the glass plates were transferred to a tank containing lx 
electrode buffer (Appendix I), and secured into place, creating two separate 
reservoirs, allowing ionic movement only through the gels. Wells were flooded 
and ensured there were no leakages between the two reservoirs. Samples were 
then loaded using `duck billed tips' (Fisher, UK). With each set of samples, a 
marker was loaded (minimum 1 lane per gel) to provide a visual protein size 
record with which protein samples could be compared. Samples were then 
resolved by electrophoresis (140-200V) for 1-2 hr depending on the 
concentration of gel used. 
2.4.3. Electrophoretic transfer ('blotting') 
Immobilon-P'' membranes (0.45mm) (Millipore, Bedford, Massachusetts, 
USA) were briefly immersed in 100% methanol (Fisher Scientific, UK), washed 
in mQH2O for 1 min and soaked in transfer buffer (Appendix I) until use. 
Alternatively, for smaller proteins, Westeran-S membrane (0.2mm) 
(Schleicher&Schuell, Bioscience, Germany), was prepared without water 
immersion. After completion of electrophoresis, stacking gels were separated 
from the resolving gel and discarded. The resolving gels were soaked in transfer 
buffer for 10 min. Fibre pads and filter paper sets (2 sets per gel), which were 
soaked in transfer buffer for at least 30 min were sandwiched in the following 
fashion: filter paper was laid over a saturated fibre pad and the resolving 
layered carefully onto the filter paper; this was topped with the permeabilized 
membrane, ensuring that no bubbles interrupted the contact between the gel and 
membrane; if necessary, more transfer fluid was poured over to flush away 
bubbles. Finally, a layer of saturated filter paper followed with a fibre pad was 
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added to complete this `sandwich', which was then inserted into casings and put 
into a tank containing 2.5L of transfer buffer. Proteins were then transferred 
with the help of electrophoresis onto the membrane (400mA constant amperage, 
for 1 hr). 
2.4.4. Primary antibody application 
Membranes were removed from the stack and the edge trimmed to mark 
orientation and membrane number. Membranes were incubated with 10% non- 
fat milk solution (Marvel Milk Powder, Premier Brands, Merseyside, UK) 
diluted in 0.5% PBS-polyoxyethylene sorbitan monolaurate (Tween 20 (0.1% 
(v/v), Sigma, Dorset, UK) on an orbital shaker for at least 1 hr or overnight in 
the cold room at 4°C to block non-essential proteins. Membranes were then 
rinsed repeatedly in PBS and finally in 1% PBS-Tween20 (PBS-T). Primary 
antibody was prepared in sufficient quantity to cover the surface of the 
membrane at a concentration of 0.05% PBS-T and incubated with the membrane 
in a 5OmL falcon tube at 4°C overnight. After approximately 14 hr at 4°C, 
membranes were washed three times in lOmL PBS (120mM, pH 7.6) and then 
finally in an excess of 1% PBS-T (120mM). Filters were then returned to the 
shaker for three 10 min washes in excess 1% PBS-T (120mM). Alternatively, if 
the membranes were blocked overnight, the primary antibody incubation period 
was shortened to about 1 hr at RT and then washed accordingly. 
2.4.5. Secondary antibody application 
The secondary antibody was made up in 0.5% PBS/PBS-T and membranes 
incubated at RT for 1 hr on an orbital shaker at medium speed (80- 
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100cycles/min). The membranes were rinsed three times in PBS (120mM, pH 
7.6) and after each of the three subsequent 10 min washes in excess 1% PBS-T. 
2.4.6. Immunodetection of antibody labelled proteins 
The function of the secondary antibody is to make specific proteins visible by 
acting as a catalyst for luminol, a substrate that transmits light, which is 
provided by an ECL Western blotting detection system and its stronger version 
like ECL plus and ECL advance (Amersham Pharmacia Biotech, Little 
Chalfont, Buckinghamshire, UK). The secondary antibody binds to the primary 
antibody that is attached to the protein under scrutiny. Chemiluminescence was 
achieved by a reaction, which is based on the oxidation of the cyclic 
diacylhydrazide luminol (see Figure 2.4.6. ). The addition of HRP and peroxide 
catalyses the oxidation of the lumigen PS-3 acridan substrate generating 
acridinium ester intermediates, which produce a sustained, high intensity 
chemiluminescence with reaction with peroxide under slightly alkaline 
conditions The light emitted was then registered by application of photographic 
X-ray film. 
The Membranes were removed from the secondary antibody and washed in an 
excess of PBS (120mM, pH 7.6) followed by three 10min washes with 1% PBS- 
T (120mM). They were placed protein side-up on saran wrap. Equal volumes of 
ECL solution A (tris buffer) and B (acridin solution in dioxane and ethanol) (or 
appropriate mixtures of ECL-plus, or ECL advance solutions to allow 3mL per 
4cm2 area of membrane) were mixed and each membrane covered. This was 
incubated for 1 min (or 5 min for ECL-plus and for ECL advance), with excess 
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ECL poured away and the corner of the membrane blotted on tissue paper to 
remove excess ECL solutions. 
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Figure 2.4.6.: Chemiluminescent reaction of Lumigen PS-3 with horseradish 
peroxidase (Adapted from Isacsson, 1974). 
Membranes were placed between two sheets of clear plastic, further excess ECL 
removed with tissue paper and placed into a film cassette. The filters were then 
exposed to photographic X-ray film (Kodak, UK) for varying times (15 s- 12 
hr) 
2.4.7. Quantification of Western blot bands 
The density of the bands on the autoradiographs were quantified by gel blot 
analysis using UVP Gel Blot Analysis System (UVP, UK) and statistically 
analysed, as detailed in the individual results chapters. 
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2.5. RNA Isolation and preparation for PCR 
2.5.1. Extraction and quantification of RNA. 
In order to extract mRNA from deep frozen adipose tissue, a piece of 5g was 
taken, placed into 1mL of QlAzol Lysis Reagent and disrupted with a 
homogeniser. In preparation for RNA extraction of adipocytes, a freshly isolated 
and centrifuged sample (see above) of 200µL was taken from the densely 
packed adipocyte layer and placed into sterile 1.5mL eppendorf tubes with 
800µl RNALaterTM (Ambion, AMS Biotech, UK). Adipocytes were then kept at 
4°C overnight and transferred to -70°C for storage. For the extraction, the 
samples were carefully thawed and the top layer containing adipocytes taken off 
the RNALatefm fluid and similarly placed into 1mL QIAzol Lysis Reagent and 
disrupted with a homogeniser. 
2.5.2. RNA isolation and purification. 
Total RNA was isolated from whole AT using a column-based method, 
according to the manufacturer's instructions (RNeasy Lipid Tissue Mini Kit, 
Qiagen, UK). After RNA elution, the sample was digested with 7µL 
(1000units/mL) of DNase enzyme (DNase Kit, Sigma, UK) and 7µL reaction 
buffer (DNase Kit, Sigma, UK) to remove contaminating genomic DNA. These 
reactants were incubated for 15 min at standard RT. The reaction was stopped 
through the addition of 7µL stop solution (50mM EDTA) (DNase Kit, Sigma, 
UK) and subsequently samples were incubated at 70°C for 10 min. (Solutions 
are outlined in appendix I). 
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2.5.3. RNA quantification 
The total RNA concentration of each individual sample was quantified using a 
spectrophotometer (wavelength 260nm, Nanodrop, Labtech, UK) and the RNA 
assessed using the absorbance ratio 260/280nm. Protein contamination of RNA 
was calculated by measuring optical density of each sample at 260nm (OD260) 
(wavelength for RNA detection) and 280nm (wavelength for protein detection). 
The ratio of these two readings is an indication of RNA concentration. The 
conversion factor for RNA is 0.040µg/jL per OD260 unit and the quantity of 
undiluted RNA was 1/µL, with: 
Concentration (µg/jL) = A260 x dilution factor x conversion factor 
2.5.4 Reverse transcription of mRNA. 
MRNA (1 µg) from each sample was pipetted into a sterile microcentrifuge tube 
along with 0.5µL of random hexamers mixed in equal quantities. To standardise, 
nuclease free water was then added to each aliquot to make up a final volume of 
11µL and samples heated to 70°C for 10 min. A reverse transcriptase (RTn) 
master mix was pre-mixed (see Table), containing appropriate quantities of 
RNase inhibitor enzyme (RNasin), avian myeloblastosis virus reverse 
transcriptase enzyme (AMV), reaction buffer (10X), magnesium (Mg2++, 25mM 
stock), deoxynucleoside triphosphates (dNTPs containing guanine, thymine, 
adenine and cytosine) (Promega, UK), and nuclease free water sufficient for the 
chosen number of RTn reactions. After 10 minutes of incubation, 10µL of RTn 
master mix was added to each sample of RNA. After a vortex and centrifugation 
samples were heated to 37°C for 1 hr, after which the reaction was quenched by 
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a consecutive incubation at 95°C for 5 min to denature the enzymes. The 
resultant cDNA product was stored at -20°C for further use. 
Contents of Reverse 
Transcription Master 
Mix 
Concentration in final 
20µL Volume 
Quantity added (µL) 
Reverse transcription 
lOx Reaction buffer 
(Mg2++ free) 
lx (v/v) 2.0 
Mg ++ (25mM) 5mM 4.0 
dNTPS (10mM) I mm 2.0 
AMV (20u/µL) 0.5u/lL (v/v) 0.5 
RNasin (40u/jL) lu/µL (v/v) 0.5 
Nuclease free H2O 5% 1.0 
Table 2.5.4: Quantities if substances for the reverse transcription master mix. 
The final volume of cDNA sample is 20µL where 1µL equals 50ng of single 
stranded cDNA. 
2.5.5. Principles of the polymerase chain reaction 
The theory of cDNA synthesis from DNA is discussed in Appendix H. Genes 
were amplified using the polymerase chain reaction (PCR) which is based on 
cycling temperatures, which allows the amplification of millions of copies of the 
gene of interest. 
2.5.6. Quantitative Real-Time PCR 
The real-time PCR reaction was performed with volumes of 25µL on 96 well 
plates, in a reaction buffer containing Taqman universal PCR master mix, 3mM 
Mn(Oac)2,200pM dNTPs, 1.25units ampliTaq gold polymerase, 1.25units 
ampErase UNG, 100-200nmoL Taqman probe, 900nmoL primers and 25-125ng. 
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Thermal 
Cycler 
Times and Temperatures 
First Steps 1 of 44 cycles 
Melt Anneal/Extend 
ABI Prism 
7500 Sequence 
Hold Hold Cycle 
Detector 
2 min 10 min 15 s 1 min 
50°C 95°C 95°C 62°C 
i ame L. ß. 6.: Kt-ILK reaction conditions as pre-set on the ABI 7500. 
All reactions were multiplexed with the housekeeping gene for the 18S ribosomal 
subunit, provided as a pre-optimised control probe (PE Biosystems, UK) 
enabling data to be expressed in relation to an internal reference which allowed 
for differences in RT efficiency. Data were obtained as the cycle number at 
which logarithmic PCR plots cross a calculated threshold line or the Ct value. In 
accordance with the manufacturer's guidelines zCt values were determined (ACt 
= Ct of the target gene minus Ct of the housekeeping gene). Measurements were 
carried out in triplicate and the target gene probes were labelled with the 
fluorescent label FAM, and the housekeeping gene with the fluorescent label 
VIC. The settings of the thermal cycler are described in table 2.5.6. and the 
required solutions for quantitative real time PCR are given in appendix I. 
2.5.7. Data handling and statistical analysis for RNA 
To exclude a potential bias due to averaging data, which had been transformed 
through the equation 2'°°c`, all statistics were performed at the OCt stage. For 
both mRNA and protein findings, statistical analysis was undertaken using an 
unpaired Student's t-test. The threshold for significance was p<0.05. Data in the 
text and figures are presented as mean ± SEM. 
88 
2.6. Microarray analysis 
2.6.1 Outline 
After RNA extraction and quantification as described in section 2.5.1. RNA was 
reverse transcribed using a T7-Oligo(dT) Promoter Primer in the first-strand 
cDNA synthesis reaction and second- strand cDNA synthesized. The double- 
stranded cDNA was then purified and used as a template for the in vitro 
transcription (NT) reaction which was carried out in combination of T7 RNA 
Polymerase and a biotinylated nucleotide analog/ribonucleotide mix for 
complementary RNA (cRNA) amplification and biotin labelling. The 
biotinylated cRNA targets were then cleaned up, fragmented, and hybridised to 
GeneChip expression arrays. 
2.6.2. Preparation of controls 
To provide exogenous positive controls and to enable monitoring of the entire 
eukaryotic target labelling process, a set of poly-A RNA controls is supplied in 
the GeneChip Eukaryotic Poly-A RNA Control Kit. Each of this probes contains 
probe sets for several B. subtilis genes that are absent in eukaryotic samples (lys, 
phe, thr, and dap). These poly-A RNA controls and the polyadenylated 
transcripts for the B. subtilis genes are pre-mixed at staggered dilutions before 
being amplified, labelled together with the samples and spiked directly into 
RNA samples to achieve the final dilutions. Analysis of the hybridisation 
intensities of these controls on GeneChip arrays help to monitor the labelling 
process independently. 
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2.6.3. First-strand cDNA synthesis 
Extracted RNA (5µg) was mixed with diluted poly-A RNA controls and T7- 
Oligo(dT) Primer and water to a final volume of 12µL in 200µL centrifuge 
tubes. After being briefly centrifuged and incubated for 10 min at 70°C, the 
samples were cooled at 4°C for at least 2 min and briefly spun. 
RNA/T7-Oligo(dT) Primer Addition of : 
Mix Preparation 
Extracted variable First strand master mix Total 
sample volume 
RNA 
Diluted 2µL 5X Buffer 4µL 
poly-A 
RNA 
controls 
T7- 2µL 
Oligo(dT) DTT (O. IM) 2µL 
Primer 
RNase-free variable dNTP 
Water 
(10mM) lpL 
Volumes of 12µL 7µL 19µL 
components 
Addition 
of: Su erScri t21L 
Total 20pL 
volume 
Table 2.6.3.: Reagents for first-strand cDNA synthesis ana their voiumes 
A First-Strand Master Mix was prepared separately (Table 2.6.3. ) of which 7NL 
was added to each RNA/T7-Oligo(dT) Primer mix for a final volume of 19µL. 
The tube was flicked a few times and centrifuged briefly, and then immediately 
incubated at 42°C for 2 min. 1µL of SuperScript II was then added to each 
sample for a final volume of 20pL The tubes were mixed and centrifuged briefly 
before immediately being incubated at 42°C for 1 hr. After incubation the tubes 
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were cooled to 4°C and briefly spun before immediately continuing with second 
strand cDNA synthesis. 
2.6.4. Second-strand cDNA synthesis 
Second-strand master mix (130NL), which was prepared as described below, 
was added to the above sample, mixed, briefly centrifuged and incubated at 
16°C for 2 hr. T4 DNA polymerase (2µL) was added to each tube and incubated 
for a further 5 min at 16°C. After incubation, the reaction was stopped with 
addition of 10µL EDTA (0.5M). 
Above sample Addition of: 
Second strand 
Master Mix 
5X Buffer 30NL T4 DNA 
polymerase 
E. coli DNA 1µL 
EDTA 
ligase (0.5M) 
E. coli DNA 4p L 
Polymerase I 
RNase-free 91 µL 
Water 
dNTP 3µL 
(10mM) 
RNase H lpL 
Volumes of 20NL 130µL 2µL 10µL 
components 
Total volume 162pL 
Table 2.6.4.: Reagents of second-strand cDNA synthesis and their volumes 
2.6.5. Cleanup of double stranded cDNA 
To each of the above, cDNA preparation 600µL of cDNA binding buffer was 
added and briefly vortexed. This mix was loaded onto a cDNA cleanup spin 
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column and centrifuged for 1 min at 10,000 x g, the flow through was discarded 
and the column transferred to a new collection tube. After this, 750µL of cDNA 
wash buffer was added, the column was centrifuged for I min at 10,000 xg and 
the flow through discarded. The collection tubes were then centrifuged again for 
5 min at 10,000 xg with their caps opened to allow drying of the membranes. 
The spin columns were then transferred to fresh 1.5mL collection tubes and 
14µL of cDNA elution buffer added directly to the membranes. The tubes were 
incubated for I min at RT before spinning again for I min at 10,000 xg to elute 
and the collection tubes with the sample stored. 
2.6.6. Synthesis of biotin-labelled cRNA 
To 12pL of each sample from above section, 28µL a biotin labelling master 
mix, which was prepared according to table 2.6.6., was added, mixed and briefly 
spun before being incubated for 16 hr at 37°C. 
Above sample Addition of: 
Biotin labelling master mix 
loX IVT Labelling Buffer 4µL 
IVT Labelling NTP Mix 12µL 
IVT Labelling Enzyme 
Mix 
4µL 
RNase-free Water 8µL 
Volumes of 
components 
12µL 28µL 
I Total volume 40NL 
Table 2.6.6.: Biotin-labelled cRNA master mix preparation 
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2.6.7. Cleanup of biotin labelled cRNA 
RNase free water (60µL) was added to each sample and briefly vortexed after 
which 350µL of NT cRNA binding buffer was added and mixed. 250µL of 
100% ethanol was added, the tubes were mixed well again. This mix consisting 
of a volume of 700µL was added to the IVT cRNA cleanup spin column and 
centrifuged for 15 s at 10,000 x g, the flow through was discarded. The column 
was then transferred to a fresh collection tube and 500µL NT cRNA wash 
buffer was added before spinning again for 15 s at 10,000 xg and discarding the 
flow through. Next 500µL of ethanol (80%) each was added and the collection 
tubes centrifuged at 10,000 xg for 15 s and the flow through discarded. The 
tubes were then spun again for 5 min at 10,000 xg with their caps open to allow 
the drying of the membranes. The columns were then transferred to fresh 1.5mL 
collection tubes and 11µL of RNase free water added directly to the column 
membrane, the columns were then spun at 10,000 xg for 1 min and repeated 
with a second volume of 10µL of RNase free water to be added to the column 
membrane and the eluted fluid collected into the same collection tube. 
2.6.8. Fragmenting the cRNA for Target Preparation 
The cRNA was finally quantified using the nanodrop ND-1000 
spectrophotometer as described previously. For the fragmentation reaction 20µg 
of each cRNA sample was mixed with 8µL of 5X buffer to which RNase free 
water was added to achieve a final volume of 40µL then incubated for 35 min at 
94°C and placed on ice. 
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2.6.9. Target Hybridisation 
Fragmented and labelled cRNA (15µg) for each sample was used for the 
hybridisation cocktails (Table 2.6.9. ). The 20X GeneChip eukaryotic 
hybridisation controls were incubated for 5 min at 65°C before addition to 
ensure complete resuspension of cRNA. After its mixture the samples were 
incubated for 5 min at 99°C. 
Hybridisation cocktail 
Fragmented and labelled cRNA (15µg) variable 
Control oligonucleotide B2 (3nM) 5µL 
20x Eukaryotic Hybridisation 15µL 
Controls(bioB, bioC, bioD, cre) 15µL 
2X Hybridisation mix 150µL 
DMSO 30µL 
Nuclease free water variable 
Total Volume 300µL 
Table 2.6.9.: Reagents for hybridisation cocktail 
Meanwhile the arrays (Affymetrix Human Genome U133 Plus 2.0) were 
prepared for which they were wet with 200µL of pre-hybridisation mix by 
filling through one of the septa. The arrays were incubated for 10min at 45°C 
with rotation in the hybridisation oven. The hybridisation cocktail was also 
transferred to a 45°C incubation for 5 min before being centrifuged at 10,000 x 
g for 5 min in order to collect any insoluble material. The arrays were then 
removed from the hybridisation oven, vented with a clean pipette tip and the 
pre-hybridisation mix was removed. The arrays were refilled with 200µL of the 
clarified hybridisation cocktail and were placed back into the hybridisation oven 
set to 45°C and rotated at a rate of 100 g for 16 hr. 
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2.6.10. Array completion 
Following hybridisation, the arrays were removed from the oven, vented and the 
hybridisation cocktail removed and replaced by 250µL of wash buffer A. For 
each array one 1.5mL amber microcentrifuge tube containing 600µL of stain 
cocktail 1 was placed into the fluidics station; in addition clear 1.5mL 
microcentrifuge tubes containing 600µL of stain cocktail 2 and 800µL array 
holding buffer were added for each array. The probe arrays were inserted into 
the designated module of the fluidics station and the fluidics protocol 
FS450_0001 run. On completion of the wash and stain protocol, the arrays were 
removed from the fluidics station and sequentially scanned using the Affymetrix 
GeneChip scanner 3000. 
2.7. Immunohistochemistry 
Immunohistochemistry was used for assessment of the presence of specific 
proteins in various tissues as outlined below. 
2.7.1. Embedding tissue in wax 
Sections of tissue were processed in agreement with local ethical committee 
guidelines. Cubes of -1.5cm3 tissue (e. g. adipose tissue) were fixed by placing 
them in an excess of 10% formalin (Sigma, UK) diluted in mQH2O for between 
7 and 10 days (depending on size of block). Very small, thin blocks of tissue 
were fixed within 24-48 hr. Tissue was then dehydrated in varied concentrations 
and changes of ethanol for the following times; 
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70% Ethanol 2-3hr x2 changes 
90% Ethanol 2-3hr x2 changes 
100% Ethanol 4-8hr x 2-3 changes 
The tissue was cleared of ethanol using 100% xylene (Fisher, UK) for between 
1-5 hr (or until transparency was achieved) and xylene changed twice within the 
incubation time. The subsequent 8hr impregnation period included three 
separate dippings of tissue into molten wax (2-30°C above the melting point of 
wax) after which the tissue was cut into 3 micron thin slices and mounted onto 
electrostatically charged slides (Superfrost plus Slides, BDH Laboratory 
Supplies, Poole, UK). 
2.7.2. De-waxing of tissue sections 
Labelled slides were de-waxed by complete immersion in 100% xylene (Fisher, 
UK) with two 5 min washes; this was followed by two 3 min washes in IMS 
alcohol (100%). All slides were then re-hydrated by washing thoroughly under 
running tap water. Individual slides were placed in a coplin jar and treated with 
methanol-hydrogen peroxide (0.6%) to block endogenous peroxidase activity. 
Slides were then rinsed repeatedly in excess water. Slides were assembled in the 
Sequenza define (Shandon, UK) and rinsed in excess PBS solution (0.05mol/L, 
pH 7.6). Sections were blocked using 10% donkey serum (100µL) (DS) (ABC 
detection Kit, The Binding Site, UK) diluted in PBS for 30 min at RT. Slides 
were rinsed with PBS solution (0.05moIL, pH 7.6). 
96 
2.7.3. Incubation with primary and secondary antibody 
The labelled slides were incubated with 100µL of the primary antibody solution 
for lhr at room temperature. The solution contained 10% normal swine serum in 
PBS solution (0.05mol/L, pH 7.6) In order to produce a negative control, the 
primary antibody was omitted for the control slides. All tissue sections were 
rinsed with excess of PBS solution, the same which was used to dilute the 
secondary `universal' antibody to 1: 100 in PBS solution (0.05mol/L, pH 7.6). The 
latter was added to the slide sections for 30 min. The slides were rinsed again with 
PBS solution (0.05mol/L, pH 7.6) and incubated with avidin-biotin complex 
(ABC reagent) for 30 min. The ABC reagent was prepared 30 min before use 
(containing 1mL PBS (0.05mol/L, pH 7.6), 10µL avidin (Reagent A) and 10µL 
biotin (Reagent B), which is used to amplify and detect the secondary antibody. 
Following incubation the slides were placed on a staining tray and immersed 
into the DAB/urea mix (containing 10mg 3,3'-diaminobenzidine (DAB) and urea 
(0.17mg/mL) (Sigma, UK) dissolved in 20mL PBS) and incubated for 5-6 min 
or until a brown stain appeared. The reaction was stopped by rinsing with tap 
water. 
2.7.4. Counter-staining of sections and dehydration 
Sections were counter-stained with excess Mayer's haematoxylin (BDH, Poole, 
UK) for 30 s. The reaction was terminated by fully immersing slides in tap 
water. Slides were immersed for 5 min in 2 sequential tanks of IMS alcohol 
(100%), followed by 2 min submersion in two changes of xylene (100%). Slides 
were mounted in a xylene-based mountant (DPX; BDH, Poole Dorset, UK) by 
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placing a drop onto a glass coverslip and covering section. Pressure was applied 
to expel air bubbles from the coverslip and allow DPX to fully cover the section. 
2.7.5. Peptide Blocking 
Pre-absorption with immunising peptides was used to demonstrate the specificity 
of the antibodies. This was done by pre-incubation of the primary antibody for 1 hr 
with a peptide containing the epitope which was originally used to raise the 
antibody. This was performed in a solution containing 10% normal swine serum 
in PBS solution (0.05mol/L, pH 7.6) at room temperature. After 1 hr the 
antibody/peptide mixture was applied to sections in the sequenza slide rack and 
incubated as described above. 
2.7.6. Image acquisition 
The slides with stained mounted sections were analyzed under a standard light 
microscope; for magnification above x1000, an oil immersion technique was 
used. A real time digital image capture system (Amersham Biosciences, UK) 
was used to photograph sections. 
2.8. Separation of serum and plasma from blood 
In preparation of serum samples, whole blood was drawn directly into a BD- 
vacutainer® (BD) serum tube containing silica clot activator. Each sample was 
left at room temperature for 30 min to allow the blood to clot. Once clotted, the 
samples were centrifuged at 700 g for 15 min at room temperature. Supernatant 
was carefully drawn off and stored in labelled 1.5mL tubes at -70°C. A similar 
procedure was followed for plasma (vacutainer ® (BD) plasma tube. 
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2.9. Enzyme linked immuno-absorbant assay (ELISA) 
The following describes the basic procedure of ELISA, which varied according 
to antibody utilized. The microtiter ELISA plate is coated with a monoclonal 
human antibody, which is captured by corresponding protein molecules of the 
samples. The samples are loaded in appropriate dilutions according 
manufacturers recommendation. In the case of cerebrospinal fluid analysis, the 
required dilution ratio was judged by precedent assessment of different 
dilutional states and their agreement with the standard curve. After loading of 
standards, quality control and samples a further antibody was added and the 
plate was incubated for 2 hr. The immobilized antibody was treated with an 
enzyme solution, the free enzyme solution was removed after a further 
incubation period of usually 30 min and the activity of remaining and 
immobilized enzyme solution bound to the antibodies sample complex measured 
with help of chemo-luminescence. These were derived from enzyme activity 
after activation through a light sensitive substrate. A spectrophotometer was 
used to measure the intensity of absorbance of the samples. The values are then 
interpolated into a standard curve derived from samples with known protein 
concentrations generated in the same assay and concentrations of the protein in 
unknown samples obtained. Further details are given in the individual chapters. 
2.10. Glucose estimation 
Glucose was collected in vacutainers containing Fluoride and EDTA and 
immediately centrifuged at 3500 xg for 20 min and consequently assessed in the 
lab with an enzymatic colourimetric assay, the Glucose GOD Method. Glucose 
was oxidised by glucose-oxidase (GOD) to gluconolactone and hydrogen 
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peroxide. H202 was oxidised with phenol and peroxidase (POD) 4-amino- 
phenazone to 4-(p-benzochinone-monoimino)-phenazone, which is a red dye 
and its colour intensity and the photometrical signal directly proportional to the 
glucose concentration. 
Glucose + 02 + H2O º gluconolactone +H202 
H202 + 4-aminophenazone+ phenol º 4-(p-benzochinone- 
monoimino-phenazone) + 4H20 
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Chapter 3 
Adiponectin and resistin in human cerebrospinal fluid and 
adiponectin receptors in the human hypothalamus 
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3.1. Introduction 
Previous studies of the adipokine leptin have highlighted its role as a mediator in 
the crosstalk between adipose tissue and the brain in regulating energy 
homeostasis. Leptin's anorexic action is mediated primarily through neuronal 
targets in the arcuate nucleus within the hypothalamus where it inhibits NPY 
neurons. Recent studies also highlight that adiponectin appears to be involved in 
altering energy expenditure and thermogenesis (Qi, 2004) and resistin could affect 
hypothalamic feeding circuits (Brunetti, 2004). mRNA expression of resistin has 
also been found in the arcuate nucleus of mice (Morash, 2002). Adiponectin is a 
multimeric and multi functional protein, the levels of which are reduced in states 
of obesity and type 2 diabetes mellitus (T2DM); its effects appear mediated by 
adiponectin receptors (Wolfe, 2004; Berg, 2005; Yamauchi, 2003). In contrast, 
some reports are showing increased resistin in obesity and T2DM (McTernan, 
2006), whilst its receptors remain unknown. To date, however, little is known 
about the potential central action of either of these adipokines in humans. Many 
studies have investigated leptin, its pleiotropic functions - including its role in 
central energy homeostasis - and its passage through the human BBB. It can 
activate numerous signalling pathways (Fruhbeck, 2006) and, in particular, 
mediates its anorexigenic action through the AMPK pathway in the liver as well 
as the hypothalamus (Minokoshi, 2004). Furthermore, it has been shown that 
leptin can stimulate the sympathetic system centrally to produce feedback of fat 
mass by induction of lipolysis (Rayner, 2001). Leptin is a hormone which is 
predominantly secreted by adipocytes and also a key messenger to central energy 
homeostasis so it is likely that other adipokines contribute to the crosstalk 
between AT and the brain. 
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The aim of this study was to examine the potential central role of resistin and 
adiponectin in humans. Matched paired serum and human CSF samples from 
male and female patients were compared in order to explore the relationship 
between CSF and the corresponding serum levels and to determine the CSF/serum 
ratio as a measure of efficient uptake into the CSF. This study also considered 
possible correlations between adiponectin, resistin and leptin in CSF with age, 
gender, BMI and HOMA index. Finally, this study determined the expression and 
distribution of adiponectin receptors in the human hypothalamus. These issues 
have become particularly important in the light of recent report that adiponectin is 
not present in human CSF (Spranger, 2006) and exogenous adiponectin does not 
enter the BBB by endocytosis of rodent RBE4 cerebral microvessel endothelial 
cells (Pan, 2006). 
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3.2 Materials and Methods 
3.2.1 Subjects 
Serum and CSF matched samples were obtained from adult age and BMI matched 
subjects (men: Age: 69.8(mean±SD)8.6years, BMI: 29.4±3.4kg/m2, n=20; 
women: Age: 69.4±4.3years, BMI: 27.3±4.8kg/m2, n=19) undergoing elective 
surgery, under spinal anaesthesia and fasted for at least 8 hrs (Table 3.3.4. ). All 
samples were collected with the approval of the local ethics committees and with 
the informed written consent of all study subjects who were personally consented. 
They were approached after being identified as candidates for spinal anaesthesia 
and agreement of their individually assigned anaesthetist and surgeon. Exclusion 
criteria were malignancy, acute or chronic renal or liver disease, neurological 
disorders, the use of immunosuppressants, current or recent use of systemic high 
dose corticosteroids, antibiotics or weight modifying medication. Patients with C- 
reactive protein (CRP) levels above 10 mg/dL were also excluded. Surgical 
interventions consisted mainly of orthopaedic procedures: 10 knee and 12 hip 
replacements, 4 arthroscopies, and the remainder 16 were minor gynaecological 
and urological procedures. Patient characteristics are shown in Table 3.3.4.. 
A fasting blood sample (5mL) was taken at the time of venopuncture and a clear 
CSF sample (2mL) collected before the spinal anaesthetic agent was injected. Six 
patients had type 2 diabetes (two on daily insulin treatment) and three had 
impaired glucose tolerance (IGT). The T2DM subjects were on glucose/insulin 
infusion at the time of cannulation and could not be considered for HOMA-IR 
calculation. The HOMA index was used as a measure of insulin resistance (see 
below). Serum and plasma EDTA samples were immediately centrifuged, snap 
frozen in liquid nitrogen and stored at -80°C. CSF samples were passed through a 
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0.2micron syringe filter (Schleicher & Schuell, UK), flash frozen and stored at - 
80°C. 
3.2.2. Analysis of serum samples 
The serum samples were analysed for the determination of adiponectin (1: 500 
dilution; Linco Research Inc., Missouri, USA) with the assay limit of 0.78ng/mL, 
intra-assay %CV was 7.4% and inter-assay variability was 2.4-8.4%. Serum 
resistin levels were analyzed by ELISA (1: 5 dilution; Quantikine, R&DSystems, 
UK). Assay limits were noted between 0.01-0.055 ng/mL with intra-assay % CV 
noted as between 3.8-5.3% and inter-assay variability being 7.8-9.2%. The 
recovery of resistin in serum and cross-reactivity with resistin-like molecules 
(RELMs) was assessed as previously described (McTernan, 2002). 
The leptin ELISA (1: 100 dilution; Quantikine, R&D systems, UK) has a minimum 
detectable value of 7.8pg/mL with an intra-assay precision of 3-3.3%CV and 
inter-assay variability of 3.5-5.4%CV. The high sensitive CRP ELISA (Life 
Diagnostics Inc., USA) has a functional sensitivity of 0. lmg/dl, intra-assay 
precision of 2-7.5%CV and inter-assay variability of 2.5-4.1%CV. An insulin 
ELISA (Linco Research Inc. Missouri, USA) was utilised with the sensitivity of 
2µU/mL; intra-assay %CV was 5.96 and inter-assay variability was 10.3%CV in 
accordance with the manufacturer's protocol. Glucose levels were analysed using 
the YSI-2300 STAT PLUS, according to the manufacturer's instructions. 
The HOMA2-IR index was calculated using the HOMA calculator (available at: 
www. dtu. ox. ac. uk/index. html? maindoc=/homa/. University of Oxford, UK). 
which is suitable for use of insulin values derived by modern ELISA assays. 
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3.2.3. Analysis of CSF levels 
CSF samples were used undiluted for assessment of adiponectin (20µL), resistin 
(100µL) and (10µL) leptin. The serial dilution of CSF detected adiponectin levels 
up to a1 in 4 dilution (86% of value expected 1 in 2 dilution and 80% of value 
expected 1 in 4 dilution). A similar serial dilution was documented for resistin, 
serial dilution ranging from undiluted to 1 in 8. The use of neat CSF sample 
produced results with a recovery of 100%, and therefore deemed most acceptable 
in this system. 
The potential sources of cross-reactivity in the adiponectin ELISA was assessed 
for Clq (Abeam, Cambridge, UK), collagen type III (Sigma, Poole, UK) and 
collagen type IV (Sigma, Poole, UK). For this human recombinant (rh) Clq, rh 
collagen type III and rh type IV were analysed at two concentrations (lOng/mL, 
lOOng/mL) in either the presence of phosphate buffered saline pH 7.6 (Sigma, 
Poole, UK) or in combination with CSF. No detectable cross-reactivity occurred 
between rh Clq, rh collagen type III and rh type IV alone or in combination with 
CSF samples and adiponectin in this ELISA. The inter- and intra- assay 
coefficients were evaluated for samples ranging from 12.1-15.9ng/mL CSF 
adiponectin. The within percentage CV was 2.5% and the between CVs were 6.7, 
2.4 and 5.3%. The means between variations were calculated as described in the 
manufacturer's instructions. 
Spiking and recovery of human adiponectin in CSF was further examined. Human 
rh adiponectin (20ng/mL, 50ng/mL) was added to known concentrations of 
adiponectin in pooled CSF samples (12.3ng/mL, 15.9ng/mL respectively) and 
adiponectin content was determined in three separate assays. The percentage of 
recovery was determined according to manufacturers' instructions. We observed 
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that recovery ranged from 93 to 97% in CSF, which was within a comparable 
range as noted for serum according to the manufacturer's detailed assessments. 
Spiking and recovery of human resistin in CSF was also addressed. For these 
studies two concentrations of rh resistin (0.5ng/mL and 2ng/mL) were added to 
known concentrations of resistin in pooled CSF samples (0.03ng/mL, 0.08ng/mL 
respectively) and resistin concentration was determined in three separate ELISA 
assays. The percentage of resistin recovery ranged from 81 to 99%, with a mean 
of 88% in CSF, again similar recovery for serum findings was noted by the 
manufacturer as well as from our previous publications (McTernan, 2003). 
Blood contamination was excluded with use of the micropore filter described 
above. The cell count in CSF samples with the haemocytometer (Appendix II) did 
not show any nucleus bearing cells. Further screening of the CSF samples with 
the Haemoccult test (Hema-screenTm; Immunostics Inc, New Jersey, USA) 
(Appendix II) test was negative yet the test remained positive with spiking of full 
blood at a concentration of 1: 10,000. 
3.2.4. Immunohistochemical staining for adiponectin receptors 
Human adipose tissue was obtained from Medical Solutions (Peterborough, UK). 
Hypothalamic post-autopsy sections were obtained with the approval of the Varna 
Medical Research Ethics Committee from Varna University, Bulgaria. Paraffin 
embedded tissue sections were prepared for immunohistochemical staining as 
described in Chapter 2. Tissue was incubated with primary polyclonal AdipoRl 
and AdipR2 antibody (Phoenix Pharmaceuticals, USA) in a dilution of 1: 2500 and 
1: 200 respectively and dual stained with NPY in a dilution of 1: 400. Sections 
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were developed using peroxidase substrate kit VIP® (Vector Laboratories Ltd., 
Peterborough, UK) for AdipoR 1 and 2 and with diaminobenzidine (BioGenex, 
California, USA) for NPY. To demonstrate specific binding, the primary antibody 
was omitted for negative control for each primary antibody individually. 
3.2.5. Statistical analysis of results. 
Statistics were performed using SPSS version 14 (SPSS UK, Surrey, UK). P 
values of less than 0.05 were considered as statistically significant. Analysis of 
normally distributed variables was by linear regression analysis and two tailed 
Student's t-test. For non-parametric distributions, e. g., HOMA, we used the 
Spearman correlation. Values are expressed as mean ± standard deviation of the 
mean, unless otherwise stated. 
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3.3 Results 
3.3.1. Presence of adiponectin and resistin in CSF 
The presence of leptin was confirmed in human CSF, but the presence of both 
adiponectin and resistin were also identified. The figure below shows the 
relationship with corresponding serum samples. In relation to its serum levels, the 
CSF adiponectin proportion is much lower (1: 1000) than resistin (1: 100), however 
the absolute concentration of adiponectin in CSF is higher than CSF resistin, and 
in the range of serum resistin. The levels will be discussed further under the 
individual subheadings. 
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Figure 3.3.1.: Serum adiponectin levels (pg/mL) are 1000 times lower in CSF 
(ng/mL) and serum resistin levels (ng/mL) are 100 times lower in CSF (pg/mL). 
3.3.2. Leptin 
3.3.2.1. Serum leptin 
Mean serum levels of leptin in this study population were 17.4±2.5ng/mL with 
significantly higher levels identified in women (22.5±3.7ng/mL versus men: 
13±3ng/mL, p=0.03). Serum leptin levels were positively correlated with BMI 
(overall r=0.52, p<0.001; men: r=0.75, p=0.001; women: r=0.82; p<0.001) and 
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Serum 
showed no correlation with age. Serum leptin was higher in T2DM than in non- 
diabetic subjects (28.9t5.8ng/mL versus 12.5±8.7ng/mL, p=0.02). 
3.3.2.2. CSF levels of leptin 
The CSF levels showed a tendency towards higher leptin levels in women than 
men but this was not significant (women: 79±9pg/mL versus men: 56±9pg/mL, 
p=NS). CSF leptin was positively correlated with BMI in men and women 
(r=0.42, p=0.028) but not with age. In comparison to the observed association of 
serum leptin with diabetes there was no significant difference of CSF leptin in the 
T2DM subjects (T2DM subjects: 105±2pg/mL versus non-diabetic subjects: 
62±7pg/mL, p=NS). 
3.3.2.3. CSF/serum ratio of leptin 
To establish the proportion of serum levels which may enter the CSF, we 
calculated the CSF/serum ratio. There was a negative correlation of the 
CSF/serum ratio with serum levels, which was similar to previous reports best 
described by a logarithmic association (r=0.62, p=0.001) (Figure 3.3.5.1. A). 
Whilst there was a BMI correlation with CSF leptin in men but not in women (see 
above), an inverse correlation of the CSF/Serum ratio with BMI in women (r=- 
0.81, p=0.001) was noted, which did not show a correlation with BMI in men (r=- 
0.17, NS) (Figure 3.3.5.2. A). This means that with increasing BMI the relative or 
proportional quantity of leptin in CSF in women is lower. This CSF/Serum BMI 
correlation was previously reported and gave rise to the hypothesis of leptin 
resistance (Wiedenhoft, 1999). 
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3.3.3. Adiponectin 
3.3.3.1. Serum adiponectin 
Serum adiponectin was significantly higher in women (31.5±1.2µg/mL versus 
men: 22.2±1.1µg/mL (mean±SD), p=0.016). Adiponectin correlated positively 
with age in men (r=0.56, p=0.01), but not significantly in women (r=0.36, p=NS). 
Serum adiponectin showed a negative association with BMI in men (r=-0.46, 
p=0.04), whilst only a trend was noted in women (r=-0.27, NS). In agreement 
with previous studies, the HOMA-IR index and serum adiponectin were inversely 
correlated for the total study population (r=-0.48, p<0.001) and the levels 
significantly lower in the T2DM and insulin resistant subjects than in non-diabetic 
subjects (19.2t3µg/mL, n=9 versus 28.8±2.9gg/mL, n=30; p=0.02). 
3.3.3.2. CSF adiponectin 
Mean CSF adiponectin was 16.3±6ng/mL with a range of 7.2-41.6ng/mL, thus the 
CSF levels were approximately 1000 fold lower than the serum adiponectin levels 
(Figure 3.3.1). Unlike in the serum, CSF adiponectin did not show a sexual 
dimorphism (men: 16.7±8.3ng/mL; women: 15.9±3.6ng/mL; p=0.7). However, 
there was a positive age correlation (r=0.36, p=0.036, n=35) overall which was 
present in both men and women (r=0.55, p=0.035; r=0.5, p=0.036; respectively). 
CSF adiponectin was inversely correlated with BMI in men (r=-0.62, p=0.01) but 
not in women (r=-0.26, NS). HOMA-IR and CSF adiponectin levels showed no 
correlation or difference between the T2DM and non-diabetic subjects. 
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3.3.3.3. CSF/serum ratio of adiponectin 
The CSF adiponectin levels exhibited a positive linear correlation with serum 
levels (r=0.34, p=0.047, n=34). CSF/serum adiponectin ratios were significantly 
higher in men (1.0±0.11 (* 10"3) than in women 0.65±0.06 (* 10"3) respectively, 
p<0.01) and inversely related with serum adiponectin levels (r=-0.72, p<0.001, 
n=34), suggesting a higher entry of adiponectin into the CSF at low serum values. 
The best description of this association was achieved by a logarithmic curve fit 
(Figure 3.3.4 B). The CSF/Serum ratio was inversely correlated with BMI in 
women (r=-0.61, p=0.02) and did not show a correlation in men (r=0.026, NS) 
(Figure 3.3.5 B). 
3.3.4 Resistin 
3.3.4.1. Serum resistin 
Mean serum resistin levels were 14.8±8ng/mL and showed slightly higher levels 
in women (15.8ng/mL versus men: 14.97ng/mL) but this was not significant (t- 
test p=0.08). Resistin levels correlated positively with increasing age (r=0.45, 
p<0.01) with no correlation observed with BMI (r=-0.21, p=NS) or HOMA-IR 
(r=-0.32, p=NS) index. 
3.3.4.2. CSF resistin 
The mean CSF resistin level was measured as 0.2±0.13ng/mL, with a range of 
0.01-0.63ng/mL. CSF resistin levels were not influenced by gender (p=0.65). 
Furthermore, CSF resistin levels did not correlate with age (r=0.09, NS) and 
remained unaltered by diabetic status with no correlation with the HOMA-IR 
index (r=0.24, NS). 
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3.3.4.3. CSF/ Serum ratio of resistin 
The CSF/serum ratio did not differ significantly between males and females. 
However the CSF/serum ratio correlated strongly with the serum levels in men 
(r=-0.57, p-0.013) and women (r=-0.77, p=0.001) as best described by a 
logarithmic graph (Figure 3.3.5.1. B) similar to the correlation described for leptin 
and adiponectin. The CSF/serum ratio bore no relationship with BMI in either 
men or women (Figure 3.3.5.2. B). 
Variable All Subjects men women 
Number of 39 20 19 
subjects 
Age (years) 69.4±9 69.8±8.6 69.4±4.3 
BMI (kg/m2) 28±4.6 29.4±3.4 27.3±4.8 
Insulin (mU/L) 5.5±3.4 6.2±4 4.8±2.6 
HOMA-IR 1.34±1 1.5±1.2 1.2±0.8 
Leptin 
Serum(ng/mL) 17.4±12.5 13±11 22.5±13.7* 
CSF(pg/mL) 67±13 56±9 79±9 
Adiponectin 
Serum(pg/mL) 26.6±12 22.2±11 31.5±12* 
CSF(ng/mL) 16.3±6 16.7±8.3 15.9±3.6 
Resistin 
Serum(ng/mL) 14.8±8 14.1±7 15±8 
CSF(ng/mL) 0.2±0.13 0.2±0.15 0.19±0.12 
Table 3.3.4.: Baseline characteristics of the CSF study population and distribution 
of adipokines levels (mean±SD) between men and women. Significant gender 
differences are expressed as * p<0.05. SD: standard deviation, BMI: body mass 
index, HOMA-IR: Homeostasis Assessment Model for Insulin Resistance, CSF: 
Cerebrospinal fluid 
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3.3.5. Mode of CSF entry of the three adipokines leptin, adiponectin and 
resistin 
The CSF/serum ratio at a given serum level allows conclusion as to the pattern of 
CSF entry, e. g., a high CSF/serum ratio suggests that a relatively higher amount is 
able to enter the CSF and the transport across the BBB is facilitated. If the ratio 
remained the same, passive diffusion of the protein was more likely. 
3.3.5.1. CSF/serum ratio and its relationship with serum levels 
The inverse logarithmic curve fit of the CSF/serum ratio with corresponding 
serum levels for all three adipokines suggests that at low serum levels, there is a 
higher proportion of protein entering the CSF, which implies a saturated transport 
mechanism. 
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Figure 3.3.5.1.: Association of the CSF/serum ratio with serum levels as 
logarithmic graphs for A: leptin (inverse correlation) B: adiponectin (inverse 
correlation) C: resistin (inverse correlation) (r represents the correlation 
coefficient of curve of best fit, p values as shown on Figure). 
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3.3.5.2. Comparison of the CSF/serum ratios in relation to BMI 
Following figure shows the relationship the CSF/serum ratios with BMI for the 
three adipokines: leptin, adiponectin and resistin. Whilst neither men nor women 
show a BMI association with resistin, the curve fit in women describes a 
significant inverse correlation for leptin and adiponectin as shown in Figure 
3.3.5.2.. 
3.3.5.3. Relationship of the adipokines with insulin resistance 
As mentioned above, diabetic patients were not included in the calculation of 
HOMA-IR, since they were treated with insulin/dextrose infusion before 
obtaining the blood test. The data shown below therefore exclusively relate to a 
range of insulin resistance without considering the diabetic range. A comparison 
of serum and CSF HOMA correlation of all three adipokines shows that there is 
no correlation of CSF levels of the investigated adipokines with HOMA-IR 
3.3.5.3.1. Leptin 
As shown above, the leptin levels correlate positively with T2DM. The HOMA- 
IR or logHOMA-IR were not normally distributed and we therefore used the 
Spearman coefficient for statistical analysis. Serum leptin was positively 
correlated with HOMA-IR (r= 0.431, p<0.01), similar to that observed by 
previous studies (Silha, 2003). However, both leptin and insulin resistance are 
also affected by a positive BMI, correlation which may be responsible for this 
result (Figure 3.3.5.3.1. ). 
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Figure 3.3.5.3.1.: Association of serum and CSF leptin levels with the HOMA- 
IR. Ap value of < 0.5 is considered as significant. 
3.3.5.3.2. Adiponectin 
There is an inverse correlation of serum adiponectin with HOMA-IR, which is 
manifest in both men and women (not shown). In CSF, however, there is no 
correlation of adiponectin levels with insulin resistance. Similarly, there is also no 
correlation with CSF resistin and the index for insulin resistance. 
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Figure 3.3.5.3.1: Association of serum and CSF adiponectin levels with the 
HOMA-IR. 
3.3.5.3.3. Resistin 
Resistin is not correlated with HOMA2-IR within our non-diabetic study 
population as shown in Figure 3.3.5.3.3. 
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3.3.6. Adiponectin receptors in the human hypothalamus 
Immunohistochemistry showed the expression of AdipoRl and 2 in the neuronal 
cells in the human hypothalamus (Figure 3.3.6. ). AdipoRl was expressed in both 
the anterior and posterior hypothalamus in a diffuse distribution, whilst AdipoR2 
was concentrated in the PVN along with neurons which were dual stained with 
NPY (brown colour). 
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Figure 3.3.6: Immunohistological staining of (A) human hypothalamus with 
positive staining for AdipRi (brown; x1000 Magnification); (B) negative staining 
for human hypothalamus (blue); (C) human hypothalamus with positive staining 
for AdipR2 (brown; x1000 Mag. ) which highlights the area of the paraventricular 
nucleus and (D) shows dual staining of AdipR2 (red) and NPY (brown); note the 
dendritic projections of the neural cells and cytoplasmatic expression of AdipR2; 
(E) human adipose tissue with positive staining for AdipRl(red), (F) negative 
staining for human AT (blue; x2000 Mag. ). 
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3.4. Discussion 
This is the first study to detect the adipokines, adiponectin and resistin, in human 
CSF. Unlike the recently published findings by Spranger (2006), low adiponectin 
concentrations were detected which are on average approximately 1000 fold 
lower, in the CSF than serum. The same 1: 1000 ratio of CSF to serum adiponectin 
was also previously found in rats (Caja, 2005a), but a higher ratio (1: 100) has 
been observed in mice (Qi, 2004). Taken together, these results suggest the 
presence of adiponectin in CSF in more than one species and a probable species- 
specific variation. Determination of resistin in human CSF found resistin at 
approximately levels 100 times lower in CSF than serum. In contrast, no resistin 
was identified in the CSF of rodents (Caja, 2005b), though resistin mRNA 
expression was previously found at low levels in the hypothalamus of the mouse 
brain (Morash, 2002). The relationship between CSF and serum levels varied 
between patients depending on variables including BMI and the magnitude of the 
serum levels of the adipokine which, if high, could exceed the threshold of 
saturation in CSF. This is also the first study to identify presence of AdipoRl and 
AdipoR2 not only in the rat brain (Qi, 2004) but in the human hypothalamus, with 
concentrated expression of AdipoR2 in neuronal cells of the PVN which also 
express NPY. A previous study has demonstrated mRNA expression of AdipoRl 
and 2 on human endothelial cells of the choroid plexus (Spranger, 2006) which 
controls entry of proteins through the BBB and where functional leptin receptors 
have also been identified (Merino, 2006). Adiponectin could thus be transported 
from blood to CSF by receptor mediated transcytosis similar to what was 
proposed for leptin. A very recent publication (Fry, 2006) not only confirms that 
AdipoRl and 2 are expressed in the area postrema of the rat brain, but their 
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expression mediates adiponectin signals by electrophysiological stimulation, 
which further supports a central role for adiponectin. These data suggest that 
adiponectin enters the CSF with potential action via neuronal pathways in the 
PVN, a hypothalamic area which receives input from the arcuate nucleus -a 
region of the brain containing key appetite regulating pathways via NPY neurons 
(Cowley, 1999). Qi and co-workers (2004) have shown increased cFOS 
immunoreactivity especially in the PVN after intravenous and 
intracerebroventricular (icv) adiponectin injection into mice, which further 
strengthens the hypothesis that adiponectin acts in neuronal pathways of the PVN. 
It is possible that adiponectin's function is dependent on different neuronal 
networks to leptin, for which studies have highlighted that cFOS 
immunoreactivity was highest in the arcuate nucleus (Qi, 2004). Nevertheless, the 
same study provides some evidence of synergistic function, in that both hormones 
influence the expression of hypothalamic corticotropin-releasing hormone (CRH) 
and that both use the melanocortin pathway (Qi, 2004). Despite numerous studies, 
it is still unclear how the adipokine leptin gains access to the arcuate nucleus 
(Bjorbaek, 1998) and further studies are necessary to identify this and the 
mechanism of entry into the CNS for adiponectin. 
While there is some confirmation of the presence of adiponectin in CSF, receptor 
expression in the brain and c-Fos activity triggered by adiponectin (Qi, 2004), 
other studies have failed to establish the presence of adiponectin in human CSF 
(Spranger, 2006) or could not verify passage of adiponectin through the BBB 
(Pan, 2006). This may be due to the need for high sensitivity assays to be utilized 
for its detection. Also, entry of additional adiponectin when administered as 
radioactive labelled intravenous adiponectin would not show observable 
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difference due to the low and potentially already saturated levels of CSF 
adiponectin. 
Leptin is a known potent central appetite regulator (Schwartz, 1996b) and its 
serum levels directly correlate with fat mass (Zhang, 1994). The distribution of 
leptin levels within this study group was compared for consistency with those 
previously reported Nam, 2001; Rodrigues, 2002; Wong, 2004; Zloklovic, 2000) 
and has highlighted variation (Nam, 2001). The average leptin CSF levels in the 
above findings were relatively low in comparison with some previously reported 
data (Nam, 2001) whilst similar to other studies (Zhang, 1994; Wong, 2004). A 
comparison of CSF concentrations of fasting CSF leptin levels (mean 0.04ng/mL, 
CSF/serum ratio of 1: 100) showed that they were much smaller than those of 
either adiponectin (16.3ng/mL) or resistin (0.2ng/mL). This suggests that the 
concentrations of CSF adiponectin and resistin reside in the appropriate range to 
activate CNS effects (Corp, 1998; Zloklovic, 2000). 
AdipoRl and 2 can be activated by both globular and full-length adiponectin. 
AdipoRl shows a high affinity for globular adiponectin but data for binding 
affinities only exist for the muscle receptors in mice (Yamauchi, 2003) and not for 
neuronal cells in humans. Much lower concentrations than in the periphery are 
sufficient for activation of neural pathways and signalling in the hypothalamic 
nuclei for proteins like leptin (Campfield, 1995; Zloklovic, 2000). Adiponectin 
receptors mediate action through signalling molecules such as PPAR-x, MAPK 
and AMPK (Tomas, 2002; Fisher, 2005). Serum adiponectin exists in various 
isoforms, from truncated globular structures to high order molecules. HMW 
isoforms are attributed with more protective properties than LMW forms (Fisher, 
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2005). AMPK can be activated by globular adiponectin as well as trimers (Tomas, 
2002) and plays a critical role in the central nervous system. Its pathways are 
involved in hormonal and nutrient signalling in the hypothalamus, including the 
regulation of food intake by leptin and insulin (Minokoshi, 2004). Besides 
AdipoRl and AdipoR2, hexamers and HMW isoforms of adiponectin can also 
bind to T-cadherin (Hug, 2004) which has yet undefined biological functions. T- 
cadherin was first discovered in the central nervous system, but is also present in 
endothelial cells and smooth muscle cells. T-cadherin is unlikely to play a role in 
central appetite regulation given that HMW do not induce AMPK activation but 
mediate their action through nuclear factor-uB (NF-icB) in the periphery (Tsao, 
2003). 
In concordance with previous observations, serum adiponectin is gender 
dependent, with females showing significantly higher circulating levels 
(Okamoto, 2000). As in other studies, serum and CSF adiponectin were inversely 
correlated with BMI in men but not in women (Vilarassa, 2005). Whilst the serum 
adiponectin levels showed sexual dimorphism, intrathecal adiponectin levels 
showed no gender difference. This pattern of higher circulating serum levels in 
women with no CSF gender difference has previously been described for leptin 
(Wiedenhoft, 1999) and reaffirmed within this study population. A possible 
gender difference in transport of the BBB in regards of rate and capacity has 
previously been discussed (Blum, 1997). 
This study does not allow determining which isoforms of adiponectin enter the 
CSF directly. However, with the report of higher serum HMW in women 
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(Okamoto, 2000) and lack of gender difference in CSF, it is likely that high 
molecular structures do not enter the CSF. Additionally, due to the size of HMW 
structures (> 500kDa) these are unlikely to pass through the BBB and 
multimerisation within the CSF is unlikely. 
The CSF/ serum ratio and serum adiponectin association of leptin and adiponectin 
follows a similar pattern, thus suggesting, that adiponectin enters the CSF space 
via an active regulated and saturable transport system in a similar manner to leptin 
(Wiedenhoft, 1999). 
Resistin appears to have a role in obesity associated inflammation and insulin 
resistance which remains controversial in the human context (Hirosumi, 2002; 
McTernan, 2003). In this study raised circulating resistin levels do not correspond 
with higher CSF levels suggesting limited uptake into the CSF. The wide 
variation in resistin concentration requires further studies to examine entry of 
resistin across the BBB. No correlation between serum and CSF resistin levels 
were observed with BMI and neither of the adipokines' CSF levels were noted to 
be affected by insulin resistance. T2DM is also associated with reduced HMW 
isoforms (Fisher, 2005) and impairs the multimerisation of adiponectin (Waki, 
2003). Thus, adiponectin CSF levels may predominantly constitute of LMW 
isoforms for reasons explained above and, as such, may not be affected by 
diabetes. 
In summary, adiponectin and resistin are present in human CSF with levels 
unaffected by gender. Adiponectin receptors AdipoRl and AdipoR2 are present in 
the human hypothalamus, especially the PVN which strengthens the hypothesis 
that they are involved in central energy homeostasis in humans. These findings 
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highlight the potential involvement of adipokines in central energy homeostasis in 
humans. Based on this data, an active transport mechanism for both adiponectin 
and resistin across the BBB is likely. 
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Chapter 4 
NPY and adipose tissue 
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4.1. Introduction 
The neurotransmitter NPY has been well characterised for its central orexigenic 
function and hypothalamic levels of NPY reflect the nutritional status (Wilding, 
1992). However, NPY and its receptors are not only present in the central 
nervous system, but in many peripheral sites where they are involved amongst 
others in the regulation of angiogenesis, vasoconstriction, mood regulation and 
fertility (Chronwall, 2004). Within the periphery, NPY has been identified as a 
hormone which can promote fat accumulation through upregulation of 
lipoprotein lipase (LPL) activity, thus supporting an antilipolytic role for NPY 
(Billington, 1991). Several studies have confirmed the presence of receptors 
mediating NPY action in adipose tissue (AT) in mammals including humans 
(Castan, 1994; Labelle, 1997; Bradley, 2005). Currently, the presence of NPY in 
AT is thought to be derived through the sympathetic nervous system (SNS) 
innervation of white adipose tissue (WAT), with depot specific differences in 
rodents and humans (Dodt, 1999). NPY is coreleased with the neurotransmitter 
norephinephrine (NE) in peripheral, adrenal and central catecholaminergic 
neurons (Everitt, 1984). NE is a potent stimulator of lipolysis (Carpene, 1998) 
and an increase in SNS innervation induces increased lipid mobilisation and 
glycerol release (Dodt, 1999), which is thought to be mediated by NE. NE action 
and SNS innervation thus contradicts the antilipolytic effect of NPY. Thus for 
NPY to mediate an opposing effect to its cotransmittter NE, an independent 
source of NPY free of SNS is possible, i. e., by secretion of NPY from 
adipocytes. 
Insulin and leptin are key regulators of energy homeostasis, as discussed in 
Chapter 1. Circulating levels of insulin and leptin are directly correlated to the 
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amount of body fat mass (Considine, 1996; Bagdade, 1967); furthermore, 
intracerebroventricular (icv) administration of insulin and leptin can reduce food 
intake (Campfield, 1995; Woods, 1979), consistent with crosstalk between the 
brain and adipose tissue and a central feedback circuit for energy homeostasis. 
Icv administration of insulin and leptin not only decreases food intake, but also 
reduces the fasting induced rise of NPY mRNA in the arcuate nucleus (Porte, 
1981; Sato, 2005; Fekete, 2006). Little, however, is known about a possible 
interaction of these appetite regulators: NPY, leptin and insulin in the periphery. 
Y1 (NPY receptor 1), as one of four NPY human receptors, is thought to mediate 
the antilipolytic function of NPY (Bradley, 2005). Cleavage of proline by 
dipeptidyl peptidase-IV (DPP-IV) generates NPY3.36 from NPY1.36 and diverts 
NPY binding from Y1 to other receptors (Mentlein, 1999). Consequently, DPP- 
N can be regarded as an endogenous Y1 receptor antagonist (Zukowska-Grojec, 
1998a) to inhibit NPY's antilipolytic activity. It would therefore be of interest to 
determine whether DPP-N is present in AT and, how its expression is related to 
obesity. DPP-N inhibitors are novel therapeutic agents in the treatment of 
T2DM (i. e., vildagliptin and sitagliptin) with the purpose to increase the half-life 
of the incretin hormone glucagon like peptide-1 (GLP-1) (Burkey, 2005). GLP-1 
is also cleaved by DPP-N and DPP-IV reduces its insulin secreting potential 
(Ahren, 2004). However, the effect of DPP-IV inhibitors on NPY metabolism 
with NPY1.36 being one of DPP-IV best substrates (Mentlein, 1999) has, to date, 
received little attention. 
The aim of this study was firstly, to determine protein expression of NPY in 
adipocytes; secondly, to investigate whether NPY is regulated by insulin and 
leptin and whether its secretion is modulated by the PPARy agonist, rosiglitazone 
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(RSG); thirdly, to determine the influence of NPY on the level of adiponectin 
secretion and finally, to evaluate the expression of DPP-IV in AT, which is 
known to modulate the function of NPY. 
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4.2. Materials and Methods 
4.2.1. Subjects 
AT samples were obtained from thirty eight consenting Caucasian female 
subjects undergoing elective surgery (mean age: 42.70.3years; BMI: 
26.2t4.5kg/m2 (meantSD)). Abdominal subcutaneous (Abd Sc), omental (Om) 
and thigh tissue (Th) samples were collected with the approval of the South 
Birmingham Ethics Committee. Subjects receiving endocrine therapy (e. g., 
steroids, HRT, thyroxine) and patients with malignant diseases were excluded. A 
separate cohort of Abd Sc (n=10) AT samples from female patients (age: 
45.4±9.2years; BMI: 28.1±2.2kg/m2) was used for microarray analysis and flash 
frozen prior to RNA extraction. 
Additionally, fasting serum samples were taken from 24 non-smoking Caucasian 
healthy volunteers (13 men and 11 women) with approval of the Coventry and 
Warwickshire Ethics Committee. (Mean age: 45.4±9.2years; BMI: 
28.0±5.8kg/m2). Peri- or postmenopausal women were excluded as well as 
people with history of a recent weight change. Serum was centrifuged at 700 g 
for 15 min, snap frozen and stored at -80°C to be used for protein analyses as 
described below. 
4.2.2. Adipose tissue processing and tissue culture 
The freshly acquired AT was split into two sections. The first part was 
immediately flash frozen and stored at -80°C to be kept for later protein 
extraction with RIPA, whilst the remainder was utilised for in vitro culture of 
isolated Abd Sc mature adipocytes. The procedure of adipocyte isolation and cell 
culture are in detail described in Chapter 2.1. and 2.2. Abd Sc adipocytes were 
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treated with rh Insulin (1,100 and 1000nM) (human recombinant insulin 
expressed in Escherichia coli; Sigma, Poole, UK), insulin in combination with 
RSG (10"8mol/L) (GlaxoSmithKline, Harlow, UK) and insulin (100nmol/L) or 
RSG alone (10"8mol/L) for 48 hr. Untreated adipocytes were used as controls. 
These media were used to measure NPY secretion by ELISA. Some of the Abd 
Sc adipocytes were also treated with 1,10 and 100nmol/L of rh NPY (Sigma- 
Aldrich, UK) for 48 hr and the conditioned media used for analysis of various 
adipokines was performed (see below) by ELISA. In parallel, a series of the 
same NPY treatments was performed with addition of 1M DPP-IV (dipeptidyl 
esterase-IV blocker (Sigma, Poole, UK). 
4.2.3. Protein extraction and NPY Western blot analysis 
A small piece of frozen tissue was homogenized and extracted with RIPA buffer 
(see Chapter 2.3.1. ) The protein content was then determined using a Bio-Rad 
DC protein assay kit (BioRad, Hercules, California, USA). AT protein was 
loaded onto a 15 % gel with amounts of 20µg/lane and, adipocytes with amounts 
of 60µg/lane; then separated by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE). All samples were then heated for 5 min at 95°C in 
a sample buffer (Chapter 2.4. ). Pre-stained molecular weight markers 
(Amersham Pharmacia Biotech, Buckinghamshire, UK) were used as standards. 
Samples were electrophoresed at 140V for 1.5 hr. Proteins were transferred from 
the polyacrylamide gels to PVDF membranes by electroblotting in a vertical 
transfer apparatus tank at 100V for lhr. Membranes were blocked overnight at 
4°C in phosphate buffered saline containing Tween 20 (PBS-T: PBS + 0.05% 
Tween 20; Sigma-Aldrich, UK) containing 10% (w/v) non-fat milk powder 
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(Marvel, Moreton, Merseyside, UK). Membranes were treated with primary 
polyclonal goat NPY antibody (Santa Cruz Biotechnology, Inc. ) (1: 1000), then 
the membranes developed with a conjugated anti-goat/sheep HRP secondary 
antibody in concentrations of 1: 80,000 in PBS with 0.5% Tween. The prepro- 
NPY protein (1lkDa) and mature NPY (4kDa) were detected by 
chemiluminescent assay ECL+ (Amersham, Little Chalfont, UK), which enabled 
visualisation after exposure to X-ray film and the band intensity was determined 
by densitometry (Chemigenius). Equal loading was ensured with use of the alpha 
tubulin antibody (Abcam, Cambridge, UK). To ensure specific binding, a NPY 
blocker was used, which competes with NPY antibody binding. The blocking 
peptide (Santa Cruz Biotechnology Inc., USA) was used as recommended by the 
manufacturer. Essentially the membrane was incubated with the blocking peptide 
at a dilution of 1: 25 together with the primary antibody in PBS at 4°C overnight, 
and after a three washes in PBS/PBS Tween, the membranes were treated with 
the secondary antibody as described previously. 
Similar to NPY, the expression of the NPY receptors Y1 and Y5 was examined 
by Western blot analysis. The alterations to the protocol above included loading 
of 20 µg of protein under reducing conditions onto a 12% gel, which was run for 
1 hr and use of monoclonal human Y1 and Y5 antibodies (Bachem Peninsula 
Laboratories, USA) at concentrations of 1: 500 for 1 hr and with the secondary 
rabbit antibodies at concentrations of 1: 60,000 for 1 hr. 
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4.2.4. NPY and adipokine estimation 
Conditioned media (500µL) was concentrated with the use of a centrifuge 
evaporator and reconstituted in 50µL of assay buffer and assessed for NPY by 
the commercially available NPY ELISA kit (Bachem Peninsula Laboratories, 
USA), which was also used for analyses of undiluted serum samples (loading 
volume of 50µL). The assay sensitivity is reported at 0.04-0.06ng/mL, the intra- 
assay variation at <5% and inter-assay variation at <14%. Adipokines in serum 
and media samples were measured by commercial ELISA-based colorimetric 
kits: For the leptin ELISA (R&D Systems, Inc., Abingdon, UK) serum was 
diluted 1: 100 and cell culture media at 1: 10. The assay limit of leptin was 
7.8pg/mL, intra-assay limit 3.2%CV and inter-assay variability of 4.4%. 
Adiponectin in cell media was analysed at a dilution of 1: 50 by the ELISA kit 
from Linco Research Inc. (Missouri, USA); assay limit was 0.78ng/mL intra- 
assay %CV of 7.4% and inter-assay variability of 2.4-8.4%. 
4.2.5. Immunohistochemistry 
The histological specimens were prepared as discussed in Chapter 2.7.; incubated 
with primary polyclonal NPY antibody (Santa Cruz Biotechnology Inc., USA) in 
a dilution of 1: 400 and developed using Vector VIP peroxidase substrate kit 
(Vector Laboratories Ltd., Peterborough, UK). Rat brain tissue was used as 
positive control for NPY staining and obtained from Biological Solutions LTD. 
Slides were prepared and stained as described in Chapter 3. Sections were 
developed using diaminobenzidine (BioGenex, California, USA). Primary 
antibody staining was omitted as negative control to exclude contamination and 
artefacts. 
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4.2.6. Microarrray analysis 
The protocol of microarray analysis is in detailed in Chapter 2.6. and the method 
described in Appendix II. This technique was used to screen for presence of the 
chromosome for DPP-IV is chr2q24.3. 
4.2.7. Statistical Analysis 
Statistics was performed using the SPSS version 14 (SPSS UK, Surrey, UK). For 
assessment of protein expression and secretion, statistical analysis was 
undertaken with paired t-test for comparison of Western blots and ANOVA for 
comparison of cell treatments. Correlations of serum levels were determined with 
a Pearson correlation. P values of less than 0.05 were considered as statistically 
significant. Values are expressed as mean +/- standard error (SE) unless 
otherwise stated. 
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4.3. Results 
4.3.1. NPY protein expression in fat 
Protein studies determined that prepro-NPY (11 kDa) and mature NPY (4kDa) 
were detected in AT and isolated adipocytes. The treatment with NPY peptide 
blocker is illustrated in Figure 4.3.1. 
NPY protein expression in AT 
460* _-30kDa 
20kDa 
I IkIa Prepro NPY _11kDa 
4kDa NPY 
_4kDa 
negative positive 
NPY Blocker 
Figure 4.3.1.1.: Expression of NPY and the use of NPY blocker in Abd Sc AT. 
The left side shows that addition of the NPY blocker effectively blocks the 
antibody binding of the protein to its antibody. 
Western blot analysis was used to examine the depot expression of NPY. NPY 
was found in Abd Sc approximately with 2 fold higher protein expression than in 
either omental (Om) or thigh (Th) AT (Abd Sc: 1.87±0.23 optical density units 
(OD), Om: 1.03±0.150D, Th: 1.0±0.290D, p=0.029 and p=0.035 respectively) 
(Figure 4.3.2). 
137 
NPY depot expression 
NPY 4kDa MIVWWIWw 
a tubulin 50 kDa 
2.0 
Z 
1.5 
1.0 
.5 0.5 Z. 
xz 
0 
T 
Abd Sc Omental Thigh 
Figure 4.3.1.2.: Relative expression of NPY in comparison to thigh fat 
(allocated value of 1) and a representative Western blot shown above *p<0.05. 
NPY expression in adipocytes and preadipocytes 
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Figure 4.3.1.3.: Expression of NPY in human adipocytes (Ad) but not 
preadipocytes (PA). 
Protein expression is detectable in adipocytes but not preadipocytes as is shown 
in Figure 4.3.3.. The adipocytes and preadipocytes were derived from the same 
patient, for each assessment. 
138 
The receptors Yl and Y5 proteins are also found to be expressed in human AT, 
whilst no depot specific distribution was shown (Y 1: AbSc: 2.96±0.130D, Om: 
3.21±0.350D, Th: 2.95±0.20D, p=NS, n=6; Y5: AbSc: 2.83±0.1OD, Om: 
3.23±0.20D, Th: 3.04±0.180D, p=NS, n=6 (see Figure 4.3.4. ). 
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Figure 4.3.1.4.: NPY receptors Yl and Y5 are expressed in adipose tissue but 
show no depot-specific distribution. 
4.3.2. NPY serum levels 
Fasting serum samples were analysed to establish a possible correlation with 
BMI, gender and age in an age and BMI matched population amongst gender. A 
positive association was found for NPY serum levels with BMI (r=0.52, p=0.02, 
n=24) (Figure 4.3.2. ). There was no statistical difference between the serum 
NPY values of men (201±32ng/mL, BMI: 26.4±1.1kg/m2, n=13) and women 
(220±35pg/mL, BMI: 24.7±1.2kg/m`, n=l 1; p=NS), nor was there a correlation 
with age (r=-0.12; p=NS). 
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Figure 4.3.2.: Serum NPY levels are positively correlated with BMI, p<0.05, 
n=24. 
4.3.3. NPY secretion following insulin and rosiglitazone treatment of 
adipocytes 
To investigate the regulation of NPY by insulin, freshly harvested adipocytes 
were treated with rh insulin (see above) and changes in NPY secretion measured 
with ELISA. NPY was significantly up-regulated with insulin treatment (1,100 
and 1000nmol/L) (0.26±0.05ng/mL; 0.29±0.04ng/mL; 0.3±0.04ng/mL 
respectively; control: 0.22±0.02ng/mL, p=0.013, n= 13; Figure 4.3.3.1. ). 
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Figure 4.3.3.1.: Effect of rh Insulin on NPY secretion, nM= nmol/L, n=13; 
*p<0.05. 
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Figure 4.3.3.2.: The effect of RSG and insulin treatment on the level of NPY 
secretion from cultured adipocytes, n=7, *p<0.01 
NPY secretion from adipocytes did not differ whether the adipocytes from the 
same subject were treated with insulin 100nmo1/L, insulin 100nmol/L in 
combination with RSG 10 nmol/L, or RSG alone (insulin alone 100nmolL: 
36±5ng/mL versus insulin in combination with RSG: 33±4ng/mL or RSG alone 
33±4ng/mL, p=NS, n=7; Figure 4.3.3.2. ). 
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4.3.4. Adipokine secretion following rh NPY treatment of adipocytes 
Cell culture treatment of adipocytes isolated from female subjects 
(age=39.3±3.2years; BMI 26.4±2kg/m2 n=7) revealed a regulation of leptin, but 
not for adiponectin or TNF-a (not shown), by rh NPY. 
The basal secretion (of control sample) of both leptin and adiponectin is BMI 
dependent, therefore not the absolute values were compared, but the relative 
changes from the basal secretion as its fraction. rh NPY treatment led to a 
significant decrease of leptin release with the basal secretion adjusted to the 
value of 1 the calculated change was 0.620.09; 0.67±0.07 and 0.61±0.08 for 
treatment with rh NPY 1,10 and 100nmol/L respectively (n=9, p<0.05; Figure 
4.3.4.1. ). 
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Figure 4.3.4.1.: Abd Sc adipocytes treated with rh NPY and the relative change 
of leptin secretion in comparison to basal secretion in the control media with 
adjusted value of 1, n=9, * p<0.05. 
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Figure 4.3.4.2.: Abd Sc adipocytes treated with rh NPY and the relative change 
of secretion of adiponectin in comparison to the basal secretion of control media 
with adjusted value of 1, n=9, p=NS. 
In comparison, rh NPY treatment did not change basal adiponectin secretion 
(control 1; 1±0.06; 0.96±0.04; 1.08± 0.05 for NPY 1,10 and 100nmolIL 
respectively, n=9, p=NS; Figure 4.3.4.2. ). 
4.3.5. Immunostaining of NPY 
As demonstrated in Figure 4.3.5., NPY antibody (brown) is taken up in the 
cytoplasm of adipocytes. The staining of the rat brain with NPY, where this 
neurotransmitter is abundant, serves as a positive control. 
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ý+ ! in human AT C: positive control: 
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4.3.6. Glycerol secretion following NPY treatment 
Abd Sc adipocytes treated with rh NPY were used to assess the antilipolytic 
action of NPY through glycerol release, which was significantly reduced with 
NPY (Control: 224±37pmo1/L; NPY1nmol/L: 182±32pmol/L; NPY10nmol/L: 
171.1±26gmoVL, NPY100nmol/L 161±27gmoVL, p<0.01, n=14). Addition of 
the DPP-IV inhibitor lead to a further decrease of glycerol secretion 
(NPY1nmoVL: 145±19pmol/L; NPY10nmol/L: 148.2±17µmol/L; 
NPY100nmol/L: 127±14µmol/L; p<0.01, n=14; Figure 4.3.6. ). 
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Figure 4.3.6.: Glycerol release after treatment of adipocytes with rh NPY with 
and without DPP-IV inhibitor, **p<0.01, n=14. 
4.3.7. DPP-IV expression in adipose tissue 
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Figure 4.3.7.: Microarray expression of DPP-IV in lean versus obese Abd Sc 
AT, *p<0.05, n=10. 
Microarray analyses revealed the expression of DPP-IV in abdominal, as well as 
omental AT. Whilst there was no significant difference between lean (BMI: 
23.0±1.2 kg/m'`) and obese individuals (BM 30.3±3. lkg/m2) in omental AT (not 
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shown), the relative expression of DPP-IV was much higher in the Abd Sc AT of 
lean individuals when compared to matched obese individuals (186±29 signal 
units (SU) versus 77±6SU, p=0.018, n=10) (see Figure 4.3.7). 
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4.4. Discussion 
This is the first study to document protein expression of NPY in human AT and 
adipocytes. NPY was not only expressed within various adipose tissue depots, 
but also as a secreted protein in adipocyte conditioned media. Further evidence 
of the presence of NPY in human AT was documented through 
immunohistochemical staining of NPY in the cytoplasm of adipocytes. Other 
sources of NPY in cell culture are unlikely, as contamination of isolated 
adipocytes with blood or endothelial cells was previously excluded (Fisher, 
2002). Contamination with neural cells is also unlikely and is supported by 
evidence that the SNS loses its capacity of NA release with coculture with other 
cell lines (Landis, 1990). However, analyses of the expression of MAP2, a 
marker of dendrites, synaptotagmin or synaptophysin, which are markers of 
neural innervation may further clarify which proportion of NPY in AT is derived 
from sympathetic innervation. The production of NPY by AT is further 
supported by a cDNA array study which found NPY in human visceral AT 
(Yang, 2003). 
The findings of this study also show clear protein expression of prepro-NPY. 
Whilst the NPY ELISA has little cross reactivity with the prepro- hormone, the 
presence of converting enzymes for NPY, such as precursor convertase 2 (PC2) 
or PC3, which were previously found to be expressed in neuronal and endocrine 
cells of different species (Wulff, 1993) is likely, but remains to be proven. 
WAT innervation was discussed in Chapter 1 and is in the majority by 
sympathetic nerves, but also sensory nerves mediated by CGRP and substance P 
(Shi, 2005). Turtzo (2001) compared the effect of coculture of sympathetic 
nerves with rodent 3T3L1 preadipocyte cell lines. Whilst the study differs with 
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use of rodent preadipocyte cell lines instead of human adipocytes, it is interesting 
to note that the NPY secretion in coculture was increased by up to 7.5 times in 
relation to pure NPY neuron secretion; the study further reported a small amount 
of NPY secretion by the adipocyte cell line itself. The distribution and function 
of NPY receptors differs amongst species. For instance, whilst work by Turtzo 
(2001) also found an antilipolytic effect of NPY based on glycerol secretion in 
the mouse adipocyte cell lines, Turtzo and its co-workers (2001) only found Y5 
mRNA expression and no Y1, Y2 or Y4 mRNA expression in these mice. In 
comparison, the above experiments confirmed protein expression of Y1 and Y5 
in human adipocytes, which is compatible with the finding of Y1 and Y5 mRNA 
expression identified by Serradeil-La Gal in human adipocytes (2000). Also, it is 
now believed, that Y1 may mediate the antilipolytic effect of NPY in rodents 
(Bradley, 2005) and humans (Serradeil-La Gal, 2000) as evident by elimination 
of NPY's antilipolytic effect with the use of Y1 receptor antagonists. 
This study shows that inhibition of DPP-IV has significant effects on the NPY- 
mediated antilipolytic property, most likely mediated by preservation of the 
antilipolytic Y1 function of NPY. Furthermore, this study suggests that DPP-IV 
is differentially expressed in human AT depots and that AT is a potential site of 
DPP-IV secretion. DPP-IV gene expression appears to be downregulated in 
obesity, which could lead to augmentation of NPY's antilipolytic action. 
However, the expression of DPP-IV in the adipocyte needs further definition. 
These preliminary findings may imply that the therapeutic use of DPP-IV 
inhibitors may be ineffective in AT of obese subjects. In support of this, recent 
drug trials examining the effect of DPP-IV inhibitors failed to show a weight 
change in insulin resistant rats (Burkey, 2005) or T2DM subjects (Pi-Sunyer, 
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2007), who are usually overweight if not obese and as such our current data 
supplies a rationale for its lack of effectiveness. 
This study further identified a depot-specific expression of NPY, with its highest 
expression in Abd Sc AT, which has been associated with a higher metabolic 
risk, in contrast to gluteo-femoral fat (Abate, 1996; Garg 2004) and which can 
contribute to more than 50% of total fat mass (Hattori, 1991). Whilst the 
sympathetic innervation was reported to be very high in visceral fat which has 
also highest lipolytic activity (Hoffstedt, 1997) which is further enhanced by 
increased ß-adrenoceptor sensitivity in obese male subjects (Hoffstedt, 1997), 
there may be separate regulation and secretion of adipocyte derived NPY, 
unrelated to the NPY release by SNS innervation. 
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Figure 4.4.1.: Presynaptic adenosine receptors can differentially regulate the 
sympathetic co-transmission as shown in rodent vascular endothelium. 
Adenosine receptors A(2A) and A(3) inhibit the release of NA without affecting 
immunoreactive-NPY (Donoso, 2006). 
However, even the SNS innervation may show differential regulation of the 
cotransmission of NE, a lipolytic neurotransmitter, and NPY which is anti- 
lipolytic by presynaptic adenosine receptors as demonstrated in vascular 
endothelium (Donoso, 2006). Some adenosine receptors can inhibit the release of 
NE, without affecting the immunoreactivity of NPY (see Figure 4.4.1). It 
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remains to be confirmed whether a similar regulation exists in human WAT. 
NPY serum levels are influenced by various cofounding factors, such as 
menstrual status, chronic stress, diabetes and hypertension (Baronowska, 2000). 
A review of the current literature fails to report a direct association with BMI for 
both NPY serum levels and cerebrospinal fluid (CSF) levels (Baranowska, 2000; 
Nam, 2001). However, elevated serum levels of NPY were reported in anorexic 
and morbidly obese subjects (Baranowska, 2000). Under consideration of known 
cofounding factors this study revealed no age or gender correlation, however, 
identified a positive correlation of NPY serum levels with BMI. Apart from 
leptin, which was previously shown to be upregulated by hyperinsulinaemia 
(Saladin, 1995), these studies also observed that NPY secretion was stimulated 
by insulin, in a dose dependent manner. The antilipolytic effect of NPY may 
enhance fat accumulation and its effect may be further enhanced in the 
hyperinsulinamic state. 
It is unclear whether fat derived NPY can enter the blood stream; whilst this 
could potentially cause the observed elevated serum levels in chronically obese 
subjects and in type 2 diabetic patients (Baranowska, 2003). As such, the role of 
circulating peripheral NPY and its contribution to central energy regulation 
remains to be established. Circulating NPY is known to cross the blood brain 
barrier (Kastin, 1999) and AT derived NPY which could significantly raise 
circulating NPY in obesity may then elicit a central feedback mechanism on 
adipose tissue mass similar to leptin. The peripheral antilipolytic effect of insulin 
and its effect on NPY secretion are in contrast to the central insulin regulation, 
whereby insulin inhibits NPY gene expression (Gerozissis, 2004) and promotes 
weight loss. This may be explained by insulin promoting surplus energy storage 
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in adipocytes and fat accumulation with avoidance of further energy intake by 
reduction of appetite. 
Thiazolidinediones (TZDs), such as RSG, are insulin-sensitisers with B-cell 
preserving action (Ovalle, 2004). TZDs favourably increase circulating levels of 
adiponectin, which are amongst others cardioprotective (Tsuchida, 2005; 
Pischon, 2004). However, the use of TZDs is also associated with weight gain. 
This study did not find any effect of RSG on adipocyte derived-NPY secretion or 
adiponectin secretion, which further supports that RSG and NPY do not integrate 
a common pathway. 
Finally, this study demonstrated a decrease of leptin secretion by NPY treatment. 
A downregulation of leptin appears necessary in order for NPY to have a 
significant effect on fat accumulation via its antilipolytic function (Wang, 2000). 
An upregulation of leptin, in turn, would not allow NPY to have a significant 
overall effect on the regulation of fat mass. Central action of leptin is known to 
promote peripheral sympathetic activity (Rayner, 2001); furthermore, coculture 
of adipocytes with sympathetic neurons was shown to decrease leptin release, as 
part of a potential feedback mechanism (Turtzo, 2001). This is in contradiction 
with previous studies, which have established an upregulation of leptin by NPY 
in cultured adipocytes (Dyer, 1997; Serradeil-Le Gal, 2000). However, the 
experimental conditions differ greatly following use of either sheep adipocytes 
after iv administration of NPY, or use of preadipocyte cell lines (Serradeil-Le 
Gal, 2000). Whilst it is difficult to determine the complex interplay of these 
factors on adipogenesis, a possible resistance to certain factors, i. e., leptin, may 
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be present in isolated adipocytes of obese subjects and complicate the 
interpretation. 
In conclusion, NPY protein is expressed in AT and adipocytes in a depot specific 
manner, suggesting that NPY is not only a neurotransmitter but is also actively 
produced by adipocytes themselves. NPY may have a role in insulin resistance. 
Insulin upregulates NPY adipocyte secretion and NPY reduces leptin secretion. 
Additionally, serum NPY levels appear to be positively correlated with BMI. 
NPY's antilipolytic effect may aggravate fat mass accumulation and may further, 
in turn, worsen insulin resistance. Whether the contribution of AT-derived NPY 
in the general circulation elicits central feedback remains to be determined. This 
study suggests that AT may have a similar NPY regulation to endothelium 
(Zukowska-Grojec, 1998b), in that it possesses an organ specific autocrine 
system for NPY, which includes site-specific receptors, the NPY cleaving 
protease DPP-IV and its own production of NPY. 
152 
Chapter 5 
Ghrelin in adipose tissue 
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5.1. Introduction 
Ghrelin is a 28 amino-acid-peptide and ligand for the orphan growth hormone 
secretagogue receptor GHSR (Kojima, 1999). Whilst its best characterised 
effect is the increase in appetite via hypothalamic action (Tschop, 2000), 
ghrelin is predominantly derived from the stomach and gut (Kojima, 1999) and 
can further mediate various peripheral effects (Kojima, 2005). Human studies 
to date have demonstrated that iv administration of ghrelin stimulates appetite 
and food intake (Wren, 2001); additionally, circulating ghrelin levels are at 
their highest prior to food intake and drop subsequently, compatible with their 
roles as `meal initiators' (Cummings, 2001). The orexigenic effect is thought to 
be mediated by the action of octanylated ghrelin in the arcuate nucleus (ARC) 
of the hypothalamus (see Chapter 1). Octanylated ghrelin serves as central 
neurotransmitter; which is complicated by the observation that ghrelin may also 
be locally/centrally synthesised (Kojima, 1999; Korbonits, 2001), though this 
central production is thought to contribute little to its systemic concentration 
(van der Toorn, 2002). Des-acetylated ghrelin (also known as des-octanylated 
ghrelin) is the major circulating form of ghrelin (Ghigo, 2005). With the 
absence of the octanoyl-modification of the third serine residue, des-acetylated 
ghrelin is unable to activate GHS-Rla and mediate endocrine action (e. g., is 
unable to stimulate the release of GH, prolactin and ACTH) (Broglio, 2004). 
Therefore des-acetylated ghrelin was initially considered to lack not only any 
endocrine effect but to be biologically inactive (Hosoda, 2000). More recent 
evidence, however, suggests that both octanylated and des-acetylated ghrelin 
may mediate peripheral biological actions (Thompson, 2004); furthermore, 
there is a suggestion that both can act antagonistically (Broglio, 2004). 
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However, little is known about the exact role of the two distinct isoforms or the 
enzyme responsible for the posttranslational modification of ghrelin (van der 
Lely, 2004). 
Furthermore, few studies have established how this orexigenic neurotransmitter 
exerts feedback on peripheral energy regulation, in particular, on adipose tissue 
storage in humans. It has been demonstrated in rats that icv injection of ghrelin 
affects AT, and most likely establishes crosstalk with AT, mediated by 
sympathetic innervation similar to leptin (Theander-Carrillo, 2002). Rodent 
studies also suggest that ghrelin elicits an antilipolytic effect (Morimoto, 1998) 
and promotes adipogenesis in the bone marrow (Thompson, 2004); these 
effects are mediated by both octanylated and des-acetylated ghrelin in rodents 
(Muccioli, 2004; Thompson, 2004). GHS-R antagonists have been shown to 
reduce fat mass in vitro (Asakawa, 2003); however, the use of potent GHS-R 
agonists does not enhance the adipogenic action of ghrelin in rodents 
(Thompson, 2004). The GHS-R has not been identified in human AT 
(Gnanapavan, 2002) and thus the actual receptor through which ghrelin and 
more so, the des-octanylated ghrelin isoforms, could mediate an effect on fat 
metabolism is unrelsoved. Recent studies suggest that ghrelin can also act as 
central ligand of the Y1 receptor (Toshinai, 2003; Tebbe, 2005). However, 
there are no studies which have determined whether ghrelin is able to mediate 
peripheral effects through Y1. The receptor Y1 was discussed in more detail in 
Chapter 4 as a mediator of NPY's action on peripheral fat metabolism. Y1 
could as such potentially mediate action of ghrelin in fat similar to NPY and 
control one of the most important two enzymes coordinating lipolysis and 
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lipogenesis which are the hormone sensitive lipase (HSL) and lipoprotein lipase 
(LPL) respectively (Sztalryd, 1995). 
Therefore, the aims of this chapter are to elucidate the expression and 
distribution of ghrelin in human AT and adipocytes and the role of increasing 
adiposity on the level of ghrelin expression. Furthermore, this study will 
examine whether octanylated and des-acetylated ghrelin differ in their role in 
human fat metabolism and whether Y1 could be mediating ghrelins' antilipolytic 
action. 
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5.2. Methods 
5.2.1. Subjects 
AT samples were obtained from twenty consenting white, female subjects 
undergoing elective surgery. Mean age: 46±6.8years (mean±SD), 
BMI: 25.6±4.96kg/m2. Abdominal subcutaneous (AbdSc), omental (Om) and 
thigh tissue (Th) samples were collected with the approval of the South 
Birmingham Ethics Committee. Subjects on endocrine therapy (e. g., steroids, 
HRT, thyroxine) and patients with malignant diseases were excluded. 
Fasting serum samples were taken from 26 healthy subjects with unchanged 
body weight in the previous 6 months constituting of 13 men 
(age: 38.1±12.3years, BMI: 26.0±4.0kg/m2) and 13 women (age: 37±8.9years, 
BMI: 24.6±4.4kg/m2). Blood samples were centrifuged at 700 xg for 20 min 
and serum stored at -80°C till used for further analysis. 
5.2.2. Adipocyte isolation and cell treatment 
The isolation of adipocytes and their subsequent cell-culture was followed by 
similar principles as described in Chapter 4. Freshly prepared abdominal 
subcutaneous adipocytes suspended in cell culture medium were treated with 
human recombinant (rh) octanylated ghrelin (Diagnostic Systems Laboratories, 
Inc, USA; 1,10 and 100 nM) or rh des-acetylated ghrelin (1,10 and 100nM) for 
48 hr. These ghrelin treatments were run with and without addition of the NPY 
receptor Y1 blocker (B1BP3226, Sanofi-Synethe-labo, France) at a dose of 
100nM for full blockage as derived from receptor binding studies (Entzeroth, 
1995). Untreated adipocytes were used as controls. 
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Following incubation of adipocytes (37°C/5%CO2), conditioned media and 
adipocytes were separated by centrifugation (360 xg for 2 min). Media was 
then removed, separated into aliquots, and then stored at -80°C. The remaining 
adipocytes were treated with RIPA buffer (see Chapter 2) and frozen to be later 
used for Western blot analyses. 
5.2.3. Protein extraction 
Part of the adipose tissue was flash frozen and then stored at 70°C. Prior to use 
for Western blot analysis, a small piece of frozen adipose tissue was 
homogenised and extracted with RIPA buffer, containing: lx PBS, 1% Nonldet 
P40,0.5% Sodium Deoxycholate, 0.1% SDS, 1 complete mini protease cocktail 
(Roche Molecular Biochemicals, Germany) and 100 µg/mL ALLN 
(Calbiochem, San Diego, USA). Protein was then quantified using a Bio-Rad 
DC protein assay kit (BioRad, Hercules, California, USA). 
5.2.4. Western blot analysis of ghrelin 
Homogenised human adipose tissue (5g) and isolated Abd Sc adipocytes 
(200µL) were extracted in 400µL of RIPA buffer. Adipose tissue protein and 
adipocyte protein were quantified and loaded on a gel and separated by SDS- 
PAGE using a 15% gel. All samples were heated for 5 min at 95°C in a non- 
reducing loading buffer. Pre-stained molecular weight markers (BioRad) were 
used as standards. Proteins were transferred from the polyacrylamide gels to 
PVDF membranes by electroblotting in a vertical transfer tank at 140V for 1.30 
hr. Membranes were blocked overnight at 4°C in phosphate buffered saline 
containing Tween 20 (PBS-T: PBS + 0.05% Tween 20; Sigma) containing 10% 
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(w/v) non-fat milk powder (Marvel, Moreton, Merseyside, UK). Membranes 
were then treated with primary antibody: mouse monoclonal Ghrelin antibody 
(Abeam, Inc. ) (1: 1000); then developed with a conjugated mouse HRP 
secondary antibody in concentrations of 1: 80,000 diluted in PBS with 
0.5%Tween. The ghrelin precursor protein (12kDa) was detected by 
chemiluminescent assay ECL+ (Amersham, Little Chalfont, UK), which 
enabled visualisation following exposure to X-ray film and the band intensity 
was determined by densitometry. Equal loading was ensured with use of the a- 
tubulin (5OkDa) antibody (Abcam, Inc), which required a repeat Western blot 
after stripping the membrane of the initial ghrelin primary and secondary 
antibody as described in Chapter 2. 
5.2.5. Glycerol assay: 
Glycerol is released as a by-product of lipolysis. After the above described 48 
hr incubation with treatments, the infranatant containing media was used to 
assess the glycerol content using a commercially available colorimetric kit 
(Randox Laboratories, UK). The sensitivity of the assay, according to the 
manufacturer's protocol was estimated to be between 0-100mmol. 
5.2.6. Western blotting for HSL and LPL 
Cell treatments of isolated mature abdominal subcutaneous adipocytes with 
varying doses of octanylated and des-acetylated ghrelin were compared to 
control for A) hormone sensitive lipase (HSL 84kDa) and B) lipoprotein lipase 
(LPL 56kDa). Western blot analysis, similar to above, was performed, with 
loading of 20µg of protein and buffer containing dithiothreitol (DTT) 
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100nmol/L (Sigma, UK) and separated using 10% SDS-PAGE gels at 140V for 
1.5 hr. After electrophoresis and transfer, as described above, membranes were 
blocked overnight at 4°C with continual motion. For LPL detection, membranes 
were incubated with LPL antibody (R&D systems, USA) and diluted 1: 500 in 
PBS-T. The primary antibody was then detected by application of a secondary 
antibody (anti-sheep/goat IgG) conjugated to horseradish peroxidase (HRP) 
(The Binding Site, Birmingham, UK) diluted 1: 2,500 in PBS-T. 
The method was similar for HSL which was produced using a standard 
procedure previously detailed (Botion, 1999). The dilution for the primary 
antibody was 1: 5000 in PBS-T and the secondary antibody (anti-rabbit IgG) 
conjugated to horseradish peroxidase (HRP) (The Binding Site, Birmingham, 
UK) was diluted 1: 60,000 in PBS-T. Membranes were developed with 
chemiluminescent assay ECL/ECL+ (Amersham, Little Chalfont, UK) and the 
bands measured with densitometry. All experiments were carried out in 
triplicate. 
5.2.7. Serum ghrelin analysis and assay validation 
The serum content of total ghrelin was assayed using the commercially 
available total ghrelin ELISA kit (Diagnostic Systems Laboratories, Inc., USA), 
sensitivity: 6.2-1800 pg/mL, intra-assay variation 2-10% and inter-assay 
variation 5-15%. Rh des-acetylated and octanylated ghrelin (Diagnostic 
Systems Laboratories, Inc, USA) were used for recovery study in the 
assessment of this ELISA kit. Concentrations of 10,50 and 100pg/mL of des- 
acetylated and octanylated ghrelin were added to pooled serum (26.8pg/mL) 
and the observed values correlated with expected values. The recovery for 
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lOpg/mL des-acetylated ghrelin was 95-99% efficient (for recovery of lOpg/mL 
we expected: 36.8 pg/mL and observed: 35.6±0.56pg/mL). For 10 pg/mL 
octanylated ghrelin the recovery was: 91-99% (expected: 36.8g/mL; observed: 
34.6±1.15pg/mL). 
5.2.8. Statistical analysis 
Autoradiographs were quantified by densitometry. For assessment of protein 
expression between depots and lean and obese subgroups, statistical analysis 
was undertaken with a t-test. ANOVA was used for comparison of cell 
treatments with control for each group compared to each treatment set. Serum 
levels and BMI correlations were determined with a Pearson correlation. P 
values of less than 0.05 were considered as statistically significant. Values are 
expressed as mean +/- standard error (SEM) unless otherwise stated. 
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5.3. Results 
5.3.1. Ghrelin protein expression and depot difference 
Protein studies determined that prepro-Ghrelin (12kDa) and mature Ghrelin 
(4kDa) were expressed in adipose tissue and isolated adipocytes (Figure 
5.3.1.1. ). Western blot analyses further revealed depot-specific differences of 
ghrelin expression with highest expression in Abd Sc adipose tissue in 
comparison to omental (Om) AT and thigh AT (Abd Sc: 3.05±0.550D 
(rnean±SEM), Om: 1.5± 0.50D, thigh: 1.0±0.40D, p<0.05, n=8) (Figure 
5.3.1.2. ). 
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Figure 5.3.1.1: Protein expression of ghrelin in human abdominal 
subcutaneous adipocytes (Ad), but not pre-adipocytes (PA), as shown with 
three paired samples. 
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Figure 5.3.1.1: Expression of ghrelin is highest in abdominal subcutaneous 
tissue (Abd Sc) in comparison to omental (Om) AT and thigh AT (Arbitrary 
value of I was allocated to thigh AT). A representative Western blot for ghrelin 
is shown above together with u-tubulin expression demonstrating equal 
loading, *p<0.05. 
5.3.2. Ghrelin and BMI correlation 
5.3.2.1. Ghrelin in adipose tissue: 
Comparison of ghrelin expression in lean versus obese subjects 
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Figure 5.3.2.1.: Relative expression of ghrelin in adipose tissue of lean versus 
obese women *p<0.05, n=6 paired subjects. 
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Comparison of ghrelin expression between 6 lean (mean BMI 22.4kg/m2) and 6 
overweight/obese women (mean BMI 30.9kg/m2) showed a significant negative 
correlation (lean: 3.6±0.740D and obese: 1.64±0.450D respectively; p<0.05) 
(Figure 5.3.2.1. ). 
5.3.2.2. Serum Ghrelin 
The analysis of fasting total ghrelin in the serum of healthy individuals 
consisting of 13 men and 13 women who were matched for age and BMI (see 
above) showed a negative correlation with BMI (r=-0.54, p<0.001, n=26) 
(Figure 5.3.2.2. ). There was a significant difference of ghrelin levels between 
gender (women: 91.7±16pg/mL (mean±SEM), men: 54.8±7.2pg/ml, p<0.05) 
but this was not correlated with age (r=-0.1, p=NS). 
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Figure 5.3.2.2: Correlation of fasting serum ghrelin and BMI. r= Pearson 
correlation 
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5.3.3. Ghrelin and lipid metabolism 
The influence of the acetylation status of ghrelin on lipolysis and lipogenesis in 
cultured human adipocytes was distinguished by separate analysis of its effect 
on HSL, LPL and glycerol release. 
5.3.3.1. Lipolysis 
5.3.3.1.1. Glycerol release 
Isolated Abd Sc adipocytes were treated with increasing doses of ghrelin and 
compared for glycerol release as a by-product of lipolysis. There was no 
significant down regulation of glycerol release for octanylated ghrelin (Control: 
286±58µ1/L; O-Ghrelin 1nM: 207±31µUL; O-Ghrelin lOnM: 241.4±46µ1/L; 0- 
Ghrelin lOOnM: 209±33µ1/L, p=NS, n=7). However, des-acetylated ghrelin 
significantly suppressed glycerol release (Control: 286±58µl/L; Des-Ghrelin 
1nM: 224±38µ1/L; Des-Ghrelin lOnM: 229±23µUL; Des-Ghrelin lOOnM: 
172±13µ1/L, p<0.05, n=7). 
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Figure 5.3.3.1.1: Glycerol release after adipocyte cell treatment with increasing 
doses of A: Octanylated and B: Des-acetylated ghrelin. Statistical analysis was 
performed using ANOVA, *p<0.05, n=7. 
5.3.3.1.2. HSL production 
There was no significant down regulation of HSL expression by octanylated 
ghrelin (Control: 1±0.3; O-Ghrelin 1nM: 1.1±0.40D; O-Ghrelin lOnM: 
0.9±0.30D; O-Ghrelin 100nM: 0.8±0.40D, p=NS, n=4). Addition of the Y1 
blocker BIBP3226 did not significantly reduce HSL expression (CB: 1±0.20D, 
BO-Ghrelin InM: 1±0.30D; BO-Ghrelin IOnM: 0.7±0.35OD; BO-Ghrelin 
IOOnM: 0.9±0.30D, p=NS, n=4). However, des-acetylated ghrelin significantly 
1nM lOnM 100nM 
Octanylated-ghrelin 
Des-acetylated ghrelin and glycerol secretion 
T 
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Control 
Control 1nM IOnM 
suppressed HSL expression (C: 1±0.30D; Des-Ghrelin 1nM: 0.8±0.30D; Des- 
Ghrelin IOnM: 0.6±O. IOD; Des-Ghrelin 100nM: 0.6±0. IOD, p<0.05, n=4). 
Addition of Yl-Blocker did not change this pattern (CB: 1±0.30D; BDes- 
Ghrelin InM: 1.1±0.20D; BDes-Ghrelin IOnM: 0.8±0.1OD; BDes-Ghrelin 
IOOnM: 0.6±0.1OD, p<0.05, n=4; Figure 5.3.3.1.2. ). 
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Figure 5.3.3.1.2.: Western blot showing the effect of octanylated and des- 
acetylated ghrelin on HSL activity. On the right side of the diagram the addition 
of Yl blocker is demonstrated accordingly, n=4. C=control, CB=control with 
addition of Yl blocker. The controls were given the arbitrary value of 1, 
n=4. *p<0.05 
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5.3.3.2. Lipogenesis 
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Figure 5.3.3.2.: Western blot showing the effect of octanylated and des- 
acetylated ghrelin on LPL activity in Abd Sc adipocytes. In parallel the addition 
of Yl blocker alongside octanylated and des-acetylated ghrelin. C=control, 
CB=control with addition of Y1 blocker. The controls were given the arbitrary 
value of 1, n=4, *p<0.05. 
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Both octanylated and des-acetylated ghrelin show a significant increase of LPL 
production (C: 110.3; O-Ghrelin 1nM: 1.0±0.40D; O-Ghrelin lOnM: 
1.6±0.50D; O-Ghrelin 100nM: 2.5±0.30D, p<0.05, n=4; C: 1±0.30D; Des- 
Ghrelin 1 nM: 1.4±0.20D; Des-Ghrelin lOnM: 1.5±0.40D; Des-Ghrelin 
100nM: 0.2±0.40D, p<0.05, n=4)). This effect was not present by use of the 
Y1 receptor blocker for octanylated ghrelin (CB: 1±0.30D; BO-Ghrelin 1nM: 
1.4±0.60D; BO-Ghrelin lOnM: 0.9tO. 40D; BO-Ghrelin 100nM: 1.3±0.60D, 
p=NS, n=4) or des-acetylated ghrelin (CB: 1±O. 30D; BDes-Ghrelin 1nM: 
1.1tO. 40D; BDes-Ghrelin lOnM: 1.2t0.30D; BDes-Ghrelin 100nM: 
1.1±0.20D, p=NS, n=4; Figure 5.3.3.2. ). 
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5.4. Discussion 
This is the first study to show the protein expression of the neurotransmitter 
ghrelin in AT and adipocytes. The expression of ghrelin in human AT was 
shown to be negatively correlated with BMI and followed the BMI distribution 
of fasting circulating ghrelin. The highest protein expression of ghrelin was 
found in Abd Sc AT. Furthermore, this study shows that des-acetylated ghrelin 
inhibits HSL production and significantly reduces glycerol release and that both 
forms of ghrelin influence LPL secretion, consistent with a pro-adipogenic 
effect of ghrelin on peripheral metabolism which is isoform dependent. 
Total ghrelin serum levels were also reduced with increasing BMI. This finding 
is supported by previous observations (Purnell, 2003, Vendrell, 2004). In 
addition to this, data from this study illustrated that the same pattern of BMI 
alteration applies for WAT-derived ghrelin, which may reflect a physiological 
role of ghrelin for fat preservation as a response to the lower fat mass of lean 
subjects. Higher ghrelin levels in lean subjects could give rise to increased 
appetite stimulation of lean individuals, as supported by the ability of 
circulating ghrelin capable of entering the BBB (Banks, 2002) and by the 
reflection of the same negative correlation of ghrelin with BMI in the CSF 
(Tritos, 2003), similar to serum. It remains to be shown whether AT derived 
ghrelin can take part in a central feedback mechanism, which would in the first 
instance require AT-derived ghrelin to elicit endocrine activity by entering the 
blood stream. Taking into consideration that the preprandial rise and acute 
postprandial suppression of ghrelin accounts for less than 60 % of the overall 
ghrelin levels (Cummings, 2001; English, 2002), a considerate proportion of 
ghrelin secretion remains as a basal layer devoid of the influence of short term 
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regulation (Figure 5.4). Thus, it is possible that this baseline secretion may be 
supplied by organs such as AT, in the addition to the GI tract, which requires 
further study. The highest protein expression of ghrelin was in the Abd Sc AT 
depot, whereas the lowest expression was in the thigh AT depot; which is 
considered the metabolically least active depot in comparison to Abd Sc and 
omental fat (Tan, 2004). Furthermore, recent evidence suggests that the 
glutcofemoral depot is not associated with metabolic risk (Van Pelt, 2005). 
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Figure 5.4.: Example of ghrelin's variation over 24hr in one subject and the 
three peaks represent the preprandial rise with breakfast, lunch and dinner 
(Cummings, 2001). The grey area under the curve represents the baseline levels 
of ghrelin. 
Analysis of total ghrelin serum levels showed higher levels in women, which is 
supported by previous reports (Greenman, 2004; Akamizu, 2004). This study 
showed no age correlation of total serum fasting levels, which has been 
highlighted previously (Vilarassa, 2005; Langenberg, 2005). Interestingly, 
whilst ghrelin gene expression in rodents was reported to be age dependent 
(Liu, 2002), the age correlation of mRNA expression did not translate to the 
protein secretion of ghrelin. However, some authors found a positive age 
correlation of fasting ghrelin (Purnell, 2003), whilst others demonstrated a 
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negative age correlation (Broglio, 2003; Schutte, 2007). Reasons for such 
contradicting reports may partly be explained by unidentified cofounding 
factors, e. g., the older population may considerably differ with regards to 
overall health, co-morbidity, use of medication, sex hormone status and other 
hormones, most of which naturally decline with age. 
The results of this chapter confirm a significant effect of des-acetylated ghrelin 
on the level of glycerol release and HSL in human adipocytes and not 
octanylated ghrelin. In contrast, studies examining rodent adipocytes report an 
antilipolytic effect of both ghrelin isoforms based on a partial reduction of 
isoproterenol (non selective ß-adrenoceptor agonist) stimulated lipolysis, and 
not basal glycerol release (Choi, 2003; Muccioli, 2004). In addition, results of 
this study show that des-acetylated ghrelin as well as octanylated ghrelin 
influence LPL secretion. The predominant peripheral form of ghrelin, des- 
acetylated ghrelin, constitutes 80 to 90% of circulating ghrelin (Ghigo, 2005) 
and demonstrated more of an effect on adipose tissue metabolism; therefore 
may have a greater net-influence on overall fat mass. The two ghrelin isoforms 
have previously been shown to be antagonistic, with adverse influence on 
insulin sensitivity (Broglio, 2004). An antagonistic effect was however, not 
observed for lipid metabolism in this study. 
The ghrelin receptor GHS-R has not yet been identified in human AT. 
Furthermore, mRNA expression of GHS-R has been reported as negative for 
human WAT (Gnanapavan, 2002). There are only few reports of GHS-R 
mRNA isolation in rat AT (Kojima, 1999) and rat adipocytes (Choi, 2003), 
which has not been confirmed by others (Muccioli, 2004). Since des-acetylated 
ghrelin does not bind to GHS-R (Broglio, 2004), it has been suggested that the 
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antilipolytic effect of ghrelin could be mediated by unidentified non-GHS-Rla 
receptors (Thompson, 2004). Whilst studies using in vivo icv injections of 
ghrelin in rats suggest that ghrelin is a central ligand of Y1 receptors through 
which it can affect appetite (Shintani, 2001) and colon motility (Tebbe, 2005), 
it is not known whether ghrelin is also a ligand of Y1, the most characterised 
receptor for NPY in human WAT. 
As a result of the experiments in Chapter 4, it is evident that Yl is expressed in 
all major depots of human WAT. Labelle (1997) demonstrated that the receptor 
Yl mediates the antilipolytic effect of PYY and NPY in rat adipocytes; 
additionally, treatment of rats with antagonists of Yl has been shown to 
ameliorate weight gain through reduction of appetite as well as adipocyte cell 
size (Ishihara, 2002). Y1 does not only bind the N-terminal end of NPY (1-36) 
but it has previously been shown that it can bind other ligands of the pancreatic 
polypeptide family with potentially higher binding affinities for PYY (1-36) 
and lower affinity of PP (Sylte, 1999). This study investigated whether 
blockade of the Y1 receptor altered the effects of ghrelin adipocyte metabolism 
and further investigated Y1 as potential receptor for ghrelin. Results showed 
that blockade of the Y1 receptor with BP3226 inhibited LPL release, with no 
effect on HSL secretion and that the effect on LPL and the use of the blocker 
were similar for both acetylated and des-acetylated ghrelin. Whilst the 
antilipolytic action of PYY and NPY in human adipocytes has previously been 
shown to be mediated by Y1, and subsequently blocked by BP3226 (Serradeil- 
L. e Gal, 2000), the antilipolytic effect of ghrelin was not significantly altered by 
addition of the Yl blocker. Thus the effect of ghrelin does not appear to be 
mediated by Y1. Whilst such results are in agreement with previous reports 
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from rat physiology, which suggest that both forms of ghrelin stimulate LPL 
release (Thompson, 2004), the adipogenic effect of ghrelin was blocked by the 
use of BP3226, suggesting that both ghrelin isoforms may in fact be a ligand of 
Y1 for mediation of its lipogenic effect in humans. Ultimately, distinction of 
the individual effects of the two ghrelin isoforms requires further in vivo 
analysis. 
In summary, this study found protein expression of ghrelin in human 
adipocytes; furthermore its expression is negatively associated with BMI, 
similar to circulating ghrelin and previously reported CSF ghrelin. The 
autocrine effect of ghrelin in human WAT, with an antilipolytic and lipogenic 
effect, appears to be aimed at fat preservation and shows differences with 
rodent physiology, based on the observation that des-acetylated ghrelin is able 
to directly influence glycerol release. Whilst the antilipolytic effect of ghrelin is 
not affected by Yl, which mediates the antilipolytic effect of PYY and NPY, 
the adipogenic action of ghrelin appears to be influenced by Yl blockade and 
shared by both ghrelin isoforms, as they both elicit a similar effect on 
lipogenesis. Finally, the receptor responsible for the lipolytic action of ghrelin 
in WAT has yet to be identified. 
" 
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Chapter 6 
CHRNA and adipose tissue 
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6.1. Introduction 
Smoking influences appetite and reduces food intake by its addictive component, 
nicotine (Li, 2000; Jo, 2005). The resulting reduced body weight (Grunberg, 
1985) and post-cessation weight gain is not confined to humans (Kiesges, 1989), 
but also seen in rodents (Zhang, 2001), which suggest physiological responses to 
nicotine. Whilst nicotine can influence several pathways involved in energy 
regulation (Figure 6.1. ), nicotine also modulates NPY expression in the 
hypothalamus (Li, 2000; Frankish, 1995). 
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Figure 6.1.: Multiple pathways through which nicotine affects appetite. PNS: 
peripheral nervous system. Stars signify sites of nicotine action (Adapted from 
Jo, 2002). 
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The peripheral and central actions of nicotine are mediated by upregulation of 
the cholinergic nicotinic receptors (CHRNAs) (Peng, 1997; Ke, 1998) which are 
responsible for smoking addiction (Kelley, 2002) and appetite regulation (Jo, 
2002). Whilst chronic nicotine exposure is associated with a redistribution of 
body fat (Jensen, 1995) and enhanced lipolysis in rodents and humans (Sztalryd, 
1996; Andersson, 2001), little is known about the mechanism by which nicotine 
influences fat mass. 
Heteromeric receptor CHRNA4 Homomeric receptor CHRNA7 
Figure 6.2.: Subunit arrangement of CHRNA4 (consisting of a4ß2 subunits) and 
CHRNA7, which consists of five a7 subunits. The circles signify the binding 
sites (Adapted form Gotti, 2004) 
CHRNAs are pentameric (consistent of 5 subunits) receptors composed of a 
selection of 12 subunits (nine a- and three ß-subunits) for which 12 genes were 
cloned. Nicotinic receptors can be further divided into subfamilies, depending on 
their type of subunits (Le Novere, 1995). The two predominant forms of 
CHRNAs are the heteromeric constellation a4ß2 (CHRNA4) and the form 
containing five homomeric subunits of a7 (CHRNA7). CHRNAs can be situated 
presynaptic, where they modulate neurotransmitter release; or postsynaptic, 
where they take part in signal transduction or perisynaptic, where they take on 
diverse modulatory functions (Berg, 2002). Since both of these receptors are 
associated with smoking addiction, they have become targets for drug 
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development of antismoking agents, e. g., Vanrenicline (Yates, 1995; Mihalak, 
2006). Although these receptors are typically neural receptors which exist in the 
central and peripheral nervous system, forms of these heterogeneous receptors 
have recently been discovered in non-neuronal cells, e. g., muscle, skin, lung and 
immune cells (Gotti, 2004). The function of these receptors in the individual 
organs/cell types is not fully established (Gotti, 2004). It has not yet been 
determined whether CHRNAs are expressed in AT, where they may influence 
adipogenesis by modulation of neurotransmitter release, e. g., noradrenaline and 
NPY, similar to the previously reported downstream regulation of NPY secretion 
in the chromaffine cells of the adrenal gland (Hexum, 1989). 
Thus, the aim of this chapter was to examine the expression of CHRNAs in 
human AT and to establish a possible depot-specific distribution and to 
determine whether smoking affects circulating levels of NPY in serum, which 
could be potentially associated with CHRNA regulation in AT. 
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6.2. Methods 
6.2.1. Subjects 
Adipose tissue (AT) samples were obtained from thirty eight consenting 
Caucasian women undergoing elective surgery. Mean age: 42.7t7.3(mean±SD) 
years; BMI: 26.2±4.5kg/m2 Abdominal subcutaneous (Ab Sc), omental (Om) AT 
and thigh tissue (Th) AT samples were collected with the approval of the South 
Birmingham Ethics Committee. Subjects on endocrine therapy (e. g., steroids, 
HRT, thyroxine) and patients with malignant diseases were excluded. AT 
samples were immediately processed for adipocyte isolation and cell culture or 
flash frozen for protein or RNA extraction as described below. 
Fasting serum samples of 34 Caucasian healthy volunteers (14 men and 20 
women) were taken with approval of the Coventry and Warwickshire ethics 
committee. Characteristics of these subjects were: age: 48.7±14years, BMI: 
26.2±4.5kg/m2, all subjects are Caucasian and not treated with any medication or 
hormone replacements. Non-smokers were defined as subjects who never 
smoked. Ex-smokers were thus not included. Freshly obtained serum samples 
were centrifuged at 700 xg for 20 min, snap frozen and stored at -80°C. Serum 
was used for NPY analysis. 
6.2.2. Adipocyte isolation: 
Adipose tissue was processed as previously described in Chapter 2 and washed 
with 1X Hank's balanced salt solution containing penicillin (100U/mL) and 
streptomycin (100pg/mL). The tissue was finely cut, digested with collagenase 
class 1 (2mg/mL, Worthington Biochemical Corporation, USA) in 1X Hank's 
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balanced salt solution (Gibco, USA) for 1 hr at 37°C in a water bath, then shaken 
at 100 cycles/min at 37°C. Following digestion, the tissue was filtered through a 
sterile double-layered cotton mesh and adipocytes were separated by 
centrifugation at 360 xg for 5 min. The upper layer of mature adipocytes was 
removed from the collagenase-dispersed preparation, washed twice in phenol 
red-free medium DMEM: F12 and centrifuged at 360 xg for 2 min. Adipocytes 
were cultured in flasks (25cm2) in phenol red-free Dulbecco's modified Eagle 
medium (DMEM/F-12) medium containing glucose (15mmol/L), penicillin (100 
U/mL), and streptomycin (100pg/mL). Aliquots of lmL containing `500,000 
mature adipocytes were maintained in medium (5mL per 25-cm2 flask) for 48 
hrs. After incubation of adipocytes (37°C/5%CO2), the conditioned media and 
adipocytes were separated by centrifugation (360 xg for 2 min) and the media 
removed. 
6.2.3. Western blot analysis: 
Homogenised human AT was extracted using a 10% RIPA buffer method (see 
Chapter 2.3. ). Protein concentrations were determined using the Bio-Rad 
Detergent Compatible (DC) protein assay kit (Biorad UK). Western blot analysis 
was performed using a method described in Chapter 2.4.. In brief, 20µg/lane of 
adipocyte protein was separated by SDS-PAGE gel electrophoresis using a 12% 
gel, then electrophoresed at 120V for lhr. Samples were electroblotted in a 
vertical transfer apparatus at 100V for lhr. Membranes were blocked overnight 
at 4°C in phosphate buffered saline and Tween 20 (PBS-T: PBS + 0.05% Tween 
20; Sigma, UK) containing 10% (w/v) non-fat milk powder (Marvel, Moreton, 
Merseyside, UK). Membranes were incubated for 1 hr with primary polyclonal 
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antibody CHRNA7 (Abcam, Cambridge, UK) 1: 2000, then in conjugated anti- 
rabbit HRP secondary antibody in concentrations of 1: 20,000 diluted in PBS 
with 0.5%Tween. CHRNA7 (56kDa) was detected by chemiluminescent assay 
ECL (Amersham, Little Chalfont, UK), which enabled visualization after 
exposure to X-ray film and the band intensity was determined by densitometry. 
Equal loading was ensured with use of the alpha tubulin antibody (Abcam, 
Cambridge, UK). 
6.2.4. RNA extraction 
RNA was extracted from adipose tissue and adipocytes (n=38; age: 
40.9±96years; BMI: 24.9±2.8kg/m2) taken from abdominal subcutaneous (n=30) 
and thigh (n=8) depots, using a RNeasy Lipid Tissue Mini Kit (Quiagen, 
Crawley, UK). Genomic DNA was removed using a DNase digestion step to 
avoid contamination and quantified using the Nanodrop ND-1000 
Spectrophotometer (LabTech, UK). 1µg of RNA from each sample was reverse 
transcribed (RT) using AMV reverse transcriptase (Promega, Southampton, UK) 
according to the manufacturers' instructions. 
6.2.5. Real time PCR 
RT-PCR was performed in a reaction mix containing TagMan® Universal PCR 
Master Mix (AmpErase UNG), added to an assay mix containing 900nM PCR 
primers, 250nM FAMTM dye-labelled TagMan® MGB probe and 50ng cDNA. 
All reactions were multiplexed with the housekeeping gene 18S (Applera, UK), 
provided as a pre-optimised control probe. Messenger RNA levels were 
determined using an ABI 7700 real time PCR Sequence Detection system. Data 
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were obtained as Ct values according to the manufacturer's guidelines. OCt 
values were determined with the formula: iCt = Ct of the target gene minus Ct 
of the housekeeping gene. Measurements were repeated at least three times for 
each sample. Reactions were as follows: 50°C for 2 min, 95°C for 10 min, 40 
cycles of 95°C for 15 s, 60°C for 1 min. Primers and probes were obtained for 
CHRNA4 (ABI Taqman® Gene Expression Assay: Hs00181247_m 1) and 
CHRNA7 (ABI Tagman® Gene Expression Assay: Hs00608028_ml). 
6.2.6. NPY ELISA 
Adipocyte derived conditioned media were concentrated 10 times through 
lyophilisation with the centrifuge evaporator and reconstituted in assay buffer. 
These samples and serum samples of smokers and non-smokers were analysed 
using the commercially available NPY ELISA kit (Peninsula Laboratories Inc., 
USA). Sensitivity: 0.04-0.06ng/mL; Intra-assay variation: <5%; Inter-assay 
variation: <14%. 
6.2.7. Statistics 
Gene expression was compared using the AOCt method and statistics performed 
at the ACt stage. Statistical analysis was performed using the Student's t-test 
unless otherwise stated. The threshold for significance was p<0.05. Data in the 
text and figures are presented as mean t SEM unless otherwise stated. 
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6.3. Results 
6.3.1. mRNA expression of CHRNAs 
Adipose tissue and isolated adipocytes were assessed for mRNA expression of 
CHRNA4 and 7, using Real-time PCR, as described previously. No CHRNA4 
mRNA expression was identified in either AT or isolated adipocytes. In contrast, 
we detected CHRNA7 mRNA expression in human adipose tissue (AT) which 
was no different in AT when compared with adipocytes originating from the 
same patient and depot (Figure 6.3.1.1. ). 
CHRNA7 expression of AT and adipocytes 
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Figure 6.3.1.1.: Relative expression of CHRNA7 in human adipose tissue 
(allocated value of 1±SEM) in comparison with human adipocytes. Samples 
belong to the same depot and patients, n=8. 
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Figure 6.3.2: The graph indicates relative mRNA expression of CHRNA7 
comparing Abd Sc and thigh AT depots. A value of 1 was arbitrary allocated to 
the expression of thigh fat in non-smokers. There was a significantly higher 
CHRN7 expression in thigh sc AT (n=5 matched samples) in non-smokers than 
smokers, with an opposite pattern in Abd Sc AT; n=8). 
The comparison of the thigh and Abd Sc AT fat depot showed a higher 
expression in thigh fat (1tO. 020D), for which an arbitrary value of 1 was 
allocated. A significantly lower expression was found in age and BMI matched 
smokers (0.8tO. 030D) in comparison to non-smokers. In contrast, the 
comparison the Abd Sc AT showed a significantly higher expression of 
CHRNA7 in smokers (0.9±0.030D versus 0.79±0.050D; p<0.01) (Figure 
6.3.1.2). 
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6.3.2. CHRNA protein expression 
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Figure 6.3.2.: Protein expression and representative Western blot of CHRNA7 
expression in human fat depots with reference of thigh as (1±SEM). There is 
higher CHRNA7 expression in the Abd Sc AT depot (p<0.01) in comparison to 
thigh AT; and higher expression in the Om in comparison to Abd Sc AT 
(p<0.05). 
CHRNA7 protein expression was further examined by Western blot. CHRNA7 is 
a 56kDa protein, which is present in Sc thigh, Abd Sc AT and omental fat. Semi- 
quantitative comparison with arbitrary allocation of the value of 1 for the 
expression in thigh fat (1±0.045) (relative value in comparison to thigh AT of the 
same subject) showed significantly higher values in Sc abdominal AT (1.7± 
0.14, p<0.01), with highest levels in omental fat (2.3±0.28, p<0,05) of non- 
smokers (Figure 6.3.2). A comparison of Abd Sc AT CHRNA7 expression of 
non-smokers did not, however, show a BMI correlation (BMI of obese subjects 
32.5±2.6kg/m2 compared with lean subjects 23.2±1.2kg/m2, n=8, p=NS). 
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6.3.3. Serum NPY levels of smokers versus non-smokers 
We analysed serum levels of 34 Caucasian subjects (20 women, 14 men, age 
48.7±14yrs; BMI 26.2±4.5kg/m2) consisting of 16 current smokers and 18 non- 
smokers, which were matched by age and BMI. Correcting for these variables 
with stepwise regression analyses, the NPY levels were significantly lower in 
smokers (34.3±1.54ng/mL) versus non-smokers (103.8±16.4ng/mL, p=0.024; 
n=35) (Figure 6.3.3. ). 
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Figure 6.3.3: Fasting serum NPY levels compared between age and BMI 
matched smokers and non-smokers. 
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6.4. Discussion 
Nicotine is an exogenous ligand for CHRNA receptors, where it competes with 
the endogenous ligand acetylcholine (Berg, 2002). The ability of nicotine to bind 
to CHRNAs has made smoking and smoking-related pathologies convenient 
models for the study of these receptor types. This is the first study to demonstrate 
CHRNA7 receptor mRNA and protein expression in human fat. Although these 
receptors are typically neural receptors which exist in the central and peripheral 
nervous system, forms of these heterogeneous receptors have recently been 
discovered in non-neuronal cells (Gotti, 2004); furthermore, as these data show, 
AT and adipocytes appear to be yet another source of CHRNA7. This is 
consistent with the finding of CHRNA7 and its mRNA expression in rat 
adipocytes (Liu, 2004). Whilst both enriched macrophages and endothelial cell 
preparations have been shown to express CHRNAs (Gotti, 2004), and are 
components of AT, the data above indicates that mRNA expression of CHRNA7 
is not much different in isolated adipocytes themselves, whilst contamination of 
isolated adipocytes as source of CHRNA mRNA is unlikely, as discussed in 
Chapter 4. The presence of CHRNAs in AT is further supported by studies 
examining the effect of smoking on AT. Nicotine induces lipolysis, as 
demonstrated by differences in serum and adipocyte glycerol secretion after 
nicotine infusion in rodents (Sztalryd, 1996) or with smoking in humans 
(Andersson, 2001). Pre-treatment with the nicotinic receptor antagonist 
mecamylamine can abolish this lipolytic effect of nicotine, as demonstrated by 
microdialysis studies (Andersson, 1995). 
Furthermore, this study identified a depot-specific expression of CHRNA7 in 
AT, which could partially be responsible for the fat distribution with smoking. 
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Body fat distribution in chronic smokers is characterised by an increase in 
abdominal fat and a decrease of gluteal/thigh fat (Jensen, 1995), and a reversal of 
this distribution has been documented with smoking cessation in which 
unhealthy visceral fat diminishes and gluteofemoral fat increases (Ferrara, 2001). 
Whilst CHRNA7 protein appears to be generally more highly expressed in 
abdominal fat, similar to previously described sympathetic innervation 
(Hoffstedt, 1997), its mRNA expression is higher in the Abd Sc fat of smokers in 
comparison to non-smokers, which could have been upregulated in smokers by 
exposure to nicotine. The above experiments do not show a correlation of 
CHRNA7 protein expression with BMI in AT, which may be due to the fact that 
BMI does not reflect the depot-specific distribution of fat. 
The correlation of circulating NPY levels with smoking is in support of a link 
between CHRNA7 and NPY metabolism. A variety of neurotransmitters can be 
controlled by CHRNA7, e. g. amongst others, it modulates glutamate release in 
the hippocampus, GABA and acetylcholine (Berg, 2002). NPY release can also 
be modulated by nicotinic receptors in the adrenal gland (Hexum, 1989). 
Furthermore, CHRNA7 can participate in both: sympathetic and parasympathetic 
pathways. Further research is required to demonstrate a direct relationship 
between CHRNA7 and NPY release in Abd Sc adipocytes which could be done 
by cell treatment with selective CHRNA7 antagonists and measurement of 
subsequent changes in NPY secretion. Further analysis is also required to 
determine the influence of CHRNA7 on adipokines, which are known to be 
affected by nicotine exposure (Nicklas, 1999; Arai, 2001; Liu, 2004). The 
reduced serum NPY levels in smokers may further reduce the orexigenic 
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hypothalamic effects of NPY, in addition to the hypothalamic downregulation of 
NPY observed by Frankish (1995), and affect central appetite regulation through 
reduced food intake as result of nicotine exposure (Li, 2000). A crosstalk of 
peripheral circulating NPY with the hypothalamus is likely, given its easy entry 
into the CSF, as observed by the study of Kastin (1999), in which radioactive 
labelled NPY entered the BBB in an unsaturated manner, faster than albumin and 
similar to diffusion. NPY mediates orexigenic signals through NPY receptor 1 
(Y1), Y4 and Y5, whilst Y2 is an auto-inhibitory receptor which mediates 
appetite inhibition (Broberger, 1997). The anorexigenic gut hormone PYY, 
which belongs to the same family of pancreatic polypeptides (with 70% 
sequence homology with NPY), has also high affinity to the receptor Y2, through 
which it is thought to suppress appetite (Abbott, 2005). A potential difference in 
binding affinities of NPY and PYY to hypothalamic human Y2 has not yet been 
clarified; however, competitive binding of PYY and NPY for Y2 is possible. 
Whilst NPY is suppressed by smoking, PYY action may therefore prevail. 
Furthermore, nicotine affects the gastrointestinal PYY mRNA expression in rats 
(Gomez, 1996), little is known about the influence of nicotine exposure on 
cerebral levels of PYY, which can also cross the BBB (Nonaka, 2003). 
Whilst CHRNA may be responsible for the net decrease of circulating NPY 
levels, it may modulate NPY action in fat in a depot specific manner. Several 
studies using human adipocytes show an antilipolytic effect of NPY (Castan, 
1994; Turtzo, 2001); this was confirmed in Chapter 4, demonstrating a decrease 
of glycerol secretion as a result of rh NPY treatment of isolated cultured 
adipocytes. The increased waist-hip ratio in smokers may be induced by the 
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antilipolytic effect of NPY which shows higher expression in Abd Sc fat as 
shown in Chapter 4, and therefore requires further study. 
In summary, CHRNA 7, but not 4, is expressed by human adipocytes in a depot 
specific manner and appears to be regulated by smoking. The pattern of 
CHRNA7 fat distribution is highest in visceral fat, in which sympathetic 
innervation is predominant. Circulating NPY levels are reduced in chronic 
smokers, which may in part contribute to the reduced orexigenic hypothalamic 
NPY levels and lead to reduced food intake. Whilst this study suggests that the 
antilipolytic neurotransmitter NPY is associated with smoking, which may 
explain the smoking related fat redistribution, further research is required to 
demonstrate the signalling mechanisms of CHRNA7 in AT and the pathway by 
which it influences NPY. 
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Chanter 7 
Discussion 
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Adipose tissue, which is now widely recognised as an endocrine organ, influences 
and interacts with the brain (Mohamed-Ali, 1998). The secretion of adipokines 
enables AT to participate in overall energy regulation. The discovery of the 
adipokine leptin and its hypothalamic action provided the first example of AT 
crosstalk with the brain (Baura, 1993). As an indicator of overall energy status, 
leptin can deliver feedback to the brain and regulate appetite through hypothalamic 
pathways. Furthermore, leptin can regulate adipogenesis by central autonomic 
feedback (Rayner, 2001) to AT and by autocrine/paracrine activity in AT. 
Meanwhile, the existence of other adipokines has been reported with yearly 
acquisition of new proteins to the list, some of which, e. g., nesfatin (Oh-I, 2006) 
have been discovered recently, and have been shown to interact with the brain. 
Alternatively, evidence of adiponectin and resistin interaction with the human brain 
is lacking. In light of a `brain-to-adipose system' crosstalk, it has been suggested 
that central neurotransmitters may themselves be expressed in AT (Yang, 2003), 
whereby they may potentially alter fat metabolism by paracrine and autocrine 
mechanisms, to elicit feedback on energy homeostasis. 
The projects of this thesis established the importance of further proteins and their 
potential signalling pathways in the crosstalk between AT and the brain in human 
physiology. The studies examined the regulation of energy homeostasis using a two 
sided approach. Firstly, the crosstalk between AT and the brain by CNS action of 
adipokines was studied. Secondly, mirroring this, the CNS-AT crosstalk by 
expression of neurotransmitter and their receptors in AT was explored. The 
adipokines adiponectin and resistin were determined to have the potential to 
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function in an adipose-to-brain crosstalk system, with potential participation in 
central energy homeostasis, as suggested by their presence in the CSF. Furthermore, 
the relative distribution of adiponectin receptors in hypothalamic nuclei, which are 
important in appetite regulation, further emphasised participation of this adipokine 
in a potential adipose tissue-to-brain system. On the other hand, this thesis further 
established that the orexigenic neurotransmitters NPY and ghrelin are secreted by 
human adipocytes, where they enhance lipid accumulation. Final studies 
highlighted the influence of depot-specific innervation of AT on energy 
homeostasis, by establishing presence of nicotinic receptors in human adipocytes. 
The finding of adiponectin and resistin in human CSF has recently been published 
as result of this study (Kos, 2007) and was the first report of such in human 
subjects. Also, resistin has not previously been reported in human CSF and has not 
been detected in CSF of rodents (Caja 2005a, Caja 2005b). Whilst adiponectin in 
human CSF was not detected in a more recent study (Spranger, 2006), the 
advantage of the experiments in this thesis was the use of a more sensitive assay, as 
discussed in Chapter 3. Furthermore, within the team, we further confirmed the 
serum/CSF ratio of adiponectin of 1: 1000 by radioimmunoassay and characterised 
the predominant multimer of adiponectin in human CSF, using sub-fractionation of 
adiponectin by gel chromatography. The outcome was that adiponectin is present in 
the CSF primarily as LMW hexamers and trimers, with no presence of HMW 
structures (Kusminski, 2007). HMW structures of adiponectin have previously been 
suggested to correlate better with insulin sensitivity, than total adiponectin levels 
(Pajvani, 2004; Fisher, 2005). Therefore, it may not be surprising that no 
193 
association of CSF adiponectin was found with insulin resistance in Chapter 3. In 
order to draw conclusions on the impact of diabetes on CSF levels of these 
adipokines, a different method of CSF sampling would be required. In this study, 
diabetic patients could not be included for HOMA-IR analysis. A fasting blood test 
was performed in parallel to CSF sampling and was part of the spinal anaesthetic 
procedure, and thus taken just before the injection of the spinal anaesthetic. The 
diabetic patients were already treated with a glucose/insulin infusion at the time 
they entered the theatre, thus a fasting sample could not be taken in parallel with the 
CSF sample. It would have also been interesting to expand the BMI spectrum to the 
morbidly obese phenotype, the problem there being that these patients are unlikely 
candidates for elective surgery, e. g., because of their high anaesthetic risk. Similar 
to adiponectin, commercially available ELISAs measure predominantly total levels 
of resistin and the fractionation of resistin isoforms is difficult as they appear more 
similar in size and shape than adiponectin. 
Another achievement of this study was the demonstration of human adiponectin 
receptors at important hypothalamic appetite regulating centres, which highlights 
that central adiponectin may be involved in central energy regulation. Meanwhile, 
another study found adiponectin receptors in the area postrema of the rat brain, and 
the function of these receptors was confirmed by electrophysiological studies (Fry, 
2006). Human studies are limited by poor availability of fresh brain tissue and 
ethics, which makes such studies difficult. The research of resistin and its influence 
on central action is further complicated by the lack of identified resistin receptors. 
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This thesis led to the identification of the protein expression of the orexigenic 
neurotransmitters NPY and ghrelin in human adipocytes and AT, and further 
explored some aspects of their regulation. However, the role of NPY and ghrelin in 
the pathogenesis of obesity and the metabolic syndrome needs to be further 
clarified. This study also determined that adipocyte-derived NPY was upregulated 
by insulin in human AT, which contradicts the central action of insulin, where 
insulin reduces NPY mRNA expression (Schwartz, 1992b). An opposing central 
and peripheral regulation of insulin is not unusual; for instance, its anorexigenic 
central effects contradict its peripheral anabolic action (Spiegelman, 1996). Whilst 
this study shows that NPY and ghrelin exhibit a depot-specific distribution and 
association with BMI, it remains to be shown whether the secretion of these 
adipose-derived neurotransmitters contributes to the circulating levels, to then be 
able to enter the BBB and finally close the feedback loop from brain to fat and vice 
versa. 
The correlation of NPY with smoking as shown in Chapter 6., may constitute a 
confounding factor for serum NPY levels and may be one of the reasons for the lack 
of a previous identification of a BMI association. Whilst this study was able to 
define a positive correlation of NPY with BMI, NPY and especially its receptors, 
are a good example of species-specific differences, for which reason only human 
tissue was used in all reported experiments. 
Much is known about the central role of ghrelin in energy regulation (Tschop, 2000; 
Chen 2004; Nakazato, 2001). As a `meal initiator', it participates in central energy 
balance as orexigenic hormone; whilst its peripheral regulation of energy 
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homeostasis is less clear. Considering that ghrelin's serum and AT levels decrease 
with BMI, and as it has fat mass preserving properties, it may primarily be a 
`protector from starvation', with no defensive role against the development of 
obesity. The fact that food intake fails to suppress the already reduced levels of 
ghrelin in obesity, as described by English (2002), supports this theory. The 
majority of circulating ghrelin is derived from the GI tract and is able to regulate fat 
metabolism, thus it would be of interest to study a potential gut-fat axis of energy 
regulation. 
Nicotine can alter peripheral energy homeostasis in human subjects (Gotti, 2004), 
and the mechanism by which it can regulate AT was studied in Chapter 6. This 
thesis identified the existence of cholinergic acetylcholine receptors (CHRNAs) in 
human adipocytes, which may alter the synaptic release of neurotransmitters, such 
as NPY by exposure to nicotine. It is known that various circulating levels of 
adipokines are affected by smoking, e. g. leptin, adiponectin and ghrelin (Nicklas, 
1999; Arai, 2001; Iwashima, 2005, Langenberg, 2005). As Chapter 6 also shows 
that NPY is affected by smoking, this therefore suggests that nicotine could affect 
adipokine secretion through altered CHRNA expression. 
Finally, there remains a philosophical uncertainty as to whether the principle of 
allostasis or homeostasis prevails in human weight control. Allostasis (Greek: 
allo=variable, stasis= state) integrates the possibility of pathology like system 
failure and maladjustment as price for adaptive responses to maintain stability 
(McEwen, 2003). Homeostasis (Greek: homeo=similar, stasis=state) implies a 
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physiological response and readjustment by a dynamic equilibrium i. e. through a 
change of a set point for the control of body weight with increasing obesity. The 
projects in this thesis focus on BMI within a narrow range and have primarily 
focused on physiological regulation. Comparison of lean with morbidly obese 
subjects would help to argue whether a dysfunction and failing energy regulation is 
likely. Hypothetically, the presence of leptin resistance as well as insulin resistance, 
with insulin being a central appetite regulator, may be regarded as a malfunction of 
energy regulation, in favour of the allostatic principle. The up-regulation of 
peripheral NPY levels by insulin may be another. The numerous examples of 
energy preserving pathways established in this thesis are compatible with the theory 
of surplus evolutionary pathways to protect from starvation (Wynne, 2005). 
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Future considerations 
There is increasing evidence that adiponectin and resistin take part in central energy 
regulation. Yet their exact role in energy metabolism needs to be clarified. In the 
animal model this can be done by icv injection of these proteins and monitoring 
changes in feeding response, weight and metabolic rate. This allows study of the 
effect in brain bypassing the BBB. Whilst this study suggests that adiponectin, 
resistin and leptin cross the BBB by saturable entry, the mechanism of BBB 
transport for these proteins needs to be established and is thought to be facilitated 
by separate transporters for leptin and insulin (Banks, 2006). The corresponding 
transport systems need to be identified and it is of great interest as to whether these 
transport systems are impaired in states of obesity. An impairment or malfunction 
of the BBB is thought to account for some of the obesity-associated leptin 
resistance. Peripheral administration of leptin does not lead to a response in obese 
rats, which do however lose weight when leptin is injected directly into the brain 
(Nimi, 1999). Thus, in order to bypass the BBB as a possible site of malfunction 
(Burguera, 2000), the method of intranasal administration of leptin appears to be a 
promising method (Shimuzu, 2005; Fliedner, 2006). The mechanism of protein 
influx by intranasal administration is not clearly understood (Kastin, 2006), and 
may be by direct entry into the brain. Intranasal administration of proteins, such as 
adiponectin, could become an elegant research method for the study of central 
effects in humans, as the method of icv injection cannot be used in humans. 
Other non-invasive research methods for human studies are functional magnetic 
resonance imaging (fMRI), positron emission tomography (PET), 
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magnetoencephalography (MEG) and magnetic resonance spectrography. The 
advantage of these instruments is the study of a concert of responses of the brain to 
a certain stimulus, rather than examining only an isolated brain area. The stimuli 
can vary from visual, gustatory or intravenous administration of substances, which 
includes components of the more complex appetite regulation apart from weight 
change and absolute food intake. These methods allowed identifying brain centres 
involved in addiction and reward of food intake (Wang, 2004; Kelley, 2005). 
Hypothalamic signalling has been shown to differ between lean and obese subjects 
(Tataranni, 2003). A very recent study using PET scanning confirmed central 
insulin resistance alongside peripheral insulin resistance in the metabolic syndrome 
(Anthony, 2006). 
Alongside NPY's and ghrelin's central expression, this study also identified their 
expression in human AT. It remains to be proven whether their presence in fat 
permits endocrine activity and exceeds autocrine and paracrine functions. 
Microdialysis studies assessing arterio-venous concentration gradients of these 
proteins could help to establish whether AT-derived secretion has impact on 
circulating levels of the same. 
In summary, this thesis identified additional potential mediators for the cross-talk 
between AT and the brain. Adiponectin and resistin exist in different isoforms, and 
as a consequence of this project, it was meanwhile possible to identify which 
adiponectin oligomer was capable of crossing the BBB. In contrast, the resistin 
structure is more complex and its receptors have not yet been identified. The 
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neurotransmitters NPY and ghrelin are also expressed in human AT, and can 
potentially promote fat storage. It is as yet unclear, whether the AT-derived forms 
of NPY and ghrelin enter the circulation and participate in brain signalling. Future 
microdialysis may provide further information. The data in this thesis further show 
that DPP-IV is expressed in human adipose tissue and reduced in obesity. DPP-IV 
modulates action of several peptides like NPY, PYY and GLP-1 and its 
physiological role in energy regulation needs to be clarified. The finding of 
CHRNA receptors on adipocytes suggests that AT is highly sensitive to the effects 
of autonomic innervation as well as smoking. Finally, with obesity leading to leptin 
resistance and possibly to central dysfunction of energy regulation, the dysfunction 
under the strain of western lifestyle may be regarded as an allostatic response rather 
than following homeostatic principles. 
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Chapter 7 
Discussion 
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Adipose tissue, which is now widely recognised as an endocrine organ, influences 
and interacts with the brain (Mohamed-Ali, 1998). The secretion of adipokines 
enables AT to participate in overall energy regulation. The discovery of the 
adipokine leptin and its hypothalamic action provided the first example of AT 
crosstalk with the brain (Baura, 1993). As an indicator of overall energy status, 
leptin can deliver feedback to the brain and regulate appetite through hypothalamic 
pathways. Furthermore, leptin can regulate adipogenesis by central autonomic 
feedback (Rayner, 2001) to AT and by autocrine/paracrine activity in AT. 
Meanwhile, the existence of other adipokines has been reported with yearly 
acquisition of new proteins to the list, some of which, e. g., nesfatin (Oh-I, 2006) 
have been discovered recently, and have been shown to interact with the brain. 
Alternatively, evidence of adiponectin and resistin interaction with the human brain 
is lacking. In light of a `brain-to-adipose system' crosstalk, it has been suggested 
that central neurotransmitters may themselves be expressed in AT (Yang, 2003), 
whereby they may potentially alter fat metabolism by paracrine and autocrine 
mechanisms, to elicit feedback on energy homeostasis. 
The projects of this thesis established the importance of further proteins and their 
potential signalling pathways in the crosstalk between AT and the brain in human 
physiology. The studies examined the regulation of energy homeostasis using a two 
sided approach. Firstly, the crosstalk between AT and the brain by CNS action of 
adipokines was studied. Secondly, mirroring this, the CNS-AT crosstalk by 
expression of neurotransmitter and their receptors in AT was explored. The 
adipokines adiponectin and resistin were determined to have the potential to 
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function in an adipose-to-brain crosstalk system, with potential participation in 
central energy homeostasis, as suggested by their presence in the CSF. Furthermore, 
the relative distribution of adiponectin receptors in hypothalamic nuclei, which are 
important in appetite regulation, further emphasised participation of this adipokine 
in a potential adipose tissue-to-brain system. On the other hand, this thesis further 
established that the orexigenic neurotransmitters NPY and ghrelin are secreted by 
human adipocytes, where they enhance lipid accumulation. Final studies 
highlighted the influence of depot-specific innervation of AT on energy 
homeostasis, by establishing presence of nicotinic receptors in human adipocytes. 
The finding of adiponectin and resistin in human CSF has recently been published 
as result of this study (Kos, 2007) and was the first report of such in human 
subjects. Also, resistin has not previously been reported in human CSF and has not 
been detected in CSF of rodents (Caja 2005a, Caja 2005b). Whilst adiponectin in 
human CSF was not detected in a more recent study (Spranger, 2006), the 
advantage of the experiments in this thesis was the use of a more sensitive assay, as 
discussed in Chapter 3. Furthermore, within the team, we further confirmed the 
serum/CSF ratio of adiponectin of 1: 1000 by radioimmunoassay and characterised 
the predominant multimer of adiponectin in human CSF, using sub-fractionation of 
adiponectin by gel chromatography. The outcome was that adiponectin is present in 
the CSF primarily as LMW hexamers and trimers, with no presence of HMW 
structures (Kusminski, 2007). HMW structures of adiponectin have previously been 
suggested to correlate better with insulin sensitivity, than total adiponectin levels 
(Pajvani, 2004; Fisher, 2005). Therefore, it may not be surprising that no 
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association of CSF adiponectin was found with insulin resistance in Chapter 3. In 
order to draw conclusions on the impact of diabetes on CSF levels of these 
adipokines, a different method of CSF sampling would be required. In this study, 
diabetic patients could not be included for HOMA-IR analysis. A fasting blood test 
was performed in parallel to CSF sampling and was part of the spinal anaesthetic 
procedure, and thus taken just before the injection of the spinal anaesthetic. The 
diabetic patients were already treated with a glucose/insulin infusion at the time 
they entered the theatre, thus a fasting sample could not be taken in parallel with the 
CSF sample. It would have also been interesting to expand the BMI spectrum to the 
morbidly obese phenotype, the problem there being that these patients are unlikely 
candidates for elective surgery, e. g., because of their high anaesthetic risk. Similar 
to adiponectin, commercially available ELISAs measure predominantly total levels 
of resistin and the fractionation of resistin isoforms is difficult as they appear more 
similar in size and shape than adiponectin. 
Another achievement of this study was the demonstration of human adiponectin 
receptors at important hypothalamic appetite regulating centres, which highlights 
that central adiponectin may be involved in central energy regulation. Meanwhile, 
another study found adiponectin receptors in the area postrema of the rat brain, and 
the function of these receptors was confirmed by electrophysiological studies (Fry, 
2006). Human studies are limited by poor availability of fresh brain tissue and 
ethics, which makes such studies difficult. The research of resistin and its influence 
on central action is further complicated by the lack of identified resistin receptors. 
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This thesis led to the identification of the protein expression of the orexigenic 
neurotransmitters NPY and ghrelin in human adipocytes and AT, and further 
explored some aspects of their regulation. However, the role of NPY and ghrelin in 
the pathogenesis of obesity and the metabolic syndrome needs to be further 
clarified. This study also determined that adipocyte-derived NPY was upregulated 
by insulin in human AT, which contradicts the central action of insulin, where 
insulin reduces NPY mRNA expression (Schwartz, 1992b). An opposing central 
and peripheral regulation of insulin is not unusual; for instance, its anorexigenic 
central effects contradict its peripheral anabolic action (Spiegelman, 1996). Whilst 
this study shows that NPY and ghrelin exhibit a depot-specific distribution and 
association with BMI, it remains to be shown whether the secretion of these 
adipose-derived neurotransmitters contributes to the circulating levels, to then be 
able to enter the BBB and finally close the feedback loop from brain to fat and vice 
versa. 
The correlation of NPY with smoking as shown in Chapter 6., may constitute a 
confounding factor for serum NPY levels and may be one of the reasons for the lack 
of a previous identification of a BMI association. Whilst this study was able to 
define a positive correlation of NPY with BMI, NPY and especially its receptors, 
are a good example of species-specific differences, for which reason only human 
tissue was used in all reported experiments. 
Much is known about the central role of ghrelin in energy regulation (Tschop, 2000; 
Chen 2004; Nakazato, 2001). As a `meal initiator', it participates in central energy 
balance as orexigenic hormone; whilst its peripheral regulation of energy 
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homeostasis is less clear. Considering that ghrelin's serum and AT levels decrease 
with BMI, and as it has fat mass preserving properties, it may primarily be a 
`protector from starvation', with no defensive role against the development of 
obesity. The fact that food intake fails to suppress the already reduced levels of 
ghrelin in obesity, as described by English (2002), supports this theory. The 
majority of circulating ghrelin is derived from the GI tract and is able to regulate fat 
metabolism, thus it would be of interest to study a potential gut-fat axis of energy 
regulation. 
Nicotine can alter peripheral energy homeostasis in human subjects (Gotti, 2004), 
and the mechanism by which it can regulate AT was studied in Chapter 6. This 
thesis identified the existence of cholinergic acetylcholine receptors (CHRNAs) in 
human adipocytes, which may alter the synaptic release of neurotransmitters, such 
as NPY by exposure to nicotine. It is known that various circulating levels of 
adipokines are affected by smoking, e. g. leptin, adiponectin and ghrelin (Nicklas, 
1999; Arai, 2001; Iwashima, 2005, Langenberg, 2005). As Chapter 6 also shows 
that NPY is affected by smoking, this therefore suggests that nicotine could affect 
adipokine secretion through altered CHRNA expression. 
Finally, there remains a philosophical uncertainty as to whether the principle of 
allostasis or homeostasis prevails in human weight control. Allostasis (Greek: 
allo=variable, stasis= state) integrates the possibility of pathology like system 
failure and maladjustment as price for adaptive responses to maintain stability 
(McEwen, 2003). Homeostasis (Greek: homeo=similar, stasis=state) implies a 
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physiological response and readjustment by a dynamic equilibrium i. e. through a 
change of a set point for the control of body weight with increasing obesity. The 
projects in this thesis focus on BMI within a narrow range and have primarily 
focused on physiological regulation. Comparison of lean with morbidly obese 
subjects would help to argue whether a dysfunction and failing energy regulation is 
likely. Hypothetically, the presence of leptin resistance as well as insulin resistance, 
with insulin being a central appetite regulator, may be regarded as a malfunction of 
energy regulation, in favour of the allostatic principle. The up-regulation of 
peripheral NPY levels by insulin may be another. The numerous examples of 
energy preserving pathways established in this thesis are compatible with the theory 
of surplus evolutionary pathways to protect from starvation (Wynne, 2005). 
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Future considerations 
There is increasing evidence that adiponectin and resistin take part in central energy 
regulation. Yet their exact role in energy metabolism needs to be clarified. In the 
animal model this can be done by icv injection of these proteins and monitoring 
changes in feeding response, weight and metabolic rate. This allows study of the 
effect in brain bypassing the BBB. Whilst this study suggests that adiponectin, 
resistin and leptin cross the BBB by saturable entry, the mechanism of BBB 
transport for these proteins needs to be established and is thought to be facilitated 
by separate transporters for leptin and insulin (Banks, 2006). The corresponding 
transport systems need to be identified and it is of great interest as to whether these 
transport systems are impaired in states of obesity. An impairment or malfunction 
of the BBB is thought to account for some of the obesity-associated leptin 
resistance. Peripheral administration of leptin does not lead to a response in obese 
rats, which do however lose weight when leptin is injected directly into the brain 
(Nimi, 1999). Thus, in order to bypass the BBB as a possible site of malfunction 
(Burguera, 2000), the method of intranasal administration of leptin appears to be a 
promising method (Shimuzu, 2005; Fliedner, 2006). The mechanism of protein 
influx by intranasal administration is not clearly understood (Kastin, 2006), and 
may be by direct entry into the brain. Intranasal administration of proteins, such as 
adiponectin, could become an elegant research method for the study of central 
effects in humans, as the method of icv injection cannot be used in humans. 
Other non-invasive research methods for human studies are functional magnetic 
resonance imaging (fMRI), positron emission tomography (PET), 
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magnetoencephalography (MEG) and magnetic resonance spectrography. The 
advantage of these instruments is the study of a concert of responses of the brain to 
a certain stimulus, rather than examining only an isolated brain area. The stimuli 
can vary from visual, gustatory or intravenous administration of substances, which 
includes components of the more complex appetite regulation apart from weight 
change and absolute food intake. These methods allowed identifying brain centres 
involved in addiction and reward of food intake (Wang, 2004; Kelley, 2005). 
Hypothalamic signalling has been shown to differ between lean and obese subjects 
(Tataranni, 2003). A very recent study using PET scanning confirmed central 
insulin resistance alongside peripheral insulin resistance in the metabolic syndrome 
(Anthony, 2006). 
Alongside NPY's and ghrelin's central expression, this study also identified their 
expression in human AT. It remains to be proven whether their presence in fat 
permits endocrine activity and exceeds autocrine and paracrine functions. 
Microdialysis studies assessing arterio-venous concentration gradients of these 
proteins could help to establish whether AT-derived secretion has impact on 
circulating levels of the same. 
In summary, this thesis identified additional potential mediators for the cross-talk 
between AT and the brain. Adiponectin and resistin exist in different isoforms, and 
as a consequence of this project, it was meanwhile possible to identify which 
adiponectin oligomer was capable of crossing the BBB. In contrast, the resistin 
structure is more complex and its receptors have not yet been identified. The 
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neurotransmitters NPY and ghrelin are also expressed in human AT, and can 
potentially promote fat storage. It is as yet unclear, whether the AT-derived forms 
of NPY and ghrelin enter the circulation and participate in brain signalling. Future 
microdialysis may provide further information. The data in this thesis further show 
that DPP-IV is expressed in human adipose tissue and reduced in obesity. DPP-IV 
modulates action of several peptides like NPY, PYY and GLP-1 and its 
physiological role in energy regulation needs to be clarified. The finding of 
CHRNA receptors on adipocytes suggests that AT is highly sensitive to the effects 
of autonomic innervation as well as smoking. Finally, with obesity leading to leptin 
resistance and possibly to central dysfunction of energy regulation, the dysfunction 
under the strain of western lifestyle may be regarded as an allostatic response rather 
than following homeostatic principles. 
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APPENDIX I: Chemicals and Solutions 
A1.1. Western blotting solutions: 
4% sodium dodecyl sulphate (SDS) 
4g SDS powder 
100m1 mQH2O or 
10ml 20% SDS solution 
50m1 mQH2O 
Solution was stored at RT 
Non reducing loading buffer 
625µL Tris-HC1(pH 6.8) 125mM 
500µL SDS 4% 
1000µL Glycerol 
125µL Bromophenol blue 
250µL Distilled water 
For reducing loading buffer 200µL DTT was added 
Electrode buffer for SDS-PAGE electrophoresis: 
REAGENT FINAL CONCENTRATION QUANTITY 
(X5) (DILUTED IN 1L) 
Tris 1.24x10'1M 15g 
Glycine 
(Biorad, Hercules, 9.6x10"'M 72g 
USA) 
SDS 
20%(v/v) 25m1 
Table AI. 1.1.: Components of electrode buffer 
Electrode buffer was stored at 4°C. 
Transfer buffer for electrophoresis: 
REAGENT FINAL CONCENTRATION 
(X 1) 
QUANTITY 
(DILUTED IN 4L) 
Tris 25mM 15.15g 
Glycine 192mM 72. Og 
Methanol 100% IL 
Table AI. 1.2.: Components of transfer buffer 
The buffer was stored at 4°C in the cool room. 
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Phosphate buffered saline (PBS) (pH7.6) 
11 of distilled water was mixed with 5 tablets of: 
PBS 120mM 
NaC12.7Mm 
KCL 10mM 
The solution was stored at RT. 
1.0% PBS-tween (PBS-T) 
1L PBS (prepared as above) 
lml Polyoxyethylene Sorbitan Monolaurate (`Tween20' (0.1% (v/v), Sigma UK) 
Solution was stored at room temperature. 
20 % blocking solution for Millipore® filters 
20g non-fat Milk solution (Marvel Milk Powder) 
200m1 PBS 0.5% Polyoxyethylene Sorbitan Monolaurate (Tween 20 (0.1% (v/v), 
Sigma UK) 
0.5% PBS/PBS-T (diluents for antibodies) 
2m1 1.0% PBS-T (prepared as above) 
2m1 PBS (prepared as above) 
A1.2. Cell culture solutions: 
Phosphate buffered saline (PBS) (pH7.6) 
PBS 120mM 
NaC12.7mM 
KCL, 10mM 
Solution was filtered and penicillin (pen) (100units/ml) and streptomycin (strept) 
(100mg/ml) added. Solution was stored at room temperature. 
Lysis buffer 
Ammonium chloride (NH4CI) 
Potassium bicarbonate (KHCO3) 
Ethylenediaminetetraacetic acid (EDTA 0.5M) 
Solution was stored at room temperature. 
Trypsin solution 
Trypsin 2.5% 
Ethylenediaminetetraacetic acid (0.25mM) 
Phosphate buffered saline (pH7.6) 
0.154 mol/L 
l Ommol/L 
0.1 mmol/L 
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Pre-adipocyte cell growth medium 
Dulbecco's minimal essential medium (DMEM/F-12) 
15% filtered foetal calf serum (FCS) 
penicillin (100units/ml) and streptomycin (strept) (100mg/ml) added 
Growth medium was stored at 4°C. 
Phenol red free medium 
Dulbecco's minimal essential medium (DMEM/F-12) 
Phenol red free medium 
1% transferrin (see below) 
Penicillin (100units/ml) and streptomycin (strept) (100mg/ml) were added 
and medium was stored at 4°C. 
Transferrin 
Transferrin binds Fe 2' and prevents its oxidisation to Fei+. Transferins are 
important extracellular antioxidants. The binding of iron to transferrins is very 
effective under physiological conditions so that virtually no free iron exists which 
could catalyse the production of free radicals. 
AI. 3. Protein extraction solution (RIPA) 
RIPA buffer (10m1) 
9mL 1xPBS 
0.1 mL I% Nonldet P40 
0.05mL 0.5% sodium deoxycholate 
0. O1mL 0.1% SDS 
1 mL 1x complete mini protease inhibitor cocktail 
100µg/mL ALLN 
AI. 4. Solutions for RT PCR 
RNA isolation: 
DNase I REACTION 
BUFFER 
STOP 
SOLUTION 
lunit/tL in 200mM Tris-HC1(pH 8.3) 50mM EDTA 
50% glycerol 20mM MgC12 
10mM Tris-HCl (pH7.5) 
10mM CaC12 
10mM MgC12 
Table AI. 4.: Solutions for RNA isolation 
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Taq DNA polymerase for visualisation of PCR products 
50mM Tris-HC1(pH 8.0) 
100mM NaCI 
0.1mM EDTA 
1 mM DTT 
50% glycerol 
1% Triton® X-100 
Reverse Transcription (RTn) Buffer 
100mM Tris-HC1(pH 9.0 at 25°C) 
500mM KC1 
1% Triton® X-100 
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APPENDIX II: Methods 
ALL1. Rainbow markers for protein size comparison in western blot analysis 
M, 220K 
97K 
1'h, nl, luýn!. 1 I" 'ý'rtný'ý' 66K 
vcý+trý 45K 
.... .. n 
IOK 
I -1wii inhibitor 
20.1 K 
I., ý. ui, für "MV 
14.1 K 
Figure AH.!.: A Marker for medium range molecular weights (Amersham 
Pharmacia Biotech, Buckinghamshire, UK). The marker is resolved on a SDS- 
PAGE gel; after electrophoresis the gel was dried and photographed. Black bands 
represent the gel exposed to photographic film (HyperfilmTM ß-max) and the 
protein weight estimated by relating the black bands on photographic film with the 
colour coded bands on the membranes. 
AII. 2. Cell count with the use of a haemocvtometer 
Cover slip 
0.25 mm = 0.01mm 
02m 
Area filled by counting solution 
0.05 m  Area across which the grid is etched 
on the slide 
  Areas for counting red blood cells 
  Areas for counting white blood cells 
Dinxnsions of Neubauer ruling on Hatmocytometer Ha. mocytometer in cross section 
Figure AIL2.: Picture shows a standard haemocytometer and its profile in cross 
section. 
The haemocytometer is viewed at 100x magnification using a light microscope 
(magnification is a multiple of IOx ocular and IOx objective). 
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Each square of the haemocytometer represents a total volume of 0.1 mm3 or 10-4 
cm3. Cell concentrations are calculated as follows (as lcm3=1m13): 
cells per ml = the average count per square * dilution factor* 104 (count 10 
squares) 
cell viability = total viable cells (unstained)/ total cells (stained and unstained) x 
100 
AII. 3. Calculation of protein content of samples for Western analysis 
Samples were analysed on a spectrophotometer at 655nm. The optical densities were 
converted to protein content (µg) by the construction of a standard curve (Figure 
AII. 3. ) with known concentrations and serial dilutions of bovine serum albumin 
(BSA). 
0.16 
0.14 
E 0.12 
In 
0.1 
0.08 
0.06 
. a 
0.04 
0.02 
0 
Bovine Serum albumin (pg/pL) 
Figure AII. 3.: The created standard curve is used as a reference to calculate 
protein content in samples of proteins extracted from cultured adipocytes, pre- 
adipocyte cells and tissue. Bovine serum albumin was diluted in mQH2 0 and the 
absorbance is read at 655nm on a spectrophotometer. 
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AII. 4. Glucose oxidase method 
The glucose oxidase method is a technique that allows for accurate quantification 
of glucose concentration in both serum and plasma preparations of blood (Lott, 
1975). Blood glucose is oxidized to gluconic acid, liberating hydrogen peroxide 
by an enzyme called glucose oxidase. The liberated hydrogen peroxide is 
converted by peroxidase to water and oxygen. The level of converted oxygen can 
be measured using an oxygen accepter termed 4 aminophenazone, which takes up 
oxygen forming a pink covered chromogen which can be detected. 
AII. 5. RNA extraction and Real time PCR 
5.1. mRNA sequence 
The deoxyribonucleic acid (DNA) or genetic code that encodes the protein 
structure is divided into introns (non-coding) and exons (coding) regions. When a 
gene is transcribed from the DNA strand by RNA polymerase, messenger 
ribonucleic acid (mRNA) is produced, which comprises only the exons. Each gene 
can comprise of a varied number of exons which describe the specific polypeptide 
chain to be assembled within the ribosomes located in the cytoplasm. Quantitative 
mRNA analysis determines the `blueprint' prepared for protein synthesis. 
5.2. RNA content in extracted samples 
After extraction of RNA contaminating genomic DNA was removed using lµ1 
DNase diluted in 5µ1 reaction buffer. Protein contamination of RNA was 
calculated by measuring optical density of each sample at 260nm (OD260) 
(wavelength for RNA and DNA detection) and 280nm (wavelength for protein 
detection). The ratio of these two readings is an indicator of the samples purity. 
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The conversion factor for RNA is 0.040µg/µ1 per OD260 unit and the quantity of 
RNA diluted is 4p. 1 per lml. Therefore for a reading of OD260 0.10; 0.10 * 
(1000/4) * 0.040 =1 µg/mL. 
5.3. RT-PCR 
The polymerase chain reaction relies on complementary DNA as a template, 
therefore DNA must be synthesised from the extracted RNA. This process is 
termed reverse transcription (RTn), and allows the synthesis of complementary 
DNA (cDNA). This involves the `reading' of the mRNA sequence and then a 
cDNA chain assembled that comprises the complimentary base to that on the 
mRNA strand (guanine always bonds with cytosine and adenine to thymine) 
(Figure AII. 5.3. ). 
mRNA 3' 
G T T A T C C A Complementary bases 
cDNA 3' 51 on the cDNA strand (A+-+T, GHC). 
C A A T A G G T 
mRNA 5' 3' 
T G C C G A T C Complementary bases 
cDNA 5' 31 on the cDNA strand 
(AF-, T, G+-, C) 
A C G G C T A G 4 
Figure AII. 5.3.: This diagram illustrates the messenger RNA double strand, 
which is then digested in the reverse transcription process to yield single strands. 
Each cDNA strand is then composed using complementary bases to those on the 
mRNA strand. 
5.4. Quantitative Real-Time PCR 
Quantitative real-time PCR uses fluorescence technology to monitor amplification 
production. Real-Time PCR is designed to collect data as the reaction is 
proceeding, (ie, in real time). This is more accurate for DNA and RNA 
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quantitation and does not require laborious post PCR like the traditional PCR 
methods. The accumulation of product (amplicon) during the reaction is then 
measured at the exponential phase of the PCR reaction. 
p ('ý 
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Q 
C eavacý.:! 
1 
R`ý ýýQ 
ý, w 
Figure A1I. 5.4.: Diagram showing TaqMan chemistry. When the probe is cleaved 
from the DNA during amplification the reporter dye is removed from the quencher 
and fluoresces. 
In this study MRNA levels were analysed using an ABI 7700 Sequence Detection 
system which utilizes TaqMan chemistry. The TaqMan probe is designed with a 
high-energy dye termed a reporter at the 5' base end, and a quenching dye 
typically on the 3' base that suppresses the reporter. The quencher prevents 
emission of any fluorescence while the probe is intact. If the gene of interest is 
present, the probe anneals between the forward and reverse primer sites within the 
PCR product. When the Taq DNA polymerase replicates a template on which a 
TaqMan probe is bound, its 5' exonuclease activity cleaves the probe. This 
removes the reporter from the proximity of the quencher, resulting in a florescent 
signal that accumulates with each cycle. The fluorescent signal yielded can be 
quantitatively measured by a laser and charged coupled device (CCD) camera, 
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enabling real time detection of cDNA amplification. (Figure AII. 5.4. ). There is an 
increase in intensity with every amplification cycle. The threshold line is the level 
of detection at which a reaction reaches a fluorescent intensity above background 
(Figure AII. 5.5. ). 
b, o 0 
Cycle threshold 
(Ct) at which the 
sample crosses the 
Threshold 
CYCLE # 
Figure AII. 5.5.: Log view of real time PCR. The threshold line is set in the 
exponential phase of the amplification for the most accurate reading. The cycle at 
which the sample reaches this level is called the Cycle Threshold, Ct. 
AII. 6. Microarray 
A schematic overview of the `One-cycle target labelling' protocol is shown in 
figure 11.6. and is derived from the `GeneChip® Expression Analysis Data 
Analysis Fundamentals' manual and the `GeneChip® Expression Analysis 
Technical Manual' both available at http: //www. affymetrix. com. 
A GeneChip @ probe array consists of a number of cells (square-shaped areas on 
the array) and each contains many copies of a unique probe. Probes are tiled in 
probe pairs consisting of a perfect match (PM) and a mismatch (MM) which are 
only distinguishable by a base substitution in the middle of the MM probe 
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sequence. The significance of the differences between PM and MM was expressed 
by calculation of a p-value using a one-sided Wilcoxon's Signed Rank test. 
One-CycleTarget Labeling 
(for 1-15 pg total RNA or 0.2-2 pg mRNA) 
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Figure AIL 6.: The `One-cycle target labelling' protocol 
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AII. 7. Haemoccult-test 
The Haemoccult-test is used for screening of GI blood loss. A few drops of 
sample are put onto filter paper, incubated for 1 hr, treated with developer and 
read within 45 seconds. The test reads positive up to a blood concentration of 
1x10-'µl. 
Figure ALL7.: Haemoccult-test. 
The picture shows a positive and 
negative test and the positive 
control underneath. 
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